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Mycobacterium tuberculosis is an ancient pathogen, which has been infecting humans for 
millennia. It remains globally spread, infecting one third of the world’s population and 
causing around two million fatal cases per year. The treatment of this infectious disease 
remains complex, time consuming, resource demanding and costly. In the absence of 
adherence, good quality drugs and appropriate treatment regimens, the pathogen is highly 
likely to develop resistance to the antibiotics used during treatment. Searching for new drug 
targets and developing new drugs are constantly in progress to address these issues.  
 
Type VII secretion system (T7SS) is a signature protein secretion system in mycobacteria, 
associated with virulence and nutrient acquisition. There are five copies of the T7SS in M. 
tuberculosis, namely ESX-1 to -5, with ESX-3 being essential for the bacterial growth in 
vitro. The importance of ESX-3 is supported by the fact that it influences two major iron 
uptake pathways in mycobacteria, namely mycobactin-mediated iron acquisition and heme 
acquisition. Mycosin-3 is the only membrane core component of ESX-3 that has a subtilisin-
like serine protease signature and plays an essential role in ESX-3 secretion. Mycosin-3 has a 
unique catalytic specificity and its substrates are unknown. Elucidating the protein structure 
and determining the function of mycosin-3 will help the design of effective inhibitors to 
abolish the protease function providing for a potential therapeutic option. 
 
In this study, the mycosin-3 gene from the M. tuberculosis genome was cloned and expressed 
in Escherichia coli and the protein was purified in vitro, with the aim of conducting structural 
studies. However, the amount of soluble and stable mycosin-3 was insufficient to progress to 
X-ray crystallography for protein structure determination. According to the literature, this 
technical difficulty is not uncommon for M. tuberculosis genes because the gene transcription 
and protein production machineries in mycobacteria are distinct from the conventional 
protein production host E. coli. In vitro expression analysis suggested that mycosin-3 
possibly exerts a toxic effect on the expression hosts: E. coli and Mycobacterium smegmatis. 
To overcome these complexities, M. smegmatis was used as a model organism for functional 
studies; the mycP3 gene was deleted from the genome, and the proteomes of the wild type and 
mycosin-3 deletion mutant were compared. No major phenotypic differences were observed 
between the wild type and mutant possibly because the model organism has an alternative 
exochelin-mediated iron acquisition pathway. Interestingly, in the absence of mycosin-3, one 
component of the mycobactin export system, MmpL5, was not detected in the whole cell 
lysate (containing both cytosolic and membrane fractions) by mass spectrometry although the 
mmpL5 gene was transcribed, suggesting rapid protein degradation. We hypothesize that 
mycosin-3 may plays a role in maintaining the integrity of the membrane protein MmpL5 
prior to its secretion and in facilitating its localization on the membrane. The direct 
involvement of mycosin-3 in the posttranslational modification of MmpL5 is currently under 
investigation. This study provides evidence that mycosin-3 may be an attractive drug target - 
abolishing mycosin-3 could disable mycobactin export, with ensuring toxicity from 
intracellular mycobactin accumulation thereby eliminating M. tuberculosis. 






Mycobacterium tuberculosis is ‘n patogeen wat mense reeds eeue infekteer en tuberkulose 
veroorsaak. Vandag kom tuberkulose steeds wêreldwyd voor en veroorsaak ongeveer twee 
miljoen sterftes jaarliks. Die behandeling van hierdie aansteeklike siekte bly kompleks, 
tydrowend, hulpbron-veeleisend en duur. Sonder toepaslike behandeling, goeie kwaliteit 
antibiotika en nakoming van behandelings regimente, is dit waarskynlik dat antibiotika 
weerstandigheid ontwikkel. Dit is gevolglik belangrik om nuwe antibiotika teikens te vind. 
 
Die Tipe VII sekresie sisteem (T7SS) is ‘n kenmerkende protein sekresie sisteem in 
mycobacteria en word met virulensie en die opname van voedingstowwe assosieer. Daar is 
vyf kopieë van T7SS in M. tuberculosis naamlik ESX-1 tot -5. ESX-3 is noodsaaklik vir 
bakteriële groei in vitro. Die belangrikheid van ESX-3 word beklemtoon deur die feit dat dit 
die twee hoof paaie vir ysteropname, naamlik mycobactin-bemiddelde-ysterverkryging en 
heme vekrygings paaie, in mycobacteria beïnvloed. Mycosin-3 is die enigste membraan kern 
komponent van ESX-3 wat ‘n subtilisin-agtige serien protease motief het en dit speel ‘n 
belangrike rol in ESX-3 sekresie. Mycosin-3 het unieke katalitiese spesifisiteit en die 
substrate daarvan is onbekend. Bepaling van die proteïen struktuur en funksie van mycosin-3 
sal help met die ontwerp van effektiewe inhibeerders van die protease funksie. Dit kan 
gevolglik ‘n potensiële terapeutiese opsie verskaf. 
 
In hierdie studie is die mycosin-3-geen van die M. tuberculosis genoom gekloon en uitgedruk 
in Escherichia coli. Die in vitro proteïen is gesuiwer om strukturele studies te doen. Die 
hoeveelheid oplosbare en stabiele mycosin-3 was egter onvoldoende om te vorder tot X-
straalkristallografie vir proteïen struktuur bepaling. Volgens die literatuur, is hierdie tegniese 
probleme nie ongewoon vir M. tuberculosis gene, aangesien die geen transkripsie en proteïen 
produksie masjinerie van mycobacteria uniek is en dus van die konvensionele masjinerie in 
die E. coli gasheer verskil. Analise van in vitro proteïen uitdrukking eksperimente stel voor 
dat mycosin-3 moontlik ‘n toksiese effek op die gasheer, E. coli en Mycobacterium 
smegmatis, kan hê. Om hierdie probleem te oorkom, is M. smegmatis as ‘n model organisme 
gebruik om funksionele studies te doen. Die mycP3 geen is uit die M. smegmatis genoom 
verwyder om ‘n delesie mutant te maak. Die proteome van die wilde-tipe en mycosin-3 geen 
delesie mutant is vergelyk. Daar was geen opmerklike verskille in die fenotipe van die wilde-
tipe en mutant nie, moontlik omdat die model organisme ‘n alternatiewe exochelin-
bemiddelde yster verkrygings pad het. Interessant genoeg, is een komponent van die 
mycobactin uitvoer sisteem, MmpL5, afwesig in die heel sel extrakte (van beide die sitosol en 
membraan fraksies) wanneer mycosin-3 afwesig is, volgens massa spektrofotometriese 
analise. Die mmpL5 geen is egter getranskribeer, wat daarop dui dat die proteïen vinnig 
degradeer. Ons hipotese is dat mycosin-3 moontlik ‘n rol speel in die integriteit van die 
membraan proteïen MmpL5 voordat dit uitgeskei word en in die fasilitering van MmpL5 se 
posisionering in die membraan. Die direkte betrokkenheid van mycosin-3 in die 
posttranslasionele wysiging van MmpL5 word tans ondersoek. Hierdie studie bewys dat 
mycosin-3 'n aantreklike antibiotika teiken kan wees aangesien die afwesigheid van  




mycosin-3 veroorsaak dat mycobactin uitvoer afgeskaf word en gevolglik tot toksiese opbou 
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Chapter 1. General Introduction 
1.1 General Introduction 
 
World Health Organization (WHO) has announced tuberculosis as a global health emergency 
(WHO, Global tuberculosis report 2013). Tuberculosis is an infectious disease primarily 
affecting human lungs and leading to respiratory failure if not treated. Mycobacterium 
tuberculosis, the pathogen that causes the disease, is a gram-positive bacterium with a thick 
and complex cell wall that is naturally resistant to many antibiotics and toxins. M. 
tuberculosis is a slow-growing bacterium with a doubling time of 24 hours, and it may enter a 
dormant state when stimulated by certain molecules (e.g. CO, NO) in the host environment 
(Voskuil et al., 2003). Therefore the treatment of tuberculosis is usually prolonged and 
sometimes ineffective. The standard 6-month regimen consists of the first 2 months with four 
antibiotics, isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months with 
two antibiotics, isoniazid and rifampicin (WHO, Global tuberculosis report 2013). This 
regimen minimizes the risk of the bacteria developing drug resistance during the treatment. 
However, these drugs have many side effects, making it very difficult for the patients to 
adhere to the 6 month treatment. Patient’s non-adherence and clinical mis-management are 
two major factors driving the emergence of resistance to all the first-line anti-TB drugs and 
some second-line drugs. Discovery of new drug targets and development of new drugs is 
therefore urgently required to shorten the duration of treatment and to effectively treat drug 
resistant TB.  
 
A good drug target should be responsible for essential metabolic functions in M. tuberculosis 
and it should have no homology to human proteins to minimize drug toxicity to the host. The 
Type VII secretion system (T7SS) is a specific protein secretion system in mycobacteria. M. 
tuberculosis has five copies of T7SS which contribute to virulence and nutrient acquisition. 
Chapter 2 gives a thorough literature review about this recently described bacterial secretion 
system, delineating its substrates, its functions in M. tuberculosis and the host, the 
components of the secretion machinery, the secretion mechanism, and its influence on the 
pathogenicity of the mycobacteria. One of the five copies of T7SS, ESX-3, is essential for 
bacterial growth in vitro. In fact, ESX-3 enables the functioning of the two major iron 
acquisition mechanisms in mycobacteria, mycobactin-mediated iron acquisition and heme 
acquisition. Accordingly, ESX-3 was chosen for further investigation in this study. Chapter 3 
provides a detailed literature review on iron and heme homeostasis in mycobacteria, 
including their acquisition mechanisms, regulation of the transcription of the genes encoding 
the machineries, the link between the two pathways, and how ESX-3 influences their 
functionalities.  
 
The most appropriate drug target in ESX-3 appears to be mycosin-3. Unlike other membrane 
core components of the system, mycosin-3 has a unique subtilisin-like serine protease 
signature which is essential for ESX-3 secretion. Inhibitors could therefore be designed to 




disrupt the integrity of its catalytic site. Although the substrates of mycosin-3 are unknown, it 
is evident that this enzyme is essential for the bacteria and it is probably able to modify 
certain components in the iron and heme acquisition pathways. A better understanding of the 
structure and substrate specificity of mycosin-3 is a prerequisite to inhibitor design. Chapter 4 
describes the progress of structural genomics of M. tuberculosis H37Rv to date, providing a 
background for the structural analysis of mycosin-3, which is described in Chapter 5. In 
Chapter 6, M. smegmatis was used as a model to elucidate the function of mycosin-3. The 
proteomes of a mycosin-3 deletion mutant of M. smegmatis were compared to wild-type M. 
smegmatis to determine the downstream effects of the presence/absence of mycosin-3 on the 
proteome of M. smegmatis. The main findings of the structural and functional studies are 
summarized in Chapter 7, where suggestions of future research directions are made also. 
 
The main objectives of this study are: 
 
1. To understand the literature on Type VII Secretion System; 
2. To understand the literature on iron transport and metabolism in mycobacteria; 
3. To summarize the progress and experience from the past structural genomics research on 
M. tuberculosis H37Rv; 
4. To attempt to study the 3D structure of mycosin-3; 
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Tuberculosis (TB) is one of the infectious diseases in the world. The causative agent, 
Mycobacterium tuberculosis is a successful human pathogen which manages to survive and 
replicate inside the hostile environment of human macrophages, spread to healthy 
neighbouring cells, migrate to other tissues and organs of the body, causing disease in its 
hosts. Its persistence and ability to avoid attacks from the host immune system are intriguing 
knowledge gaps. The mechanisms of its virulence remain under the spotlight of tuberculosis 
research.  
 
The well-known TB vaccine, the attenuated Mycobacterium bovis strain BCG (Bacillus 
Calmette–Guérin), derived from M. bovis by numerous passaging in the laboratory, has 
several regions of difference (RD) identified by comparative genomic studies with the 
virulent parent strain. These RDs are believed to be responsible for the virulence of the 
bacteria (Mahairas et al., 1996). RD1 appears to be the most important region because it is 
directly related to the secretion of potent T-cell antigen ESAT-6 (Early Secreted Antigenic 
Target 6 kDa) and CFP-10 (Culture Filtrate Protein 10 kDa) (Andersen et al., 1991). The 
counterparts of the RD1 region in M. tuberculosis spans from Rv3871 to Rv3879c (9.5 kbp). 
Deletion of this region in M. tuberculosis led to the attenuation of the strain, similarly to the 
BCG attenuated phenotype, in the macrophage and mice infection models (Lewis et al., 
2003). Re-introducing RD1 into BCG enabled the secretion of ESAT-6 and CFP-10 into the 
culture supernatant (Pym et al., 2003) and improved bacterial growth in mice, although BCG 
remained avirulent (Pym et al., 2002a).  
 
It is believed that RD1 contains genes encoding part of a secretion system which secretes 
multiple virulence factors including ESAT-6 and CFP-10 (Cole et al., 1998; Gey Van Pittius 
et al., 2001; Tekaia et al., 1999). The complete gene cluster, named the ESAT-6 secretion 
system 1, ESX-1, contains 20 genes (Rv3864 – Rv3883c) (Brodin et al., 2004). There are 4 
more copies of the ESAT-6 gene cluster (ESX-2, ESX-3, ESX-4 and ESX-5) in the M. 
tuberculosis genome and homologues of the ESAT-6 gene clusters exist throughout the 
mycobacteria and some other gram positive bacteria (Figure 1) (Gey Van Pittius et al., 2001). 
With ESX-4 as the ancestral copy and the ESX-5 as the most recently evolved copy, the 
evolutionary sequence for the five ESX gene clusters is ESX-4, ESX-3, ESX-1, ESX-2 and 
ESX-5 (Gey Van Pittius et al., 2001). The evolution of the ESX drove the duplication and 
expansion of the PE (Pro-Glu) and PPE (Pro-Glu-Glu) gene families, with the ancestral gene 
copies located within the ESX gene clusters (Gey van Pittius et al., 2006). Except for ESX-4, 
all of the gene clusters contain PE and PPE gene pairs (Figure 1) (Bitter et al., 2009). While 




ESX-2 and ESX-4 are not well described, ESX-1 and ESX-5 have been associated with the 
virulence of pathogenic mycobacteria and ESX-3 was shown to be involved in mycobactin-
mediated iron acquisition (Siegrist et al., 2009). Moreover, ESX-1 participates in conjugation 
in M. smegmatis (Coros et al., 2008) and sporulation in Streptomyces coelicolor (Akpe San 
Roman et al., 2010). 
 
Besides the PE and PPE proteins, the ESX gene clusters contain genes encoding the secretion 
system membrane core components, EccB, EccC, EccD and EccE (ESX Conserved 
Components) (Houben et al., 2012), the secreted substrates, the Esx (ESAT-6 family proteins) 
and Esp (Esp stands for ESX-Specific Protein) proteins, as well as the mycosins, membrane-
anchored subtilisin-like serine proteases (Brown et al., 2000). The ESAT-6 secretion system 
has a different secretion mechanism from the other six types of secretion systems discovered 
previously in terms of their secretion signals and two-step secretion pattern, and was thus 
identified as a novel type of secretion system termed the Type VII secretion systems (T7SS) 
(Abdallah et al., 2007). This review will focus on the functions of the components and 
substrates of T7SS, its secretion mechanism, the regulation of its gene expression, and the 




Figure 2.1. The genetic organization of the five ESX gene clusters of Mycobacterium tuberculosis. 
The abbreviations are explained in the text. The figure is adapted from Bitter, et al., 2009. 
 




2.2 Type VII Secretion System Working Model 
 
The T7SS recognizes a specific secretion signal on some of its substrates which recruit other 
substrates in the cytoplasm before delivering them to the ATPase-containing secretion core 
machinery on the plasma membrane. The ESX-1 of M. tuberculosis and M. marinum are the 
best studied T7SS models in terms of the substrate identities and the secretion mechanism. 
This section describes the ESX-1 in detail. The different ESXs are presumed to have similar 
secretion mechanisms although their substrates may differ.  
2.2.1 The Secretion Signal 
 
The T7SS is sec-independent and its substrates do not possess the N-terminal signal sequence 
characteristic of the sec-dependent secretion systems (Ligon et al., 2012). An ESX secretion 
signal sequence was identified on the C-terminus of certain substrates of the secretion system. 
The last 25 amino acids of CFP-10 were found to be essential for CFP-10 to interact with the 
membrane component EccCb to ensure its secretion. Deletion of these 25 amino acids 
abolishes CFP-10 secretion and secretion of other substrates which are CFP-10-dependent 
(Champion et al., 2006). The paralogues of CFP-10 (EsxB), namely ExJ, EsxK, EsxP, EsxM, 
and EsxW lack the CFP-10-signal sequence implying that their secretion is not ESX-1-
dependent and that other secretion systems are needed for their secretion (Champion et al., 
2006). PE25 and PPE41, which form a heterodimer before secretion, are substrates of ESX-5. 
Deletion of 7 or 15 amino acids from the C-terminus of PE25 completely abolished the 
secretion of both PE25 and PPE41 (Daleke et al., 2012a). More specifically, the Tyr12 and 
the Asp/Glu 8 from the C-terminus are the key residues determining secretion. This specific 
YxxxD/E motif is not only found in the flexible C terminus of PE25, but is also present on 
the PE domain of LipY (Daleke et al., 2011), PE domain of PE_PGRS33 (Cascioferro et al., 
2011), PE35 protein, CFP-10, EspC and EspB (Daleke et al., 2012a). This general signal 
sequence, YxxxD/E, can be used to search for additional substrates of the ESX systems in the 
M. tuberculosis genome (Daleke et al., 2012a). However, this signal cannot differentiate 
between the different ESX systems. The additional signal for ESX specificity lies on the ESX 
secretion chaperone protein EspG which does not possess a distinct signal sequence (Daleke 
et al., 2012b).  
 
2.2.2 The substrates and their potential functions 
 
There are three groups of known substrates of ESX-1, the M. tuberculosis primary potent T-
cell antigen Esx proteins including EsxA (ESAT-6) and EsxB (CFP-10), the Esp group 
including EspE, EspF, EspG1, EspH, EspJ, EspK, EspL, EspB, EspA, EspC and EspD, and 
the PE and PPE families of proteins. They may perform a variety of functions after being 
secreted, which remain to be elucidated. 
 




2.2.2.1 Esx proteins 
 
EsxA (ESAT-6) and EsxB (CFP-10) are among the first discovered and studied secreted 
proteins from M. tuberculosis (Berthet et al., 1998; Sørensen et al., 1995). There are 22 
known Esx genes in the M. tuberculosis genome (Cole et al., 1998) and the homologues of 
EsxA and EsxB are usually arranged in pairs in the same operon and are co-transcribed 
(Berthet et al., 1998; Poulsen et al., 2014). EsxA and EsxB form a tight heterodimeric 1:1 
protein complex before secretion and are mutually dependent for secretion (Renshaw et al., 
2005, 2002). The role of the EsxA-EsxB complex in host pathogenicity is still under 
investigation. Interestingly, EsxA was found to enhance the permeability of artificial 
membranes (Hsu et al., 2003). The EsxA-EsxB complex is able to interact with the host cell 
surface, but it does not disrupt the membrane integrity (Renshaw et al., 2005). EsxB showed 
weak and non-specific binding to the cell membrane (de Jonge et al., 2007). EsxA alone does 
not disrupt cell membrane integrity (Guinn et al., 2004), however, it has a high affinity to 
artificial liposomes, particularly when dimyristoylphosphatidylcholine (DMPC) and 
cholesterol are incorporated (de Jonge et al., 2007). EsxA may dissociate from EsxB under 
acidic conditions and perform a membrane-lysing activity on the liposome (de Jonge et al., 
2007). De Jonge et al. (2007) proposed that the macrophage phagosome has a low pH 
environment which favours the dissociation of EsxA from EsxB and that EsxA is directly 
involved in biomembrane disruption. But this effect of EsxA has not been demonstrated in 
macrophage infection models (de Jonge et al., 2007). 
 
2.2.2.2 Esp proteins 
 
A unique feature about ESX-1 is that an extra genomic region espACD (Rv3616c-Rv3614c) 
is associated with its functions where the main ESX-1 substrates and the gene products of the 
espACD operon are mutually dependent for secretion (Fortune et al., 2005; MacGurn et al., 
2005). In the ESX-1 gene cluster and its functionally associated espACD operon, there are a 
number of Esp genes, the encoded proteins which the functions are still largely unknown 
although many of them affect the stability and secretion of EsxA, EsxB and other Esps.    
 
EspE is not secreted into the extracellular space but remains cell envelope associated 
(Carlsson et al., 2009) and treatment with the detergent Tween-80 cannot remove EspE from 
its location. This implies that EspE might have interactions with the host (Sani et al., 2010). 
However, deleting the espE gene does not affect the virulence of the bacteria (Brodin et al., 
2006). The two esp genes downstream of espE, namely espF and espG1
 
(Figure 2.1), are co-
transcribed independently from the upstream espE and the downstream espH genes (Bottai et 
al., 2011). Disruption of the espF and espG1 genes did not affect the secretion of EsxA and 
EsxB but the mutant still became severely attenuated (Bottai et al., 2011; Champion et al., 
2009). EspF and EspG1 probably play important roles in ESX-1 mediated pathogenicity. 
EspF is abundant in both the culture supernatant and the bacteria pellet of M. marinum but is 
scarce in both environments in M. tuberculosis. It interacts with EsxA without which EspF is 
not secreted (Brodin et al., 2006). EspG1 is a cell envelope associated protein. It affects either 




the gene expression or protein stability of PPE68, the PPE protein in the same ESX region 
(Bottai et al., 2011). The EspG proteins secreted by the ESXs are specific chaperone proteins 
for the PPE family proteins or the PE/PPE protein complexes secreted by the specific ESX. 
EspGs do not bind to the YxxxD/E secretion signal but to the core domain of the PE-PPE 
complex forming a 1:1:1 complex before secretion (Daleke et al., 2012b). For example, 
EspG1 interacts with the ESX-1 substrate PPE68 but not with the ESX-5 substrate PPE41 
while EspG5 (Rv1794, the EspG1 homologue in ESX-5) interacts with ESX-5 substrates 
PPE33 and PPE41 but not PPE68 (Daleke et al., 2012b). EspG must possess a secretion 
signal which directs the PPE protein or PE/PPE protein complex to its specific ESX for 
secretion. The presence of PE and PPE proteins which are not the substrates of a particular 
ESX is not affected when this ESX is disabled (Sani et al., 2010). Similarly to EspE, EspF 
and EspG1, the proteins EspH, EspJ, EspK and EspB are not required for EsxA and EsxB 
secretion (Brodin et al., 2006; McLaughlin et al., 2007). There is very little information about 
the functions of EspH, EspJ and EspL but EspI was found to affect the secretion of EsxA and 
EsxB by abolishing EspA secretion (Fortune et al., 2005).  
 
EspB is dependent on EspK but not EspG1, EspH or EsxB for secretion (McLaughlin et al., 
2007) although it was believed to form a temporary complex with the EsxA-EsxB 
heterodimer to facilitate secretion (Xu et al., 2007). EspB and EspK physically interact with 
one another and EspK was shown to interact with EccCb and act a chaperone that delivers 
EspB to the secretion machinery (McLaughlin et al., 2007). After secretion via ESX-1, EspK 
remains cell envelope associated (Sani et al., 2010). Interestingly, after secretion EspB is 
cleaved by Mycosin-1 at two sites at the C-terminus after secretion (McLaughlin et al., 2007; 
Xu et al., 2007), namely Pro332 and Ala392 (Ohol et al., 2010). The physiological or 
pathogenic significance of this cleavage is unknown. 
 
The proteins encoded in the espACD operon, outside the ESX-1 gene cluster are substrates of 
ESX-1 and are inter-dependent with the ESX-1 substrates, except EspB (Chen et al., 2013b), 
for secretion (Callahan et al., 2010; Fortune et al., 2005; MacGurn et al., 2005). EspA can 
only be secreted when coupled to the EsxA-EsxB complex (Fortune et al., 2005), where the 
binding is dependent on the Trp55 and Gly57 residues in the putative WXG motif of EspA. 
Disruption of this motif abolishes EsxA-EsxB secretion (Chen et al., 2013a). The same point 
mutations also affect EspD stability and secretion, leading to M. tuberculosis attenuation. 
Point mutations at Phe50 and Lys62 destabilize EspA and also abolish EsxA-EsxB secretion, 
attenuating M. tuberculosis. However, if Phe5 and Lys41 are mutated, M. tuberculosis is not 
attenuated, although EspA is destabilized and EsxA-EsxB and EspD secretions are abolished 
(Chen et al., 2013a). Perhaps these two specific amino acids on EspA are responsible for the 
interaction of EspA with other virulence-related proteins in M. tuberculosis. Moreover, after 
secretion, EspA forms a dimer via disulfide bonds, disruption of which does not affect ESX-1 
secretion but severely attenuates the ability of M. tuberculosis to survive and cause disease in 
mice and also significantly disrupts the stability of the mycobacterial cell wall (Garces et al., 
2010). EspA was found localized within the cell envelope, suggesting that it plays a role in 
maintaining the bacterial cell wall integrity (Garces et al., 2010). These studies dissociate the 




EsxA and EsxB secretion from the virulence of M. tuberculosis, changing the paradigm of the 
function of these two major T-cell antigenic proteins (Champion, 2013; Chen et al., 2013a). 
 
EspC, possessing the Type VII general secretion signal (YxxxD/E), is recognized by EccA 
through its C-terminus. It is required for EsxA, EsxB and EspA secretion and is itself a 
substrate of ESX-1 (Champion et al., 2009). Truncating the C-terminal 7, 14, or 25 amino 
acids of EspC abolishes EspA secretion. EspC also affects the stability and/or the expression 
of EspA because the EspA level was reduced in the EspC deletion mutant (Champion et al., 
2009). 
 
EspD is a secreted protein, but unlike EspA and EsxA, it is not a substrate of ESX-1 and even 
the RD1 mutant strain of M. tuberculosis secretes EspD (Chen et al., 2012). EspD stabilizes 
EspA and EspC. Without EspD, the EspA and EspC cellular levels are significantly 
decreased and the secretion of EsxA and EsxB are disabled. However, there is no direct 
interaction between EspD and either EspC or EspA. Abolishing the secretion of EspD does 
not affect EsxA secretion. Without EspA, EspD is not produced or secreted indicating an 
inter-dependent mechanism between the two proteins (Chen et al., 2012). 
 
2.2.2.3 PE and PPE proteins 
 
The PE and PPE proteins are unique to the mycobacteria. They constitute almost 10% of the 
coding capacity of the M. tuberculosis genome (Cole et al., 1998). The PE and PPE genes in 
the ESX gene clusters represent the ancestral PE and PPE gene copies from which the rest of 
the family members were copied (Gey van Pittius et al., 2006). The more recently evolved PE 
and PPE proteins usually contain various lengths of C-terminal sequences which classify 
them as members of the PE-PGRS (Polymorphic GC-rich Repetitive Sequence) and PPE-
MPTR (Major Polymorphic Tandem Repeat) sub-families (Gey van Pittius et al., 2006). In 
the M. tuberculosis genome there are 28 PE and PPE genes identified in operons, with the PE 
gene located directly upstream of the PPE gene and they are co-transcribed (Tundup et al., 
2006). These PE and PPE protein pairs can only be produced solubly in vitro when co-
expressed and co-purified (Strong et al., 2006; Tundup et al., 2006). Different PE and PPE 
proteins are secreted using specific ESXs when associated with a particular EspG protein. 
The general secretion signal was identified in some PE proteins (Daleke et al., 2012a). The 
secreted PE and PPE proteins may perform a variety of functions which are still 
undetermined. PPE68, a substrate of ESX-1, is localized in the cell envelope, and is able to 
elicit interferon (IFN)-gamma production in mice infected with M. tuberculosis (Sani et al., 
2010). PPE68 may interact with EsxA (Okkels and Andersen, 2004), however, it does not 
interfere with the secretion and immunogenicity of EsxA and EsxB and it is not a major 
virulence factor of M. tuberculosis (Brodin et al., 2006; Demangel et al., 2004). The 
PE25/PPE41 complex might perform a signal function because of their resemblance to signal 
receptor proteins (Strong et al., 2006). One mycobacterial lipase, LipY, whose orthologue 
possesses a PE domain in M. tuberculosis and a PPE domain in M. marinum is a substrate of 
ESX-5, is secreted onto the surface of the bacteria, and is possibly involved in fatty acid 




acquisition by hydrolysing the host lipid during infection (Daleke et al., 2011). PE and PPE 
family proteins mostly are thought to be antigenic cell surface proteins. Their diverse C-
terminal protein sequences provide a large range of antigenic specificities. The expression of 
PE and PPE family proteins is regulated by a variety of independent mechanisms (Voskuil et 
al., 2004). With a changing microenvironment within the host which might be influenced by 
oxidative stress, macrophage IFN-gamma activation, nitric oxide elevation, etc., different sets 
of PE and PPE proteins are produced providing a dynamic antigenic profile (Voskuil et al., 
2004). However, the significance of this phenomenon is unknown. Perhaps it exerts less 
pressure on genetic mutation of the bacteria and enables the mycobacteria to respond faster to 
the changing immunity of the host. 
 
2.2.3 The ATPases 
 
EccA plays a substrate recruiting role for the EsxA-EsxB complex and some Esp complexes 
similar to EspG for the PE and PPE proteins (Houben et al., 2013a). Unlike EspG, which 
provides a signal for the substrate delivery, EccA supplies energy for the recruitment and 
delivery process. EccA has two functional domains: the N-terminal domain contains 6 
tetratricopeptide repeats which allow the interaction with the secreted substrates (Wagner et 
al., 2014) and the C-terminal ATPase domain hydrolyzes ATP molecules. Without EccA, 
EsxA and EsxB are not secreted (Brodin et al., 2006) and the stability of EspB is affected in 
its absence (Xu et al., 2007). 
 
Besides facilitating substrate secretion for ESX-1, EccA seems to affect mycolic acid 
biosynthesis. An EccA-ATPase mutant showed a significant decrease in mycolic acid content 
in the cell wall, making the mutant defective in intracellular growth and reducing its 
virulence. EccA may be able to shuttle the enzymes involved in mycolate biosynthesis to 
their production sites, making the process more efficient (Joshi et al., 2012). 
 
EccCb, a component of the ESX-1 membrane complex, also possesses an ATPase domain 
(Champion et al., 2009). EccCb works cooperatively with EccA (Champion et al., 2009). It 
recognizes the C-terminus of CFP-10 and brings the substrate complex to the proximity of the 
ESX-1 membrane complex (Abdallah et al., 2007; Houben et al., 2013a). It is also required 
for EspE secretion (Sani et al., 2010).  
 
2.2.4 The membrane core complex  
 
In ESX-1 and ESX-5, two proteins EccCb and EccCa comprise the membrane ATPase 
complex whereas in other ESX systems, EccC homologues are encoded by a single gene 
(Figure 2.1). ESX-5 from M. marinum was used as a model to elucidate the ESX membrane 
structure (Houben et al., 2012). EccB5, EccC5, EccD5 and EccE5 constitute the ESX secretion 
membrane core structure with 6 copies of each EccB5, EccC5, EccD5 and 3 copies of EccE5 
(Houben et al., 2012). Although Mycosin-5 is a membrane-bound protein in the system, it 
cannot be isolated with the core complex, possibly indicating a weak interaction (Houben et 




al., 2012). By performing protease digestion, the middle and the C-terminus of EccC and the 
N-terminus of EccE were found to contain exposed domain whereas EccB and EccD do not. 
It is known that the C-terminus of EccC is exposed intracellularly and is required to interact 
with the substrate complex prior to secretion. The cleavage of the N-terminus of EccE may 
suggest that this plasma membrane-localized protein extends to the outer membrane (Houben 
et al., 2012). 
 
Extensive studies have shown that secretion is abolished through the deletion of any of the 4 
membrane components of the ESX system. The EccB5, EccC5, and EccD5 single gene 
deletion mutants of both M. tuberculosis (Di Luca et al., 2012) and M. marinum were unable 
to secrete EsxN, PPE41 and a number of PE proteins (Bottai et al., 2012; Houben et al., 
2012); EccB, EccCa, EccCb and EccD are also essential for the secretion of EsxA and EsxB 
in M. tuberculosis (Brodin et al., 2006; Guinn et al., 2004; Stanley et al., 2003) and M. 
smegmatis (Converse and Cox, 2005); EccC3 and EccD3 are essential for the secretion of 




The mycosins are membrane-bound subtilisin-like serine proteases (Brown et al., 2000) 
which might be shed into the extracellular matrix (Dave et al., 2002). They are essential for 
secretion through the ESX systems in M. smegmatis and M. tuberculosis (Converse and Cox, 
2005; Ohol et al., 2010). However, disabling the protease activity of Mycosin-1 increases the 
secretion of ESX-1 substrates and it causes hyperactivation of ESX-1 stimulated innate 
signalling pathways during macrophage infection (Ohol et al., 2010). Mycosin-1 may have a 
regulatory role in ESX-1 substrate secretion where a fine tuning secretion may balance 
virulence and immune detection, for successful maintenance of a long-term M. tuberculosis 
infection (Ohol et al., 2010). Mycosin-1 is believed to have multiple substrates, but only 
EspB has been found to be cleaved by Mycosin-1 in vitro and in vivo (Ohol et al., 2010; 
Solomonson et al., 2013; Wagner et al., 2013). 
 
2.3 Type VII Secretion Mechanism 
 
The Type VII secretion mechanism has mostly been studied using ESX-1 and ESX-5 in M. 
tuberculosis and M. marinum as models (Figure 2.2). ESX-1 secretion seems to be more 
complex than ESX-5 secretion. In ESX-1 a large number of substrates have been identified, 
with different roles during the secretion process. The substrates, some of which contain 
secretion signals, and some of which are secretion chaperone proteins, form protein 
complexes prior to secretion thereby stabilizing one another (Houben et al., 2013b).  
 
The ESX-1 substrate complex EsxA-EsxB coupled with EspA is recognized by EccCb via the 
secretion signal on the C-terminus of EsxB (Champion et al., 2009, 2006). EccCb brings this 




complex in proximity to the secretion machinery which transports EsxA-EsxB out of the cell, 
but retains EspA in the cell envelope. The EsxA-EsxB complex may also interact with EspF, 
which in turn binds to EspC. This protein scaffold has C-terminus secretion signals on EsxB 
and EspC which are recognized by EccCb and EccA respectively (Champion et al., 2009). 
EccCb and EccA, two ATPases, work cooperatively to deliver the complex to the secretion 
machinery and transport EsxA, EsxB and EspF out of the cell, retaining EspC in the cell 
envelope (Champion et al., 2009). EspG1 acts as an ESX-1 secretion chaperone which binds 
to the PE35/PPE68 complex (Bottai et al., 2011). The C-terminus of PE35 contains a 
secretion signal which is also recognized by EccCb and then secreted by the core secretion 
complex (Daleke et al., 2012a). PE35 is secreted, and PPE68 and EspG1 remain cell envelope 
associated (Daleke et al., 2012b). EspK and EspB associate before secretion (McLaughlin et 
al., 2007). Although EspB contains a secretion signal at its C-terminus, EspK interacts with 
EccCb and brings EspB to the secretion machinery (McLaughlin et al., 2007). The C-
terminus truncated EspB can be found in the culture supernatant while EspK remains cell 
envelope associated (Sani et al., 2010). EspD stabilizes EspA and EspC but its secretion is 
independent of ESX-1 via an unknown mechanism (Chen et al., 2012). 
 






Figure 2.2. The proposed secretion mechanism of Type VII secretion system using ESX-1 from M. 
tuberculosis as a model. 
 
 
2.4 ESX-1 and Its Association with the Virulence of M. tuberculosis 
 
T7SSs are not virulence systems per se (Abdallah et al., 2007), but it has long been believed 
that ESX-1 is responsible for the virulence of pathogenic mycobacteria because RD1, 
harbouring some components of ESX-1, is absent from the attenuated M. bovis BCG strain 
(Mahairas et al., 1996). The characterization of the ESX-1 components and substrates 
confirmed that their functions are virulence-related, as deleting them leads to mycobacterial 
growth defects in macrophages and in mouse models. For instance, the M. tuberculosis 




EccCa and EccCb deletion mutants showed attenuation in THP-1 macrophages (Guinn et al., 
2004); EccD and PPE25-PE19 mutants are attenuated in both macrophages and immune-
deficient mouse infection models (Bottai et al., 2012); and the EspB deletion mutant showed 
a defect in phagosome maturation (Xu et al., 2007). Specific EspA point mutants, in which 
EsxA and EsxB secretion was abolished, remained virulent showing a dissociation of EsxA-
EsxB secretion from virulence in M. tuberculosis (Champion, 2013; Chen et al., 2013a). 
Without EsxA and EsxB, the processed form of EspB, another virulent protein, is able to bind 
to two phospholipids, phosphatididic acid and phosphatidylserine, possibly interfering with 
cell signalling in the host, facilitating virulence (Chen et al., 2013b). In fact, several other 
studies on ESX have also provided evidence to support the theory where EsxA and EsxB 
secretion does not necessarily confer virulence of M. tuberculosis. EspF and EspG deletion 
mutants were able to secrete EsxA and EsxB, but were attenuated (Bottai et al., 2011; Brodin 
et al., 2006). Non-functional EspA, where intracellular disulphide bond was disrupted, did 
not affect EsxA and EsxB secretion but disrupted the cell wall integrity thereby attenuating 
the bacteria (Garces et al., 2010). ESX-1 is required to prevent phagosome maturation, but 
none of its substrates are responsible for this virulence process (MacGurn and Cox, 2007). It 
has become evident that most of the ESX-1 substrates remain within the cell envelope after 
secretion (Figure 2.2), and serve to support the complex cell wall structure of M. tuberculosis 
rather than interacting with the host. Moreover, the observation that ESX-1 is localized at the 
new pole of a dividing mycobacterium where it seems involved in generating and modifying 
the newly synthesized cell wall, also supports this argument (Carlsson et al., 2009; Sani et al., 
2010; Wirth et al., 2012). With such a complex barrier in M. tuberculosis, some ESX-1 
substrates, such as EsxA, might not directly mediate virulence but target the bacteria’s own 
cell wall to facilitate the secretion of other virulence or metabolism related factors (Garces et 
al., 2010). 
 
2.5 ESX-5 and ESX-3 secretion systems 
 
Compared to ESX-1, studies on ESX-5 and ESX-3 are less described. ESX-5 is responsible 
for secreting ESX-5-specific substrates such as EsxM-EsxN, PE25-PPE41, PPE10, PPE13, 
PE_PGRS45, PE-LipY (M. tuberculosis), PPE-LipY (M. marinum), and perhaps more PE, 
PPE, PE_PGRS and PPE-MPTR subfamily proteins (Abdallah et al., 2009, 2006; Bottai et al., 
2012; Cascioferro et al., 2011; Daleke et al., 2011). Since PE and PPE proteins present strong 
T-cell immunogenicity (Sayes et al., 2012), ESX-5 could play an essential role in switching 
the bacterial surface structure in response to the host environment. 
 
ESX-3 is the most conserved region among the ESXs of mycobacterial species (Kato-Maeda 
et al., 2001). It is involved in mycobactin-mediated iron acquisition and heme uptake 
(Serafini et al., 2013; Siegrist et al., 2014, 2009). But how this secretion system facilitates 
iron and heme uptake is still unknown. A detailed discussion of the functionality of ESX-3 is 
given in Chapter 2. EsxG and EsxH (homologues of EsxA and EsxB) are two known 
substrates of ESX-3. The EsxG-EsxH heterodimer structure is similar to the EsxA-EsxB 




complex but contains a potential protein interaction site on the surface. There is also a 
specific zinc ion binding site on EsxH, implying a possible role in zinc ion acquisition. The 
complex does not seem to be able to bind to mycobactin (Ilghari et al., 2011). Unlike EsxA-
EsxB which might target the lipid membrane, the EsxG-EsxH complex has been found to 
target and disable the host ESCRT (Endosomal Sorting Complex Required for Transport), 
which participates in the delivery of the M. tuberculosis-containing phagosomes to the 
lysosome to restrict bacterial growth and initiate destruction (Mehra et al., 2013). 
 
2.6 Functional Regulation of the ESXs 
 
The gene regulation of the ESX-1 gene cluster and its functionally associated espACD operon 
(Figure 2.1) has attracted much attention due to their involvement in the virulence of M. 
tuberculosis. The regulation is rather complicated because of the large number of regulatory 
proteins involved.  
 
EspR (Rv3849) binds to the promoter region of the espACD operon (Rv3616c-Rv3614c) and 
represses its expression (Raghavan et al., 2008). EspR has an N-terminal dimerization 
domain and a C-terminal DNA binding domain (Blasco et al., 2012). It forms a dimer of a 
dimer with the two dimers binding at different DNA regions. Such a dimer-dimer formation 
is essential to enable EspR to modulate espACD transcriptional activity and hence 
pathogenesis (Blasco et al., 2014, 2011). The special architecture of the EspR homotetramer 
also allows it to perform long range interactions with other transcriptional regulators and 
RNA polymerase to alter the transcription of the espACD operon (Rosenberg et al., 2011). A 
global screen for the binding sites of EspR in the M. tuberculosis genome revealed 165 loci 
which includes the espACD operon, EspR itself, the ESX-2 and ESX-5 gene clusters, genes 
associated with the biosynthesis of cell wall lipids PDIM, and PE PPE cell surface proteins 
(Blasco et al., 2012). The fact that the binding sites of EspR are not restricted to promoter 
regions, together with its long range interaction with multiple genomic regions, implies that 
this protein acts as a global nucleoid-associated protein (NAP) in addition to its role as a gene 
regulator (Blasco et al., 2012). Deleting EspR attenuates the pathogen not only by disabling 
ESX-1, but also other virulence determinants such as cell wall biosynthesis machineries, 
which are under the regulation of EspR (Blasco et al., 2012). 
 
In addition, the espACD operon is negatively regulated by four other transcriptional 
regulators. MprAB and PhoRP derepress the operon in a similar fashion when the integrity of 
the cell envelope is compromised (Pang et al., 2013, 2007; Walters et al., 2006). The espACD 
operon is under the regulation of one CRP (cAMP Receptor Protein), indicating that the 
intracellular cAMP concentration may also affect the virulence of the bacteria (Rickman et al., 
2005). Another NAP, Lsr2, which is the part of the global regulation allowing the pathogen to 
enter latent state, is up-regulated and activated when M. tuberculosis is in a hostile host 
environment, thereby repressing the espACD operon (Gordon et al., 2010).   
 




The regulations of other ESXs are not well studied. For ESX-3, the gene regulation is 
described in detail in Chapter 3.  
 
2.7 ESX-1, Apoptosis and Bacterial Spread 
 
In both M. tuberculosis and M. marinum, disrupting the functions of the ESX-1 membrane 
core components or some major substrates such as EsxA, EspB and EspK prevents the 
pathogen from migrating between host macrophages (Gao et al., 2004; Guinn et al., 2004). 
Intercellular migration is enabled by the induction of macrophage apoptosis which is 
essentially an ESX-1-dependent process (Abdallah et al., 2011; Aguilo et al., 2013; Derrick 
and Morris, 2007; D. Houben et al., 2012; Smith et al., 2008). Phagosomal escape and the 
apoptosis of macrophages were only observed with pathogenic mycobacteria, and not with 
saprophytic M. smegmatis although it also contains an ESX-1 (Aguilo et al., 2013; D. 
Houben et al., 2012). EsxA (ESAT-6) may be the effector protein facilitating the pore-
formation process (Smith et al., 2008). Although none of the ESX-5 substrates is involved, 
both ESX-1 and ESX-5 may contribute to the necrosis of the host cells (Abdallah et al., 2011). 
The more capable the pathogenic mycobacteria are to secrete EsxA, the more likely they are 
to induce apoptosis in the host cells, as EsxA exerts different effects on the membrane at 
different concentrations. A low concentration EsxA causes pores to form, while a high 
concentration of 2 to 5 μg/ml may be apoptotic (Aguilo et al., 2013; Derrick and Morris, 
2007). Apparently apoptosis has been adopted by pathogenic mycobacteria as an efficient and 
safe colonization mechanism, as it allows them to find a new niche without being discovered 






Mycobacterium tuberculosis causes tuberculosis in humans, treatment of which is prolonged 
and sometimes ineffective due to factors such as drug resistance and non-compliance etc.. 
New drug targets are needed to facilitate the treatment. Type VII secretion systems play 
essential and diverse roles in the virulence and physiology of M. tuberculosis and they 
provide attractive targets for drug development. However, the substrates of T7SS are still 
largely unidentified and the downstream possible molecular interactions between these 
secreted substrates and proteins from human macrophages are also not well documented. A 
thorough investigation of the functionality of these special secretion systems is of great 
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Chapter 3. Mycobacterial Strategies for 
Acquiring Scarce Iron 
3.1 Introduction 
 
Mycobacteria, like most other living organisms, require iron for many vital functions. Iron 
forms the essential catalytic centre of the active site of various enzymes enabling enzymatic 
reactions. The ability of iron to receive and donate an electron thereby oscillating between the 
ferrous (Fe
2+
) and ferric (Fe
3+
) oxidative states enables the enzyme to catalyse redox reactions. 
For this reason, iron is often associated with cytochromes responsible for oxidative 
phosphorylation and energy production (Banerjee et al., 2011). Iron-sulfur clusters are 
essential cofactors of many enzymes involved in amino acid and pyrimidine biogenesis, the 
tricarboxylic acid cycle as well as electron transport (Saini et al., 2012). Iron is one of the 
most abundant elements on earth, however, under the earth’s oxidizing environment at 
physiological pH, iron exists predominantly as insoluble ferric salts such as iron oxide, iron 
hydroxide and iron phosphate which cannot be assimilated by bacteria. Free iron ions are 
therefore scarce. Iron acquisition is even more challenging for pathogenic bacteria because 
iron ions are bound to host iron-binding proteins, such as transferrin and lactoferrin which 
serve as host iron transporters, the iron storage protein ferritin and protoporphyrins in heme 
and hemoproteins (Weinberg, 1984). During infection, the host restricts the amount of 
circulating transferrin-bound iron in the body and reduces the uptake of dietary iron utilising 
iron-deprivation as a host anti-microbial defense mechanism (Frederick et al., 2009; 
Kontoghiorghes and Weinberg, 1995; Ratledge, 2004). Pathogenic mycobacteria are, 
however, able to cause disease despite the severely iron limited host environment. To 
overcome iron-deprivation mycobacterial pathogens have evolved iron acquiring machineries 
which are more efficient than those of their vertebrate hosts. In this review, the strategies 
mycobacteria use to access iron and the iron-dependent gene regulation responsible for the 
maintenance of iron homeostasis in mycobacteria are discussed. Additionally, a brief opinion 
is given regarding the selection of iron acquisition machineries as drug targets.  
3.2 Siderophore-mediated Iron Acquisition 
 
A major mechanism employed by mycobacteria to compete for the limited available iron is 
the use of high affinity iron chelators, siderophores, which are predominantly produced 
during iron deprivation (De Voss et al., 1999). There are three types of siderophores, 
mycobactin, carboxymycobactin and exochelin, where mycobactin and carboxymycobactin 
share a core structure which is distinct from exochelin. Mycobactin is cell envelope-
associated and facilitates the transport of iron through the cell envelope into the cytoplasm 
while carboxymycobactin and exochelin are secreted iron-chelators which acquire iron in the 




extracellular milieu and transport iron into the cytoplasm of the bacteria (De Voss et al., 
1999). 
 
3.2.1 The siderophores: Mycobactin, carboxymycobactin and exochelin 
 
Mycobactins can be isolated from almost all mycobacterial species except M. microti 
(Barclay and Ratledge, 1988), M. paratuberculosis, and M. vaccae (Messenger et al., 1986). 
They have a core structure comprising 5 amino acids with a characteristic phenyloxazolidine 
ring derived from salicylate with saturated or unsaturated alkyl side chains of various lengths 
on the hydroxylated lysine residue at the centre of the molecule (Barclay et al., 1985) (Figure 
3.1 and Figure 3.2a). The long alkyl chain confers the lipophilic property of mycobactin and 




Figure 3.1. The general structure of mycobactin from M. tuberculosis. The structure consists 
of 5 amino acids including one salicylic acid, one serine, two lysines, and one 3-
hydroxybutyric acid. A long alkyl chain extends from the side chain of the middle lysine 
residue where the length of the R-group may vary amongst the mycobacteria species. The 
asterisk (*) indicates the chelating group for the ferric ion binding. (Ratledge, 2004) 
 
  
Early studies created confusion by using the term “exochelin” to describe all extracellular 
siderophores isolated from both saprophytic and pathogenic mycobacteria. This became 
inappropriate when “exochelin” from pathogenic mycobacteria was found to have a different 
core structure from that of saprophytic mycobacteria. The former has a core structure similar 
to that of mycobactin, but with shorter alkyl side chains that terminate with either a carboxyl 
group or a methyl ester (Figure 3.2b) (Gobin et al., 1995; Wong et al., 1996). This feature 




makes these “exochelin” molecules more hydrophilic than the lipophilic mycobactins. These 
molecules were renamed carboxymycobactin (Ratledge and Ewing, 1996), although less 









Figure 3.2. Examples of mycobacterial siderophores. M. tuberculosis mycobactin (a) and 
carboxymycobactin (exomycobactin) structures contain a typical phenyloxazolidine ring (b); 
The difference between the two molecules is that the N-acyl chain on the hydroxylated lysine 
is a 19-carbon alkyl group (a) while that of carboxymycobactin is a 6-carbon alkyl group 
coupled with a carboxylic acid (b) (De Voss et al., 2000). M. smegmatis exochelin structure 
containing 5 amino acids connected with 2 unusual peptide bonds (c). (De Voss et al., 1999) 
 
 
The extracellular siderophores from saprophytic mycobacteria retained the name exochelin. 
This water-soluble molecule has a different core structure to mycobactin/carboxymycobactin. 
consisting of a formylated pentapeptide: N-(δ-N-formayl, δ-N-hydroxy-R-ornithyl)-βalaninyl-
δ-N-hydroxy-R-ornithinyl-R-allo-threoninyl-δ-N-hydroxy-S-ornithine (Figure 3.2c) (Sharman 
et al., 1995a). The two peptide bonds within the molecule are atypical making them resistant 
to peptidase hydrolysis. The structure of exochelin varies in some mycobacterial species, e.g. 




in M. neoaurum exochelin is a hexapeptide with an unusual β-hydroxyhistidine residue 
(Sharman et al., 1995b).  
 
Carboxymycobactin was thought to be exclusive to pathogenic mycobacteria until it was 
found to comprise about 5% of the total siderophore content in M. smegmatis (Ratledge and 
Ewing, 1996). The coexistence of carboxymycobactin and exochelin in M. smegmatis further 
assisted in resolving the historical confusion between the two siderophores. The difference in 
core structure of mycobactin/carboxymycobactin and exochelin necessitates distinctive 
biosynthetic pathways and transport mechanisms for the two unrelated siderophores. The 
identification of the two biosynthetic pathways further clarified the distinction between the 
two types of siderophores. The machinery for mycobactin biosynthesis is encoded in two 
gene clusters, mbtA-J (Quadri et al., 1998) and mbtK-N (Krithika et al., 2006) in both M. 
tuberculosis and M. smegmatis. The enzymes responsible for exochelin biosynthesis are 
encoded by fxbA, fxbB and fxbC genes in M. smegmatis (Fiss et al., 1994; Yu et al., 1998; 
Zhu et al., 1998). The biosynthetic pathways of the mycobactin (Madigan et al., 2012; 
McMahon et al., 2012) and exochelin (Zhu et al., 1998) are described in detail elsewhere.  
 
3.2.2 Siderophore transport 
 
The import and export of the secreted siderophores, carboxymycobactin and exochelin 
utilises unique mechanisms and machineries. Carboxymycobactin transport is dominant in 
pathogenic mycobacteria while exochelin transport is more important in saprophytic species. 
 
3.2.2.1 Carboxymycobactin transport  
 
Hydrophilic deferri-carboxymycobactin is secreted into the extracellular milieu to acquire 
iron from the environment, and presumably the host transferrin (Gobin et al., 1995) and at a 
slower rate, ferritin (Gobin and Horwitz, 1996). The ferri-carboxymycobactin is transported 
back through the mycobacterial outer membrane via the Msp family of porins (Jones and 
Niederweis, 2010). The Msp porins are abundant membrane proteins which allow a variety of 
nutrients to enter the cell by non-specific diffusion (Jones and Niederweis, 2010; Ojha and 
Hatfull, 2007).  
 
In the mycobacterial periplasmic space, ferri-carboxymycobactin either transfers its iron to 
the cell-wall associated mycobactin or delivers it to the plasma membrane-bound protein 
complex, IrtAB (iron-regulated transporter A and B, Rv1348 and Rv1349) (Rodriguez and 
Smith, 2006). IrtA and IrtB are ABC transporters, which are homologues of the YbtPQ 
system involved in iron transport in Yersinia pestis (Fetherston et al., 1999). Inactivation of 
this gene pair impairs the utilization of ferri-carboxymycobactin and affects the optimal 
growth of M. tuberculosis under low iron conditions but does not abolish the production and 
secretion of the siderophores (Rodriguez and Smith, 2006). It has been proposed that IrtA 
possesses the dual function of iron import and ferric iron reduction. It is thought to release the 




bound iron in the ferrous form, possibly due to the reductase role of its FAD-binding domain 
(Ryndak et al., 2010). However, this activity was not obtained in vitro, possibly because 
other components are also required to assist in this role (Ryndak et al., 2010). A possible 
candidate is ViuB (Rv2895c), whose homologue in Vibrio cholera encodes a cytosolic 
protein required for the utilization of ferric-vibriobactin (Butterton and Calderwood, 1994). 
ViuB forms a complex with IrtB (Farhana et al., 2008), but is not essential for iron 
acquisition (Santhanagopalan and Rodriguez, 2012). Whether ViuB is involved in 
siderophore import remains unclear. 
 
After releasing the bound iron, deferri-carboxymycobactin may either be degraded or 
secreted again to acquire more iron. Siderophore catabolism has been relatively neglected in 
the literature whereas siderophore secretion has been well described. The carboxymycobactin 
export system was shown to be the membrane complex of MmpL5/MmpS5 and 
MmpL4/MmpS4 (Wells et al., 2013). The MmpS4/S5 double mutant showed an iron 
starvation phenotype under high iron conditions in which the uptake of carboxymycobactin 
was not affected but the siderophore biosynthesis and secretion were strongly impaired 
indicating that MmpS4/S5 is directly involved in mycobactin/carboxymycobactin export.  
 
3.2.2.2 Exochelin transport  
 
Exochelin transport has not been well characterized in mycobacteria (Figure 3.3). The 
deferri-exochelin may be exported by an ABC transporter protein, ExiT, encoded in the same 
operon as the exochelin synthetase genes fxbB and fxbC (Yu et al., 1998; Zhu et al., 1998). 
ExiT appears to be involved in both the biosynthesis and export of exochelin, directly 
coupling these processes (Zhu et al., 1998). After binding extracellular iron, ferri-exochelin is 
recognized by some unknown receptors on the outer membrane and imported into the 
periplasmic space (Jones and Niederweis, 2010). There, ferri-exochelin may associate with 
FxuD, the ferri-exochelin carrier, and either transfer the iron to mycobactin or to the ferric-
exochelin importer membrane complex formed by FxuA, FxuB, and FxuC. FxuA, FxuB and 
FuxC are homologues of FepG, FepC and FepD which form the membrane-bound permease 
which is responsible for the uptake of the siderophore ferrienterobactin in Escherichia coli 
(Fiss et al., 1994). In the cytoplasm, exochelin-bound ferric iron is reduced to ferrous iron by 
















Figure 3.3. Exochelin import and export in M. smegmatis (adapted from Ratledge, 2004). The 
ferri-exochelin gets recognized by an unknown protein (indicated with a “?”) on the outer 
membrane and delivered to FxuA-B-C complex on the plasma membrane while coupled with 
FxuD. While in the cell envelope, ferri-exochelin may transfer the iron to mycobactin on the 
membrane. Once ferri-exochelin are imported into the cytoplasm, the ferric iron gets reduced 
by unidentified reductase and released for utilization. The deferri-exochelin is transported out 
of the cell via ExiT. (Fiss et al., 1994; Yu et al., 1998; Zhu et al., 1998) 
 
3.3 Heme Transport and Its Metabolism in Mycobacteria 
 
Wells and colleagues used heme as the alternative iron source to successfully rescue their M. 
tuberculosis mutants in which the mycobactin biosynthetic pathway was disabled under low 
iron conditions (Wells et al., 2013). Heme is the iron-containing prosthetic group in the 
hemoglobin molecules which are abundant in erythrocytes. Iron binds to the oxygen molecule 
allowing erythrocytes to carry and supply oxygen for cellular respiration in the vertebrate’s 
body where two thirds of iron is in the heme-bound state. Heme is therefore a reservoir of 




iron for many pathogenic bacteria and their heme acquisition systems have been well 
described (Cescau et al., 2007; Wandersman and Delepelaire, 2004; Wilks and Burkhard, 
2007). M. tuberculosis may encounter heme or heme-containing protein both intracellularly 
and extracellularly during infection. Erythrocytes are degraded in the phagosomes of 
macrophages resulting in heme release (Ganz, 2012; Soe-Lin et al., 2009), exposing M. 
tuberculosis residing in the phagosome directly to the heme. Extracellular M. tuberculosis 
may access hemoglobin in the bloodstream where hemolysins produced by M. tuberculosis 
facilitate the release of hemoglobin from the red blood cells (Deshpande et al., 1997; Rahman 
et al., 2010). Many studies have demonstrated the ability of M. tuberculosis to utilize heme as 
an iron source in low iron culture media (Jones and Niederweis, 2011; Raghu et al., 1993; 
Tullius et al., 2011). 
 
The gene cluster Rv0201c-Rv0207c was shown to be responsible for heme acquisition in M. 
tuberculosis. Rv0203 is a secreted hemophore which has similar a heme binding affinity to its 
orthologues in some gram-negative bacteria (Owens et al., 2012; Tullius et al., 2011). 
Rv0202c (MmpL11) and Rv0206c (MmpL3) are transmembrane heme importers (Figure 3.4). 
Rv0203 is secreted via an unidentified mechanism and acquires heme from hemoglobin, 
transports it across the outer membrane and delivers to the extracellular domain (E1) of either 
MmpL11 and MmpL3 (Owens et al., 2012). Inside M. tuberculosis, the heme can either be 
degraded to release iron to be incorporated into other metabolic enzymes or utilized directly 
for the synthesis of heme-containing enzymes. Heme degradation is catalysed by heme 
oxygenase (HO) in a well characterized process in which heme is broken down to biliverdin, 
releasing carbon monoxide (CO) and iron ions (Wandersman and Stojiljkovic, 2000). The 
HO orthologue in M. tuberculosis, MhuD (Mycobacterial heme utilization Degrader, 
Rv3592), however, degrades heme to mycobilin without generating CO. As CO induces M. 
tuberculosis to enter dormant state (Voskuil et al., 2003), this particular heme degradation 
mechanism does not interfere with the CO sensing of the bacteria in the host environment 
(Nambu et al., 2013). As MhuD is able to bind to two heme molecules in its inactive state, it 
may serve as an additional heme storage molecule (Chim et al., 2010). 
 
Although M. tuberculosis favours heme as an iron source, it expresses a heme biosynthetic 
enzyme, ferrochelatase, encoded by hemZ (Rv1485). This protein contains a [2Fe-2S] cluster 
and catalyzes the last step of heme biosynthesis in which ferrous iron is inserted into 
protoporthyrin IX to form protoheme (Dailey and Dailey, 2002). This gene is essential in 
vitro implying that heme is not only used as an iron source by M. tuberculosis but is also an 
essential cofactor for some metabolic enzymes (Parish et al., 2005). For example, the 
catalase-peroxidase (KatG) and the DosS/DosT redox sensing two component system 
proteins contain heme in their active sites (Svistunenko, 2005). M. tuberculosis and other 
mycobacteria may utilise iron imported via the siderophore-mediated iron acquisition system 
to produce heme to synthesize these enzymes. 
 
It is interesting that addition of heme to the low iron media could not rescue the MmpS4/S5 
double mutant, in which the mycobactin export was destroyed, unless the siderophore 
biosynthesis pathway was also disabled (Wells et al., 2013). This implies that the intracellular 




accumulation of carboxymycobactin/mycobactin exerts a toxic effect on the bacteria perhaps 
by removing irons from the bacteria’s own iron-containing proteins or from imported heme. 
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Figure 3.4. Relationships between iron acquisition, heme acquisition, siderophore export and 
the ESX-3 secretion system. It is currently thought that mycobacteria possess transport 
systems that may acquire iron from two types of iron source, one from transferrin and the 
other one from heme. Carboxymycobactin acquires iron from the host transferrin and gets 
recognized by Msp family porins on the outer membrane and imported to the periplasmic 
space where they either deliver the iron to the cell envelope associated mycobactin or to the 
importer protein complex IrtA and IrtB. IrtA contains an intracellularly-located FAD domain 
which might perform reductase function releasing ferrous iron from carboxymycobactin. The 
deferri-carboxymycobactin gets exported through MmpL5/4 MmpS5/4 siderophore export 
complex and acquires more iron if necessary. Mycobacteria release heme-binding protein 
Rv0203 which acquires heme from hemoproteins in the host and delivers the heme to the 
heme importers, MmpL11 and MmpL3. Once inside the bacteria, heme either gets degraded 
to release iron by MhuD or utilized by bacterial heme-binding proteins such as katG, DosT 
and DosS. Heme can also be synthesized by mycobacteria via the ferrochelatase HemZ, 
which catalyzes the addition of iron to protophorphyrin IX to form protoheme. The iron and 
heme acquisition processes are enabled by the ESX-3 components or their substrates. The 
detailed roles played by ESX-3 on these processes are to be investigated. 
 
  




3.4 The role of ESX-3 in siderophore and heme transport 
 
M. tuberculosis contains five copies of the Type VII protein secretion system, namely ESX-
1- to -5 (Abdallah et al., 2007; Gey van Pittius et al., 2001). ESX-1 and ESX-5 are involved 
in virulence in pathogenic mycobacteria (Abdallah et al., 2008, p. -5; Banu et al., 2002; Hsu 
et al., 2003; Lewis et al., 2003; Pym et al., 2002b). ESX-3 has shown to be involved in the 
acquisition of iron from the mycobactin-mediated iron acquisition pathway, but not the 
exochelin pathway in M. smegmatis (Siegrist et al., 2009). In M. tuberculosis, ESX-3 is 
essential for in vitro growth (Griffin et al., 2011; Sassetti et al., 2003). The growth defect of 
the M. tuberculosis conditional ESX-3 knock-out strain in 7H9 was only rescued by the 
addition of extremely high concentrations of iron and zinc (Serafini et al., 2009). This implies 
that alternative iron acquisition systems exist in M. tuberculosis and sustain the bacteria with 
a basal iron supply. The transcriptional profile of the M. tuberculosis ESX-3 conditional 
mutant resembles that of iron starvation even under these high iron conditions (Serafini et al., 
2013). Repression of ESX-3 expression has a negative effect on iron import, but ESX-3 is not 
directly responsible for iron uptake. This suggests that ESX-3 may participate in iron uptake 
by allowing the modification and secretion of unidentified factors which assist in iron 
acquisition, as suggested by the survival of the ESX-3 conditional mutant in the culture 
supernatant of wildtype M. tuberculosis (Serafini et al., 2009). Alternatively ESX-3 may 
modify the M. tuberculosis cell membrane surface composition, thereby facilitating the 
import of ferri-carboxymycobactin (Serafini et al., 2009) (Figure 3.4).  
 
ESX-3 also appears to influence the heme uptake pathway in M. tuberculosis. Heme 
supplementation could not rescue the M. tuberculosis ESX-3 conditional mutant under low 
iron conditions (Serafini et al., 2013). As the heme uptake pathway has been well 
characterized (Tullius et al., 2011), ESX-3 is not directly involved in heme uptake, but may 
play a similar supportive role as observed for mycobactin-mediated iron acquisition where 
ESX-3 may modify and secrete unknown factors which are essential for iron and heme 
acquisition in M. tuberculosis. Further characterisation of the role of ESX-3 in both iron and 
heme acquisition is of great significance due to the essential nature of these processes. 
 
 
3.5 Iron-dependent gene regulation 
 
Mycobacteria utilise elaborate molecular mechanisms to maintain iron homeostasis. Iron 
acquisition mechanisms are activated in response to low intracellular iron levels to acquire 
iron from the environment. When there is sufficient intracellular iron, excess iron is stored to 
prevent it from participating in the Fenton reaction, which would generate harmful hydroxyl 
radicals (Rodriguez, 2006). Mycobacteria have developed complex gene regulation 
mechanisms which respond to different iron levels to maintain iron homeostasis. 
 




The iron dependent regulator, IdeR, of M. tuberculosis was identified based on homology to 
the Diphtheria Toxin Repressor (DtxR), an iron-dependent gene expression regulator in 
Corynebacterium diphtheria. IdeR is essential in M. tuberculosis in vitro (Pandey and 
Rodriguez, 2014; Rodriguez et al., 2002). Abolishing the iron-responsive regulator leads to 
attenuation of M. tuberculosis in macrophages and the mouse model (Pandey and Rodriguez, 
2014). IdeR binding sites have been identified throughout the M. tuberculosis H37Rv genome 
(Gold et al., 2001; Rodriguez et al., 1999). The expression of 153 M. tuberculosis genes is 
regulated in response to iron concentration and 44 of these genes are regulated directly by 
IdeR (See examples in Table 3.1 and Table 3.2). 
 
Of the 40 genes that are repressed by IdeR in high iron conditions, 32 encode proteins 
involved in three iron acquisition related processes: 1. Iron acquisition including the ESX-3 
secretion system and the siderophore import transmembrane protein pair IrtA/IrtB; 2. 
Siderophore biosynthesis; and 3. Siderophore export, MmpL4/S4 (Rodriguez et al., 2002) 
(Table 3.1). The expression of four genes is induced by IdeR under high iron levels, two of 
which encode the iron storage bacterioferritin proteins (bfrA and bfrB). The same 
transcriptional response was observed in M. tuberculosis infected macrophages implying that 
the macrophage presents an iron-deprived condition (Gold et al., 2001). Similarly in M. 
smegmatis, under high iron conditions, IdeR negatively regulates the expression of fxbA, 
which encodes a formyltransferase which is essential in the exochelin biosynthetic pathway 
(Dussurget et al., 1999). Mycobacteria therefore respond to high iron levels by inhibiting the 
expression of the iron acquisition and transport machineries while increasing the production 
of iron storage proteins. These activities show that mycobacteria maintain iron homeostasis 
by preventing excessive iron uptake which could cause oxidative damage and storing excess 
intracellular iron for future use. 
 
Many M. tuberculosis genes were found to be regulated by iron independently of IdeR. 
Expression of 26 genes was repressed, and 23 induced, by a high iron concentration. These 
genes are involved in a variety of cellular functions, including carbohydrate metabolism, lipid 
metabolism, energy metabolism, cofactor biosynthesis, aerobic growth, transcriptional 
regulation, iron transport, and toxin-antitoxin systems (Table 3.2). Of the genes involved in 
iron acquisition related processes, the expression of mmpL5 and mmpS5 is repressed under 
high iron conditions, consistent with the other components of the siderophore export system, 
MmpL4 and MmpS4. Interestingly these four genes are not within the same IdeR regulon 
which may indicate that M. tuberculosis also utilises alternative iron regulators.  
 
One substrate of ESX-1, EspD, is also repressed under high iron condition. EspD might play 
a role in facilitating the secretion of other ESX-1 substrates thereby enhancing the virulence 
of M. tuberculosis (Chen et al., 2012), so the iron-deprived environment in macrophages 
possibly enables the functionality of ESX-1. The gene, ethA, encoding a monooxygenase 
which activates the anti-TB drug ethionamide, was also induced under low-iron condition. 
The effectiveness of this drug may correlate with different iron concentrations. Sufficient iron 
in the culture media allows the bacteria to synthesize iron-sulfur cluster-containing metabolic 




enzymes including NADH dehydrogenase (Vinogradov, 2001), so the transcription of this 
gene cluster is induced (nuoA-D, nuoH-I, and nuoK-N). 
 
 
Table 3.1 Genes that are regulated (repressed/induced) by IdeR under high iron condition, 






Regulation Gene product Function 
0116c ldtA Repressed Probable L,D-
transpeptidase LdtA 
It catalyzes the formation of 3->3 
crosslinks between peptidoglycan 
subunits in peptidoglycan 
biosynthesis 
0282 eccA3 AAA+ ATPase These genes encode ESX-3, a 
TypeVII secretion system, which 
might be involved in mycobactin-
mediated iron acquisition (Siegrist et 
al., 2009), where eccB3, eccC3, 
eccD3 and eccE3 form the 
membrane-bound secretion 
machinery (Houben et al., 2012); 
esxG, esxH, PE5 and espG3 might be 
the secretion substrates for this 
secretion system. EccA is the 
ATPase and recruiter for the 
substrates before secretion (Joshi et 
al., 2012)  
0283 eccB3 Transmembrane 
protein (1 TM) 
0284 eccC3 FtsK/SpoIIIE-like 
transmembrane 
protein (1-3 TMs) 
0285 pe5 PE subfamily 
protein 
0286 ppe4 PPE subfamily 
protein 
0287 esxG esx family protein, 
CFP-10 like 
0288 esxH esx family protein, 
ESAT-6 like 
0289 espG3 ESX secretion 
protein 3 
0290 eccD3 Transmembrane 
protein (10-11 
TMs) 
0291 mycP3 Mycosin-3, 
subtilisin-like serine 
protease 
0292 eccE3 Transmembrane 
protein (2 TMs) 
0766c cyp123 Probable 
cytochrome 
P450 123, Cyp123 
Heme-thiolate monooxygenases. It 
may oxidize a variety of structurally 
unrelated compounds, including 
steroids, fatty acids and xenobiotics. 




Together with MmpL5 and MmpS5, 
the four protein constitute a 
membrane-bound protein complex 
which is responsible for siderophore 
export, maintaining iron homeostasis 
within the bacteria (Wells et al., 
2013) 
0451c mmpS4 Probable conserved 
transmembrane 
transport protein 














Regulation Gene Product Function 
1343c lprD Repressed Probable conserved 
lipoprotein LprD 
Unknown 
1344 mbtL Acyl carrier protein 
MbtL 
Involved in the mycobactin 




AMP ligase MbtM 
Involved in the mycobactin 
biogenesis (LaMarca et al., 2004) It 
activates the acyl chain and transfer it 
to holo-MbtL to form covalently 






It catalyzes the double bond 
formation in the fatty –acyl moiety of 
mycobactin (Krithika et al., 2006; 
Quadri et al., 1998) 
1347c mbtK Lysine N-
acetyltransferase 
MbtK 
Involved in the mycobactin 
biogenesis (Card et al., 2005) where 
it catalyzes the transfer of a variety of 
aliphatic chains from mbtL onto the 
ε-amino group of lysine residue on 
mycobactin skeleton (Krithika et al., 
2006). It prefers long acyl chain-CoA 
substrates (Frankel and Blanchard, 
2008) 
1348 IrtA Iron-regulated 
transporter IrtA 
Together, IrtA and IrtB form 
complex on the plasma membrane, 
involved in the transport of Fe-
carboxymycobactin (Rodriguez and 
Smith, 2006) 
1349 IrtB Iron-regulated 
transporter IrtB 






Involved in histidine biosynthesis 
2123 ppe37 PPE family protein 
PPE37 
Function unknown 
2377c mbtH Putative conserved 
protein mbtH 
It stimulates amino acid adenylation 
steps catalysed by the non-ribosomal 
peptide synthetase (Felnagle et al., 
2010) 




Required for N6-hydroxylation of the 
two lysine residues during 
mycobactin assembly, cell membrane 
associated indicating a connection 




between siderophore biosynthesis 
and export (Wells et al., 2013) 
2379c mbtF Peptide synthetase 
MbtF 
Possibly activate the two lysine 
residues before incorporated into 





Regulation Gene Product Function 
2381c mbtD Repressed Polyketide 
synthetase MbtD 
 
2382c mbtC Polyketide 
synthetase MbtC 
 
2383c mbtB Phenyloxazoline 
synthase MbtB 
It catalyzes the amide bond formation 
between the carboxylic acid of 
salicylate and the α-amino group of 
serine in the mycobactin biosynthesis 





It catalyzes the initiation step of 
mycobactin synthesis where it 
activates the salicylic acid as 
acyladenylate and transfers it to the 





Required for N-hydroxylation of the 
two lysine residues during 
mycobactin assembly 
2386c mbtI Salicylate synthase 
MbtI 
It catalyzes the initial transformation 
in mycobactin biosynthesis by 
converting chorismate to salicylate 
(Harrison et al., 2006)(Zwahlen et 
al., 2007) 
3402c  Conserved 
hypothetical protein 
Function unknown 
3403c  Hypothetical 
protein 
Function unknown 
3839  Conserved 
hypothetical protein 
Function unknown 
3840  Possible 
transcriptional 
regulatory protein 
Involved in transcriptional 
mechanism 




It catalyzes the folding of the 
proteins, in particular cis-trans 
isomerization of proline imidic 
peptide bonds in oligopeptides 
0338c  Probable iron sulfur 
binding reductase 
Function unknown 
1876 bfrA Probable 
bacterioferritin 
BfrA 
Involved in iron storage 
3841 bftB Bacterioferritin 
BfrB 
 




Table 3.2. Genes that are regulated (repressed/induced) independent from IdeR under high 







Regulation Gene Product Function 
0279c PE_PGRS4 Repressed PE_PGRS family 
protein PE_PGRS4 
Unknown 
0464c   Conserved hypothetical 
protein 
Unknown 
0465c   Probable 
transcriptional 
regulatory protein 
Possibly involved in 
transcriptional mechanism 
0467 icl1  Isocitrate lyase Involved in glyoxylate bypass, 
an alternative to the TCA cycle 




Together with MmpL4 and 
MmpS4, the four protein 
constitute a membrane-bound 
protein complex which is 
responsible for siderophore 
export, maintaining iron 
homeostasis within the bacteria 
(Wells et al., 2013) 




0692   Conserved hypothetical 
protein 
Unknown 
0693 pqqE  Probable coenzyme 
PQQ (pyrroloquinoline 
quinone) synthesis 
protein E, PqqE 
Required for coenzyme PQQ 
biosynthesis 
0694 lldD1  Possible L-lactate 
dehydrogenase, LldD1 
Catalyze conversion of lactate 
into pyruvate in cellular 
respiration 
1169c lipX  PE family protein, 
possible lipase, LipX 
Unknown 
1184c   Possible exported 
protein 
Unknown 
1195   PE family protein, 
PE13 
Unknown 
1393c   Probable 
monoxygenase 
Unknown 
1461   Conserved hypothetical 
protein 
Unknown 
1462   Conserved hypothetical 
protein 
Unknown 
1463   Probable conserved 
ATP-binding protein 
ABC transporter 
Involved in active transport 
across the membrane. 
Responsible for energy 
coupling to the transport system 








Regulation Gene Product Function 
1464 csd Repressed Probable cysteine 
desulfurase, Csd 
Catalyze the removal of 
elemental sulfur and selenium 
atoms from L-cysteine, L-
cystine, L-selenocysteine, and 
L-selenocystine to produce L-
alanine 
1465  Possible nitrogen 
fixation related protein 
Unknown 
1466  Conserved hypothetical 
protein 
Unknown 
1520  Probable sugar 
transferase 
Unknown 
2621c  Possible transcriptional 
regulatory protein 
Involved in transcriptional 
mechanism 
2794c pptT Phosphopantetheinyl 
transferase PptT 
Involved in biosynthesis of fatty 
acid and lipids. It transfers the 
4’-phosphopantetheine moiety 
from coenzyme A to a SER of 
acyl-carrier protein. It catalyzes 
the formation of holo-ACP, 
which mediates transfer of acyl 
fatty-acid intermediates during 
the biosynthesis of fatty acids 
and lipids. 
3229c desA3 Possible linoleoyl-CoA 
desaturase 
Involved in lipid metabolism 
3230c  Hypothetical 
oxidoreductase 
Unknown 
3614c espD ESX-1 secreted protein 
EspD 
Stabilise EspA and EspC for 
their secretion but itself is not 
secreted by ESX-1 (Chen et al., 
2012) 
3854c ethA Monooxygenase, EthA It activates the pro-drug 
ethionamide (ETH); it induces 
ETH sensitivity when 
overexpressed in M. 
tuberculosis 
0706 rplV Induced 50S ribosomal protein 
L22, RplV 
It binds to 23S rRNA, important 
during early stages of 50S 
reconsititution 
1252c lprE Probable lipoprotein, 
LprE 
Unknown 
1305 atpE Probable ATP synthase 
C chain 
It is one of the three chains of 
the nonenzymatic component of 
the ATPase complex 
1908c katG Catalase-peroxidase-
peroxynitritase T, 
It exhibits both a catalase, a 
broad-spectrum peroxidase, and 









Regulation Gene Product Function 
1943c mazE5 Induced Possible antitoxin 
MazE5 
Signal programmed cell death 
pathway (Engelberg-Kulka et 
al., 2005) 
2526 vapB17 Possible antitoxin 
VapB17 
Unknown 
2549c vapC20 Possible toxin, 
VapC20 
Unknown 








2927c  Conserved hypothetical 
protein 
Unknown 
3075c  Conserved hypothetical 
protein 
Unknown 
3145 nuoA Probable NADH 
dehydrogenase I, Chain 
A 
Involved in aerobic/anaerobic 
respiration, reaction: NADH + 
ubiquinone = NAD(+) + 
ubiquinol. Those enzymes 
contain iron-sulfur clusters 
(Vinogradov, 2001) 
3146 nuoB Probable NADH 
dehydrogenase I, Chain 
B 
3147 nuoC Probable NADH 
dehydrogenase I, Chain 
C 
3148 nuoD Probable NADH 
dehydrogenase I, Chain 
D 
3152 nuoH Probable NADH 
dehydrogenase I, Chain 
H 
3153 nuoI Probable NADH 
dehydrogenase I, Chain 
I 
3155 nuoK Probable NADH 
dehydrogenase I, Chain 
K 
3156 nuoL Probable NADH 
dehydrogenase I, Chain 
L 
3157 nuoK Probable NADH 
dehydrogenase I, Chain 
M 
3158 nuoN Probable NADH 
dehydrogenase I, Chain 
N 
3246 mtrA Two component Transcriptional activator part of 








a two component regulatory 
system 




3.6 Iron and heme acquisition-centred drug target discovery 
 
Mycobacteria cannot survive without iron; a malfunctioning iron acquisition pathway causes 
a growth defect in vitro and in macrophages, and attenuates M. tuberculosis in mouse model 
(Rodriguez and Smith, 2006; Serafini et al., 2013; Siegrist et al., 2009; Wells et al., 2013). 
Intervention strategies targeting siderophore-mediated iron acquisition could be effective 
because this pathway is not only essential in M. tuberculosis but also is absent from the 
human host. Acyl sulfamoyl adenosine (acyl-AMS), an inhibitor to one mycobactin 
biosynthesis enzyme, MbtA, has been synthesized and proven to be effective in abolishing 
the pathway under low iron conditions in vitro (Ferreras et al., 2005). However, as 
mycobacteria are also able to acquire iron from heme, an abundant iron source in the host, 
this may compensate the loss of the siderophore-mediated iron acquisition pathway. This 
approach may therefore not be successful in vivo unless heme acquisition is targeted at the 
same time. Drugs which target or disable both pathways would be potentially therapeutic. 
MmpS5/S4 is a promising candidate, as disrupting this complex would not only abolish the 
siderophore-mediated iron acquisition and recycling of the siderophores, but would also 
cause intracellular siderophore accumulation, disrupting heme utilization as previously 
described where heme could not rescue the MmpS5/S4 mutant (Jones et al., 2014; Wells et 
al., 2013). MmpL3 is another candidate which is essential for cell viability in vitro 
(Domenech et al., 2005). Abolishing MmpL3 may impair trehalose monomycolate export 
preventing proper assembly of the mycobacterial cell wall (Tahlan et al., 2012) and certainly 
heme uptake (Tullius et al., 2011). Two anti-TB drugs, SQ109 (Tahlan et al., 2012) and 
BM212 (La Rosa et al., 2012), have shown an inhibitory effect on MmpL3. Drug target 
exploration and characterization regarding the heme uptake pathway is well described 
elsewhere (Owens et al., 2013). Moreover, ESX-3 also influences both the iron and heme 
acquisition pathways (Serafini et al., 2013). The substrates of ESX-3 may play a variety of 
roles in fulfilling the metabolic needs of mycobacteria, although these roles remain to be 
determined. Drugs targeting ESX-3 may have potent therapeutic effects. The iron-dependent 
regulator, IdeR, although not directly involved in iron or heme uptake, regulates the global 
iron-responsive metabolism. The M. tuberculosis IdeR mutant has a growth defect in vitro, in 
vivo and in a mouse model (Pandey and Rodriguez, 2014) making it a promising drug target, 
although delivery of the drug to the bacterial cytosol may be challenging.  
 
 






M. tuberculosis utilises elaborate iron-responsive gene regulation and various iron acquisition 
strategies to maintain intracellular iron homeostasis and overcome the challenges of 
accessing scarce iron in their natural and host environments. Numerous studies have 
demonstrated the essentiality of these mechanisms for the survival and virulence of 
mycobacteria. Therapeutic strategies targeting those pathways offer promising medical 
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Chapter 4. Assessing the Progress of 




With one third of the world population affected, tuberculosis (TB) remains one of the most 
wide-spread infectious diseases (Guideline, 2013). Its etiological agent, Mycobacterium 
tuberculosis (M. tuberculosis), is estimated to have contributed to ~1.3 million deaths in 2012 
inter alia (WHO, Global tuberculosis report 2013) through the emergence of multidrug 
(MDR) and extensive drug resistance (XDR) M. tuberculosis strains, as well as the complex 
co-infection with human immune-deficient virus (HIV) (WHO, Global tuberculosis report 
2013). The importance of identifying new drug targets and developing new drugs can thus 
hardly be overstated. Structural information on M. tuberculosis proteins can help to 
characterize known drug targets including inter alia arabinosyltransferase and DNA gyrase, 
respective targets for ethambutol (Alderwick et al., 2011) and moxifloxacin (Tretter et al., 
2010), and to identify novel molecular intervention strategies (Arora and Banerjee, 2012; 
Chim et al., 2012, 2009; Xiong et al., 2013). Understanding the structural effects of 
resistance mutations can further support the identification of compensating modifications to 
drugs to stay ahead in the evolutionary race. A comprehensive structural database of M. 
tuberculosis proteins is a treasure trove of potential drug targets. This review aims to 
summarize the current status on structural data for M. tuberculosis strain H37Rv indicating 
the progress of M. tuberculosis structural genomics, providing clues on producing “difficult-
to-express” M. tuberculosis proteins, encouraging international research group collaboration 
and the exploration on the structures of proteins unique to mycobacteria. 
 
 
4.2. Current Status of Structural Data for Mycobacterium tuberculosis 
H37Rv 
 
The first M. tuberculosis protein structure was deposited with the Protein Data Bank (PDB) 
in 1994 (Wang et al., 1994). Since then much effort has been invested in structurally 
elucidating mycobacterial proteins (Arora et al., 2011; Ehebauer and Wilmanns, 2011). By 
the end of June of 2014, the PDB contained 1612 mycobacterial protein entries including 
1045 without specified strain, 542 for H37Rv, 20 for H37Ra, four for CDC1551 and one for 
F11.  
 




The 542 PDB entries assigned to M. tuberculosis H37Rv describe 199 distinct proteins and 
are associated with 245 publications. However, this number dramatically underestimates the 
true availability of structural data for M. tuberculosis H37Rv both because many M. 
tuberculosis structures in the PDB (potentially including many H37Rv proteins) are not 
explicitly assigned to any strains and because a close evolutionary relationship of H37Rv to 
other M. tuberculosis strains or a more distant kinship to other bacteria means that structural 
data for H37Rv proteins can be directly inferred. Mapping all 4031 M. tuberculosis open 
reading frame (ORF) sequences from Tuberculist (March 2013 update) (Lew et al., 2011) to 
all PDB entries using BLAST (Altschul et al., 1990) identifies excellent structural matches 
for 324 H37Rv proteins (Table S4.1) using a cut-off of 95 in the “structural match score”, 
calculated as the product of sequence identity (%) for the best match and the sequence 
coverage (%) divided by 100. If the cut-off is lowered to 70 (Figure 4.1), 402 or ~10% of all 
M. tuberculosis ORFs may be described as structurally “well defined”.  A further 287 ORFs 
(7.1%) with match values between 30 and 70 provide intermediate to “solid structural data”. 
For this group, the overall fold or a partial model of good quality can mostly be derived. 
Overall, good structural data is thus available for ~689 M. tuberculosis H37Rv ORFs (17.1%). 
For scores below 30, structural data is limited or non-existent implying that structures need to 
be solved experimentally or that more sophisticated modelling tools may be required.   
 
 
Figure 4.1. Distribution of 4031 M. tuberculosis H37Rv ORFs by structural match score 
(sequence identity (%) x coverage (%) / 100) for the best match in the PDB. Most M. 
tuberculosis H37Rv ORFs have no or a low scoring match (≤ 30%) 
 
 
To avoid ambiguities, the following more detailed analyses will concentrate on those PDB 
entries explicitly assigned to the M. tuberculosis strain H37Rv. This decision is made based 
































that set of proteins is broadly representative of all H37Rv entries, and because the PDB 
provides a convenient platform for analysis. 
 
Structural characterization of M. tuberculosis H37Rv proteins mostly involve the elucidation 
of functional mechanisms inter alia by comparing apo-protein structures with complexes 
involving ions, inhibitors, coenzymes or protein partners bound to the protein of interest. This 
frequently results in multiple crystal structures for individual proteins and a range of separate 
publications. While publication output for entries assigned to H37Rv initially increased 
rapidly from 1998 to 2006, it clearly plateaued thereafter (Figure 4.2). Apart from 
characterizing new drug targets, the structural elucidation has also helped to correct mis-
annotation of potential protein functions (Brown et al., 2007; Layre et al., 2014; Sinha et al., 
2005), to assign functions to previously uncharacterized or “hypothetical” proteins (17–19), 
and to expand data on M. tuberculosis physiology and pathogenicity. Both X-ray 
crystallography (524 structures, or 97%) and Nuclear Magnetic Resonance Spectroscopy (18 
structures, or 3%) were used in solving this set of protein structures. 
 
 




























































4.3. Functional Categorization of M. tuberculosis H37Rv Crystal 
Structures 
 
Ideal anti-TB drug targets either involve enzymes catalysing essential biological reactions or 
signal transduction components mediating nutrient acquisition or metabolic regulation. 
Targets should further be unrelated or should share low homology to human orthologs to 
limit drug toxicity in patients. The 199 structurally characterized proteins from M. 
tuberculosis H37Rv were mostly selected according to these criteria and can be assigned to 5 
functional groups: 126 (64%) to “house-keeping metabolism” and “resistance/survival 
mechanism”, 31 (15%) to “genetic information processing”, 14 (7%) to “cellular information 
processing and substrate transport”, 11 (6%) “virulence factors”, while 17 (8%) are of 
unknown function mostly annotated as “hypothetical”. Note that house-keeping metabolism 
processes dominate amongst studied proteins while only a few virulence associated proteins 
have been characterized. Structures of previously uncharacterized “hypothetical” proteins 
were overwhelmingly elucidated by structural genomics consortia. With some exceptions, the 
structurally solved proteins in H37Rv are mostly similar in function to their recognized 
orthologs in other organisms and share structural features with other members in the same 
protein family.  
 
4.3.1 House-keeping metabolism and resistance/survival mechanisms 
 
Metabolic and environmental stress associated enzymes constitute 64% of available M. 
tuberculosis H37Rv protein structures reflecting the ability of this bacterium to synthesize 
amino acids, vitamins and cofactors, as well as cell wall components such as peptidoglycan, 
sugars and mycolic acids. As humans do not code for the latter proteins, these are particularly 
attractive as drug targets. Enzymes of carbohydrate metabolism, redox homeostasis, nutrient 
acquisition, oxidative stress relief, antibiotic and harmful chemical elimination share only 
minimal homology to their human counterparts again making for good potential drug targets. 
The 126 proteins in this group include nine in carbohydrate metabolism (Table S4.2), 28 in 
amino acid metabolism (Table S4.3), 39 in lipid and polyketide metabolism (Table S4.4), 15 
in nucleotide metabolism (Table S4.5), eight in glycan biosynthesis (Table S4.6), nine in 
cofactor and vitamin metabolism (Table S4.7), and 18 in self-defense and detoxification, 
(Table S4.8).  
 
4.3.2 Genetic information processing 
 
Genetic integrity is vital for survival. Gene transcription and protein production are hence 
critical metabolic processes. Targeting components in these pathways will kill or limit the 
growth of M. tuberculosis. Protein structures assigned to this category include 17 proteins in 
transcriptional regulation (Table S4.9), five in translation/protein folding (Table S4.10) and 
nine in DNA replication/repair (Table S4.11). 
 




4.3.3 Cellular information processing and substrate transport 
 
Cellular signalling pathways allow bacteria to sense and respond to environmental stimuli 
such chemical gradients including PO4
3-
, O2, NO, Fe
2+
, N2, cAMP. Proteins in this group 
mostly belong to two-component systems and serine/threonine kinases (Pkns) though their 





4.3.4 Virulence factors and hypothetical proteins 
 
Despite the molecular basis for M. tuberculosis pathogenicity being of critical importance, 
knowledge in this area remains quite limited. M. tuberculosis virulence factors appear to 
mostly be directed towards ensuring mycobacterial survival in human macrophages. Only 11 
of 195 or 6% of M. tuberculosis H37Rv structurally elucidated proteins belong to this group 
(Table S13). Identifying human targets of virulence factors as well as crystallizing the 
associated molecular complexes remains challenging with the result that data in this regard is 
currently not available.  
 
Structural analysis of 17 proteins of unknown function (Table S14) has led to novel fold 
discovery and the assignment of possible functions to some proteins. Thus, Rv2714 was 
found to be a representative of a new nucleoside phosphorylase-like family of actinobacterial 
proteins (20); Rv1980c represents a new family of secreted β-grasp proteins (21); Rv2827c 
has a unique DNA-binding fold although the exact function remains unknown (22); Rv1155 
resembles flavin mononucleotide (FMN)-binding proteins but has no affinity towards FMN 
(23). Rv0802, resembling members of the GCN5-related N-acetyltransferase family, utilizes 
succinyl-CoA as substrate rather than acetyl-CoA, the first in this family (24). In contrast to 
the above, no function could be identified for many structurally-elucidated hypothetical 
proteins. Examples include Rv0020c, a substrate of Ser/Thr protein kinase PknB (25), and 
Rv2140c with marked homology to phosphatidylethanolamine-binding proteins indicating a 
potential role in lipid metabolism (26) (Table S13). These highlight the important 
contribution structural biology can make to our understanding of mycobacterial biology.  
 
 
4.4. Technical Aspects of M. tuberculosis Structural Analysis 
 
Structural elucidation of M. tuberculosis proteins remains challenging mainly due to 
difficulties with gene expression, protein solubility, protein purification and crystallization. 
Unexpectedly, codon-optimization of M. tuberculosis genes has not been frequently applied. 
With costs for DNA synthesis steadily decreasing this modification may become more 




accessible in future. Overall, affinity tag fusion proteins remain popular: 168 of 199 proteins 
or 84% were produced with a tag, though tagless proteins also feature (31 or 16%). N-
terminal His6-tags dominate (56%), followed by C-terminal His6 (23%). Larger tags such as 
glutathione S-transferase (GST, 26 kDa), maltose-binding protein (MBP, 42.5 kDa) and 
intein/chitin-binding protein (CBP, 55 kDa) which may help to increase solubility were used 
less frequently. The GST-tag was correspondingly used for six proteins (3%), MBP for three 
(1%), while CBP and streptavidin tag were used once each (0.5%).  
 
Proteins used to derive the deposited M. tuberculosis H37Rv structures were with very few 
exceptions all heterologously produced in Escherichia coli (525 of 542 PDB entries or 196 of 
199 unique proteins, See Table 4.1). Established protocols and the superior efficiency of this 
host compared to M. tuberculosis account for this landslide. The M. tuberculosis genome is 
more G/C rich (>65%) and its codon usage differs from that of E. coli. It incorporates a 
higher proportion of glycine, alanine, proline and arginine and M. tuberculosis post-
translational modification machinery is lacking in E. coli (27,28). M. smegmatis, a fast-
growing saprophytic relative of M. tuberculosis, is a potential expression host for M. 
tuberculosis genes overcoming many of the restrictions of E. coli (28–31). Unexpectedly, 
however, only three proteins of H37Rv represented by 16 structures were produced in M. 
smegmatis (29,32,33). Clearly the faster growth and production rates of E. coli ensure that it 
remains the most popular expression host. Also strikingly, BL21 (DE3) was used most 
frequently to express M. tuberculosis genes despite the presence of rare codons. Only a small 
proportion of M. tuberculosis proteins were produced in Rosetta or CodonPlus strains that 
code for tRNAs of these rare codons. Again the observed bias towards BL21 (DE3) may 
largely be practical with researchers simply using the most widely available strain. In future, 
other expression strains may come to the help for non-standard proteins such as membrane 
proteins. 
 
Table 4.1. Expression host for H37Rv protein production  
 
Expression Host Number 
E. coli BL21(DE3) and its derivative strains 157 
E. coli Rosetta or BL21 CodonPlus strain  21 
E. coli B834 7 
E. coli C41(DE3) 4 
E. coli DH5α 3 
E. coli Origami 2 
Pseudomonas putida KT4224 2 
M. smegmatis mc
2
 4517 2 
M. smegmatis mc
2
 155 1 
 




Production conditions were optimized for most proteins. Overwhelmingly lac promoter 
constructs (T7 and tac) were used for isopropyl β-D-1-thiogalactopyranoside (IPTG) 
induction in Lysogeny Broth (179 of 199 proteins). Only for three proteins was Terrific Broth 
(TB) used, auto-inducing media for 11, and arabinose induction for six proteins. Plotting 
IPTG concentration against production temperature (Figure 4.3) indicates that IPTG 
concentration between 0.1 and 0.5 mM and production temperatures between 16 and 25ºC 
were most common, with additional spikes at 37°C and 30°C. IPTG concentrations between 
0.01 and 0.1 mM are known to minimize protein insolubility, growth inhibition and cell lysis 
(34). Similarly low temperatures (16-25ºC) limit heat shock protein production, proteolytic 
degradation, protein aggregation (inclusion bodies) and improve protein stability (34). 
Though only rarely reported, E. coli strains such as Arctic Express and expression vectors 
such as pCOLD, co-produce cold shock chaperone proteins which help to overcome 
production hurdles for M. tuberculosis proteins. Arylamine N-acetyltransferase (TBNAT), for 




 Figure 4.3. M. tuberculosis H37Rv strain protein production in E. coli; expression 
temperature is plotted against IPTG concentration. Most proteins were expressed at 
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Protein constructs resulting in successful structures are mostly small to medium in size (10-
60 kDa) with neutral pI (Figure 4.4). A majority of proteins are further inherently soluble and 
stable enzymes or signal transduction components. These features clearly enhance successful 
production in E. coli but indicate that future progress will presumably be much slower.  
Membrane protein structures are correspondingly rare with structural studies mostly being 
limited to soluble domain such as in MmpS4 (35) MmpL3 and MmpL11 (36). 
 
 
Figure 4.4. A plot of pI versus molecular weight of all M. tuberculosis H37Rv protein 




Insolubility of target M. tuberculosis proteins remains a major hurdle for structural analysis. 
The solubility of secreted target proteins may be improved by co-expressing the soluble 
domain of the membrane-anchored disulphide bond-forming (Dsb) protein (Rv2969c) (37,38). 
Similarly, GlgB (Rv1326c), Cyp125A1 (Rv3545c), and tuberculosinyl transferase (Rv3378c) 
were converted to soluble proteins by co-producing E. coli chaperone proteins (15,39,40). 
Corresponding M. tuberculosis chaperones such as Cpn60.1, an ortholog of E. coli GroEL, 
significantly improved the solubility of DprE1, the target for the drug benzothiazinone (41). 
Protein solubility may also be optimized by co-expressing other proteins of the same 
metabolic pathway. Siroheme-dependent sulfite reductase (Rv2391) was hence solubly 
produced by co-producing uroporphyrinogen III C-methyl-transferase (Rv2847c) (42). 
Similarly, non-ribosomal peptide synthetases, MbtE and MbtF of mycobactin biosynthesis, 
were solubly produced only by co-producing 8 kDa MbtH with a previously unknown role in 
the pathway (43,44). Yet another strategy of obtaining structural data for difficult or insoluble 
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and Mycosin-3 proteases from ESX-1 and ESX-3 Type VII secretion systems were 
structurally characterized from M. smegmatis in place of their M. tuberculosis counterparts. 
Amino acid sequence identities of 72% and 60%, respectively ensure that structural features 
may directly be inferred for the latter (45–47). Underlying causes for difficulties in producing 
M. tuberculosis proteins mostly remain unresolved as projects are generally discontinued if 
problems prove intractable.  
 
 
4.5. Scope of future structural genomics studies 
 
In choosing targets for structural analysis, proteins unrelated to existing PDB entries may be 
of most interest as they may represent new protein families or new functions. Rv2179c, for 
example, discovered to have RNase activity but without structural similarity to other RNases, 
was identified as the founding member of a large family of bacterial RNases (17). Many 
proteins without structural counterparts in the PDB, however, are membrane proteins limiting 
rapid progress in structural analysis. Furthermore some M. tuberculosis H37Rv ORFs code 
for highly unusual proteins. Rv3512 for example contains 598 glycines (55%) and 140 




4.6. Structural Biology Research Group World Wide 
 
Table S4.15 lists the principle investigators, the institutions, the countries and the category of 
proteins analysed. Overall, 113 principle investigators contributed to the 245 publications for 
M. tuberculosis H37Rv protein structures in the PDB. Of these, 58 involved with more than 
one publication are listed. Groups are mostly based in Europe and Northern America but 
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Chapter 5. Optimization of Cloning and 
Expression of Mycosin-3 from 
Mycobacterium tuberculosis H37Rv 
5.1 Introduction 
 
Pathogenic bacteria utilise different types of secretion systems to transport virulence factors 
into host cells to manipulate their immune mechanisms (Finlay and Falkow, 1997). The Type 
VII Secretion System (T7SS) is the most recently described bacterial secretion system 
(Abdallah et al., 2007) and it is found mostly in mycobacteria and some other high GC gram-
positive bacteria (Gey van Pittius et al., 2001). Mycobacterium tuberculosis (M. tuberculosis), 
the etiological agent of tuberculosis, has five copies of T7SS, namely ESX-1 – ESX-5 
evolved via gene duplication (Gey van Pittius et al., 2006). ESX-1 and ESX-5 are involved in 
the virulence of virulent mycobacteria (Houben et al., 2013a) whereas ESX-3 participates in 
mycobactin-mediated iron acquisition (Siegrist et al., 2014, 2009). Owing to the close 
associations with these fundamental processes, T7SS has been extensively studied, with 
ESX-1 and ESX-5 from M. tuberculosis and M. marinum, being the most highly studied 
(Houben et al., 2013b). The working mechanisms, involvement in pathogenicity and gene 
regulation of the T7SS are discussed in detail in Chapter 2. 
 
Previous studies have shown that the mycosins, as one essential component of the T7SS, 
could not be isolated with the core machinery (EccB, EccC, EccD and EccE), indicating a 
weak interaction on the membrane (Houben et al., 2012). Mycosins have enzymatic 
signatures similar to the subtilisin-like serine proteases and they share the conserved catalytic 
traid (Asp-His-Ser) (Brown et al., 2000). However, the initial screening experiments did not 
reveal their substrates and it was believed that the substrates are more specific than other 
subtilisin family members (Brown et al., 2000) hence their functions remained unknown. In-
depth studies on Mycosin-1 revealed that EspB is one substrate where it was cleaved twice 
upon its secretion (Ohol et al., 2010). Although the reason for the processing of EspB by 
Mycosin-1 is unknown, it is speculated that it could facilitate the maturation of EspB which 
become a functional effector to interact with the host targets. Mycosin-1 is essential for the 
secretion of ESX-1 substrates but abolishing its protease activity up-regulates the substrate 
secretion (Ohol et al., 2010). Possibly Mycosin-1 plays a regulatory role on maintaining the 
balance between immune detection and virulence to achieve the long term persistence for M. 
tuberculosis (Ohol et al., 2010). EspB is unlikely to be the only mycosin substrate, as the 
espB gene is not present in the other 4 ESX regions in M. tuberculosis. 
 
Mycosins contain, from N-terminus to C-terminus, a signal sequence, a “pro-peptide”, the 
catalytic domain, the proline-rich linker region and the hydrophobic transmembrane region 
(Figure 5.1) and it was believed that the mycosins would only be active when the “pro-




peptide” is removed (Brown et al., 2000). The crystal structure of Mycosin-1 (MycP1) from 
both M. smegmatis and M. thermoresistabile and Mycosin-3 (MycP3) from M. smegmatis 
suggest that the “pro-peptide” does not have such a regulatory role on the activities of 
mycosins; instead it wraps around the catalytic domain and stabilizes it. Retaining the “pro-
peptide” does not affect the protease activity (Solomonson et al., 2013; Wagner et al., 2013). 
Thus the “pro-peptide” was renamed as the “N-terminal extension region” (Solomonson et al., 
2013; Wagner et al., 2013). Moreover, Solomonson and colleagues found that their M. 
smegmatis MycP1 orthologue was inefficient at cleaving EspB in vitro and they argued the 
reason is that the MycP1 was separated from the rest of the secretion system in the 
experiments. It was not fully activated but showed leaky activity (Solomonson et al., 2013).  
Although the Mycosin-1 orthologues in M. smegmatis and M. thermoresistabile have more 
than 70% amino acid sequence identity with that in M. tuberculosis, their substrate 
specificities may differ considering the Mycosin-1 orthologues in those saprophytic species 
may not be involved in virulence related processes. Both research groups did not manage to 
produce the recombinant M. tuberculosis orthologue of Mycosin-1 or Mycosin-3 
(Solomonson and Korotkov, personal communication). 
 
 
1-   MIRAAFACLAATVVVAGWWTPPAWAIGPPVVDAAAQPPSGDPGPVAPMEQRGACSVSGVI 








Figure 5.1. The primary sequence of MycP3 from M. tuberculosis. Red: signal peptide; Blue: 
“pro-peptide”; Brown: proline-rich linker; Purple: hydrophobic transmembrane region; Green 











In this study, the mycP3 gene from M. tuberculosis was cloned and expressed. Although the 
role of MycP3 remains enigmatic, it is essential to M. tuberculosis survival in vitro (Griffin et 
al., 2011; Sassetti et al., 2003) making it a potential anti-TB drug target (Frasinyuk et al., 
2014; Wagner et al., 2013). Extensive efforts were undertaken to optimize the production of 
MycP3 to increase protein yield, solubility and stability. While small amounts of protein were 
produced, this could not be easily handled limiting its use in downstream analysis such as 
substrate library screening and X-ray crystallography. The description below outlines the 
many efforts undertaken to clone mycP3. This may prove useful in future if a related project 








5.2 Methods and Materials 
 
5.2.1 Media, Plasmids and Bacteria Strains 
 
Lysogeny broth (LB) was used to culture all Escherichia coli strains including XL-1 blue 
(Promega), BL21 (DE3) pLysS (Promega), Arctic Express (Agilent Technologies), and 
Origami (Novagen). Middlebrook 7H9 broth and 7H11 agar, each supplemented with 0.2% 
Tween 80, 0.5% glucose and 0.5% glycerol, were used to culture M. smegmatis MC
2
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strain in liquid and solid media respectively. E. coli expression vector pET-28a (Novagen) 
(Figure S5.2), pGEX-6P-1 (EMBL) (Figure S5.3), pCOLD (Takara) (Figure S5.4) were used 
to produce C-terminal His6-tagged, N-terminal glutathione S-transferase (GST)-tagged, and 
N-terminal His6-tagged fusion proteins respectively while pET-21a (Novagen) was used for 
in vitro tagless construct expression. 
 
5.2.2 Cloning, Expression and Purification 
 
A range of truncated mycP3 constructs were generated by Phusion DNA polymerase 
(ThermoScientific) using specific primer pairs (Table 5.1) in polymerase chain reactions 
(PCR).  The PCR experiments were conducted with the following procedure: 1. initial 
denaturation at 98°C for 15 min; 2. 35 cycles of amplification including denaturation step at 
98°C for 30 sec, annealing step at 56°C for 30 sec, and extension step at 72°C for 1 min; 3. 
extension at 72°C for 8 min; and 4. cooling at 4°C for 10 min. The PCR products were 
ligated into pJET2.1 cloning vector (Thermo Scientific) (Figure S5.1) using T4 DNA ligase 
(Promega). The recombinant pJET2.1 vector was restriction digested and the insert ligated 
into the expression vectors. Deletion constructs of Mycosin-3 were generated using 
QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies) as per manufacturer’s 
instructions. The recombinant or mutated expression vectors were electroporated into the 
expression host cells, where 1 μl of the vector is mixed with 50 μl of electro-compotent E. 
coli cells and the mixture was then transferred into an electroporation cuvette and the 
electroporation was conducted at 2.4 kV and the resistance was set at 4 kΩ using a 
GenePulser (BioRad, USA). 
 
For the expression in E. coli, an overnight 50 ml starter culture was prepared from a single 
transformant colony. An aliquot of the starter culture was re-inoculated into 1 liter LB media, 
allowed to grow to mid-log phase (OD600nm = 0.6 to 0.8) at 37°C and induced with 0.1 to 0.5 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 16, 25 and 30°C for 18 hours for test 
expression. E. coli Arctic Express strain and pCOLD E. coli transformants were induced with 
0.1 mM IPTG at 13°C and expression continued for 40 hours. 
For the expression in M. smegmatis, a 1 ml starter culture in 7H9 medium was prepared from 
a single transformant colony. It was re-inoculated to a 10 ml and then to a 500 ml enriched 
7H9 medium. The expression construct p19Kpro (Ashbridge et al., 1989) and pDMN1 




(Mailaender et al., 2004) did not require inducer while 50 ng/ml anhydrotetracycline (ATc) 
(Sigma) was used to induce MycP3 expression in pSE100/pMC5m Tet-on expression system 
where ATc binds to TetR which is coded in pMC5m causing it to dissociate from tet operon 
located in pSE100 thereby allowing the transcription of the downstream gene cloned in the 
same vector (Ehrt et al., 2005). The expression was carried out for 16 hours at 37°C. 
 
For the GST-tagged fusion protein purification, cultures were harvested by centrifugation at 
4000 x g at 4°C for 10 min. The pellet was resuspended in phosphate buffered saline (PBS) 
and stored at -80°C overnight. The frozen resuspension was thawed and sonicated using a 
probe sonicator (MSE) at an amplitude of 20 μm for 5 cycles of 30 s with 30 s incubation on 
ice. The soluble and insoluble fractions of the cell lysate were separated by centrifugation at 
14000 x g at 4°C for 45 min. The supernatant was mixed and incubated with PBS-
equilibrated glutathione agarose beads (ABT) at 4°C on a roller mixer for 1 hour for efficient 
coupling. The mixture was poured into an empty drip column and the flowthrough was 
allowed to elute under gravity. The column was washed with 20 column volumes (CV) of 
PBS. The fusion protein was either digested on column by PreScission protease (Roche) or 
eluted with elution buffer (25 mM Tris-HCl, pH 7.4, 150 NaCl, 15 mM reduced glutathione) 
followed by fusion protein digestion in solution. The elution fractions containing MycP3 were 
pooled and concentrated using a centrifugal filter device (Millipore) and applied to Superdex 
75 size exclusion column (GE HealthCare) for further purification. The desired fraction was 
collected and pooled. 
 
For the purification of The His6-tagged fusion proteins, the M. smegmatis cell pellet was 
resuspended in lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM imidazole) and 
lysed by a tissue and cell homogenizer FastPrep-24 (MP Biomedical) at a speed of 6 M/s for 
5 cycles of 30 s with 30 s incubation on ice in between. The soluble fraction was separated as 
described above and the target protein was coupled to Ni-NTA beads (Qiagen). The beads 
were loaded into an empty drip column and washed with 20 CV wash buffer (25 mM Tris-
HCl, pH 7.4, 150 NaCl, 20 mM imidazole) and eluted with elution buffer (25 mM Tris-HCl, 
pH 7.4, 150 NaCl, 250 mM imidazole). 
 
MycP3 was also produced using PURExpress In Vitro Protein Synthesis Kit (New England 
Biolab) as per manufacturer’s instructions. The quantity of the protein production and the 
presence of MycP3 during purification were monitored using SDS-PAGE (Laemmli, 1970) 
and mass spectrometer (Central Analytical Facility, Stellenbosch University). 




Table 5.1. Primers used to generate the starting M. tuberculosis mycP3 construct (Construct A, not codon-optimized), Eleven codon-optimized 
mycP3 constructs (Constructs B to L) including 3 deletion constructs (Constructs I to K), as well as three M. smegmatis expression constructs 







Expression Host Expression 
Vector 





 E. coli BL21 
(DE3) pLysS 
pET-28a forward: 5’-CCATGGCGATCGGGCCGCCGG-3’ (NcoI) 
reverse: 5’-CTCGAGGTTGCGCGGTGTGGTG-3’ (XhoI) 





 pET-28a forward: 5’-CCATGGAACGCGGTGCGTGCAG-3’ (NcoI) 
Construct A reverse primer 
pGEX-6P-1 forward: 5’-GGATCCCGCGGTGCGTGCAG-3’ (BamHI) 





 pGEX-6P-1 forward: 5’-GGATCCGGTGCATGTAGCG-3’ (BamHI) 





 pGEX-6P-1 forward: 5’-GGATCCGGTGTTATTCCGG-3’ (BamHI) 





 pGEX-6P-1 forward: 5’-GGATCCGGTACAGATCCGG-3’ (BamHI) 





 pGEX-6P-1 forward: 5’-GGATCCGTTCCGACCCCGAG-3’ (BamHI) 





 pGEX-6P-1 forward: 5’-GGATCCCAGACCATGCTG-3’ (BamHI) 
Construct C reverse primer 




pCOLD forward: 5’-CATATGCAGACCATGCTGAATC-3’ (NdeI) 
Construct C reverse primer 





 E. coli BL21 pGEX-6P-1 forward: 5’-GGATCCCTGCCAGCAGCATG-3’ (BamHI) 
Stellenbosch University  http://scholar.sun.ac.za




(DE3) pLysS Construct C reverse primer 
















pGEX-6P-1 forward: 5’-GAGCTGAGCGTTGCAAGC-3’ 
reverse: 5’-GAGCGGATTGCTATCACAG-3 












 E. coli Origami pGEX-6P-1 forward: 5’-GGATCCATTGGTCCGCCTGTTG-3’ (BamHI) 



































*The underlined sequence reflects the sequence of restriction site the name of which is indicated in the brackets following the sequence
Stellenbosch University  http://scholar.sun.ac.za






5.3.1 Protein Production in E. coli 
 




) plays in MycP3 remains unknown. As it 
is common for signal sequences and pro-peptide regions of proteases to be cleaved off during 


















 (Construct B), eliminating the 
signal sequence, “pro-peptide” and transmembrane region. Both constructs A and B were 
cloned into the expression vector pET-28a. However, neither pET-mycP3 constructs produced 
sufficient amounts of MycP3-His6 fusion protein to be visible by SDS-PAGE.  
 
E. coli codon usage differs significantly from that of mycobacteria (Scapoli et al., 2009). A 





optimized for expression in E. coli (GeneArt), was cloned into pGEX-6P-1 expression vector 




) production in 
E. coli BL21 (DE3) at 37ºC is little (Figure 5.2) and mostly insoluble (Figure 5.3a). The 
soluble fraction of the fusion protein was unstable and prone to rapid proteolysis and 
precipitation (Figure 5.4 and 5.5). It co-purified with E. coli chaperonin DnaK (69.1 kDa) and 
heat shock protein (60 kDa) identified by mass spectrometry (Figure 5.4). Adding ATP and 
detergent Triton X-100 allowed chaperone removal (Schönfeld et al., 1995) while increasing 
the rate of precipitation and degradation (Figure 5.5) hampering purification. Expression at 
lower temperatures (16, 25, and 30ºC) and a range of IPTG concentrations for long periods 















A) in E. coli BL21 (DE3) pLysS strain. The black arrow indicates the increasing amount of 
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    (b) 
Figure 5.3. Solubility test on Construct A produced from E. coli BL21 (DE3) pLysS strain 
under a range of IPTG concentrations and temperatures with (a) for 30 and 37°C and (b) for 
16 and 25°C. The fusion protein was produced mostly as inclusion bodies under all 
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Figure 5.4. Construct A purification profile with on-column PreScission Protease digestion. 
After on-column digestion, the flowthrough (F) contained MycP3 and the eluent (E) 
contained undigested fusion protein and GST. AD lanes were loaded with digested fusion 
protein before purification. Band T was identified as Chaperonin DnaK (MW = 69.1 kDa) 
from E. coli. Band M was identified as the mixture of heat shock chaperonin (60 kDa) from E. 
coli and MycP3 from M. tuberculosis. Band B was identified as MycP3 from M. tuberculosis. 
F: flowthrough; E: eluent; M: protein ladder. 
 
 
Figure 5.5. Construct A purification profile with on-column PreScission Protease digestion 
where ATP and Triton X-100 were added in all buffers (Black arrow: DnaK; Red arrow: 
MycP3). DnaK were dissociated from DnaK-MycP3 complex. However DnaK elimination 
was not achieved and MycP3 became ready to precipitate and susceptible to proteolysis after 
DnaK detachment. M: Protein Marker; FT: Flow Through; ATP: eluent fraction containing 
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At the time of undertaking the studies outlined here, structural information for MycP3 from M. 
tuberculosis H37Rv was not available. It is not clear what the factors are that made it difficult 




). Analysing MycP3 for inherently disordered 









 as disordered. Secondary structure was predicted using a range of different software 
(http://www.expasy.org/tools/). Aligning the IDRs to the secondary structure predictions 
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) together with the next 20 amino 
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 (Construct H). These six constructs were cloned into the expression vector 
pGEX-6P-1 as the resulting N-terminal GST-tagged fusion proteins were produced at higher 
levels than the fusion proteins with C-terminal His6-tag from pET-28a. Production of six 
MycP3 protein variants was first attempted at 37ºC inducing with 0.1 mM IPTG. Protein 
production levels of constructs C and D proved low while those for constructs E, F, G and H 
were higher (Figure 5.6). However, the GST-MycP3 fusion proteins were invariably 
incorporated into insoluble inclusion bodies (Figure 5.7). Expression at reduced temperatures 
(16, 25 and 30ºC) did not improve the solubility of the resulting protein significantly. 
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Figure 5.6. Test expression of 6 truncated constructs of MycP3 (Constructs C to H). The 
protein production levels of construct C (a) and D (b) were low while those of constructs E 
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     (a) 
 
     (b) 
Figure 5.7. Solubility test for construct E and F (a), G and H (b) because they showed high 
expression levels. All four constructs were expressed insolubly at 0.1 mM IPTG under 37°C. 
The lanes are labelled according to the construct used (e.g. EP: Construct E pellet; ES: 
Construct E supernatant). M: Protein Marker; “un”: the culture was un-induced; “in”: the 
culture was induced with IPTG. 
 
 
Exposed hydrophobic regions of a partly (mis)folded protein may increase intermolecular 
interaction and hence precipitation. Removing exposed hydrophobic regions of MycP3 could 
improve its solubility in E. coli. Threading the amino acid sequence of MycP3 onto the best 
structural model thermitase, by Swiss Model (Arnold et al., 2006) revealed three probable 
surface exposed hydrophobic regions (Figure 5.8). Using Construct G as a template the three 














). However, none of the three constructs showed improved solubility of MycP3 under a 
range of incubation temperatures and IPTG concentrations. The high expression level was 
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           (a)      (b)    (c) 
Figure 5.8. Identification of three possible surface hydrophobic regions in MycP3 following 
















Some E. coli expression vectors, such as pCOLD (Takara), and certain strains, such as Arctic 
Express (Agilent Technologies), are designed specifically to increase the solubility of 
produced proteins (Hayashi and Kojima, 2008). Construct G was thus cloned into pCOLD 
vector resulting in an N-terminal His6-tagged mycP3 recombinant gene. Even with the co-
expression of cold-shock chaperone proteins in the pCOLD vector, MycP3 was still produced 
insolubly in both BL21 (DE3) and Arctic Express strains (Figure 5.9). However, expression 
of Construct G in pGEX-6P-1 vector in Arctic Express was successful and resulted in the 

























Figure 5.9. Test expression for construct G in pCOLD expression vector in BL21(DE3) strain 
(a) and Arctic Express strain (b). The N-terminal His6-tagged fusion protein was produced as 
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Figure 5.10. Test expression and solubility test for Construct G expressed in E. coli Arctic 
Express strain. High expression level can be observed in both soluble and insoluble fraction 
of the cell lysate. M: Protein Marker; E: Empty (the proteins in those lanes were from 
adjacent lanes by overflow); P: Cell Lysate Pellet; S: Cell Lysate Supernatant. 
 
 
Further problems were encountered when it was found that the soluble GST-tagged MycP3 
fusion protein bound only weakly to glutathione agarose (GA) beads while conducting 
affinity chromatography (Figure 5.11). The purified fusion protein and unbound fusion 
protein in the flow through could both be cleaved by PreScission protease (Figure 5.12). 
However, removal of the GST-tag destabilized MycP3 resulting in rapid precipitation (Figure 
5.13). Addition of detergents (glycerol and Triton X-100) and reducing agents (β-
mercaptoethanol and DTT) at various concentrations did not improve the stability of MycP3 
(results not shown). Omitting reducing agent from purification buffers resulted in”smears” 
above proteins bands in SDS-PAGE indicating intermolecular disulfide bonds (Kim and 
Robinson, 2006) implying that the MycP3 was not folded properly. During this study, the 
structures of the  MycP1 ortholog (MycP1, PDB ID: 4J94 & 4KPG) in M. smegmatis and in 
M. thermoresistibile ATCC 19527 (PDB ID: 4HVL), and the MycP3 ortholog in M. 
smegmatis (PDB ID: 4KG7) were solved (Solomonson et al., 2013; Wagner et al., 2013). 
These orthologs have at least 70% sequence identity with MycP3 in M. tuberculosis. In these 
studies, the “pro-peptide” region was included in the constructs while the signal peptide, 
proline-rich linker region and transmembrane regions were excluded. The “pro-peptide” was 
re-annotated as an “N-terminal extension region”, because it does not possess pro-peptide 
function but seems to maintain the stability of the subtilisin domain in these organisms. 
Cysteine
51
 residue in M. smegmatis MycP1, Cysteine
46
 residue in M. thermoresistibile MycP1 
and cysteine
54
 residue in M. smegmatis MycP3 were all essential for the formation of 
disulfide bonds with one of the other 3 cysteine residues, contributing to the stability of the 
overall structure. As an ortholog to those mycosins, cysteine
54
 in M. tuberculosis MycP3 
should also play an essential role in protein stability and functionality. Following this 








, which is homologous to the deposited constructs 
described above, was generated and cloned into pGEX-6P-1 vector. This recombinant 
expression construct was expressed in disulfide bond promoting E. coli Origami strain 
(Novagen). The protein production was conducted at a range of temperatures (16, 25, 30, and 
37ºC) and IPTG concentrations (0.1, 0.2, 0.5, and 1 mM). However, the production of GST-
tagged MycP3 fusion protein remained insignificant (results not shown). At 16ºC, the 






Figure 5.11. GST affinity chromatography purification profile. Besides a significant amount 
of fusion protein was produced as inclusion bodies (P), majority of fusion proteins came out 
in the flowthrough (FT) and some was washed off during extensive washing (W). A small 
quantity of the fusion proteins together with GST came off the column during elution (E). 
The beads (B) (column matrix after elution) bound to the residual fusion proteins and GSTs. 
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Figure 5.12. The purified GST-tagged MycP3 fusion protein and the unbound fusion protein 
in the flowthrough can both be cleaved by PreScission protease (black arrows show MycP3 
without GST-tag), further confirming the true identity of this over-expressed fusion protein. 
M: Protein Marker; FT: FlowThrough; FTP: Protease treated FlowThrough; Em: Empty; E: 
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Figure 5.13. Protein purification profile of size exclusion chromatography following GST 
affinity chromatography. There are 3 peaks on the chromatogram (a), where the first peak (P1) 
is the remaining un-cleaved fusion protein (b), the second peak (P2) is GST (b), and the 3
rd
 
peak was identified as reduced glutathione in the solution. The cleaved MycP3 was supposed 
to eluted between the 1
st
 peak and the 2
nd
 peak. However, it was very unstable and 




5.3.2 Protein production in M. smegmatis and in vitro 
 
M. smegmatis has often been regarded as a better M. tuberculosis protein production host 
compared to E. coli due to its similar cellular environment as M. tuberculosis (Daugelat et al., 












































pDMN1 (Mailaender et al., 2004) two mycobacterial non-inducible expression vectors both 
containing C-terminal His6 tags. The transformed cultures were grown at 37ºC for 40 hours 
resulting in insignificant fusion protein production (results not shown). The growth of M. 
smegmatis transformants harbouring pDMN1-MycP3 was severely inhibited due to the 
possible toxicity of over-expressed MycP3 (results not shown) compared to the wild type 
strain transformed with empty pDMN1 vector. An inducible mycobacterial gene expression 
system (pSE100 and pMC5m) with a teton promoter (Ehrt et al., 2005) was used in an attempt 
to eliminate the growth inhibition. However, although the growth of this transformant was 
normal, the fusion protein production was insignificant (results not shown). 
 
To eliminate all possible host cell inhibitory factors to exogenous protein production, MycP3 
construct G was cloned into pET-21a and expressed taglessly in vitro. The expression quality 
and conditions were carefully controlled but no MycP3 protein was produced while a couple 
of translational machinery components such as translation initiation factor IF-2 and 





Figure 5.14. Cell free expression profile for pET-MycP3 recombinant expression construct. 
Brown arrow: positive control expression; blue arrow: elongation factor Tu1 and Tu2, 43.3 
kDa; black arrow: translation initiation factor IF-2, 97.3 kDa. M: protein marker; -ve: 
negative control; +ve: positive control; mix: using mixed positive control DNA with pET-
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5.4 Discussion and Conclusion 
 
Optimization of MycP3 protein production constitutes the main body of this work. Two 
mycP3 constructs originated from M. tuberculosis and 12 different codon-optimized truncated 
mycP3 constructs were expressed with 7 expression vectors in 3 E. coli expression strains, 1 
M. smegmatis strain as well as in vitro (Table 5.1). In silico sequence analysis and N-
terminal/C-terminal truncation were instrumental to determine which construct was the 
highest expression construct (Construct G). The E. coli Arctic Express strain enabled this 
construct to produce soluble fusion protein. However, the soluble GST-tagged truncated 
MycP3 fusion protein was only partially folded, making it unstable and possibly non-
functional. The reason for this is not clear. 
 
During the time that this study was conducted, two structural biology groups solved the 3-D 
structures of three other mycosin orthologues from environmental mycobacterial species with 
high homology to their M. tuberculosis counterparts (Figure 5.15). M. smegmatis MycP1 has 
an identity score of 71.97 to M. tuberculosis MycP1 while that of M. thermoresistibile has a 
score of 71.11 to M. tuberculosis MycP1 (Table 5.2) (Larkin et al., 2007). The sequence 
identity score between two MycP1 orthologues of the two environmental species is the best, 
78.78 (Table 5.2). The analysis showed that the best match for M. tuberculosis MycP3 is M. 
smemgatis MycP3 with a score of 59.04. Swiss Model also used MycP3 from M. smegmatis as 
the model structure for M. tuberculosis MycP3 (Figure 5.16) with the QMEANZ-score of -
1.45 which indicates a relatively poor model (Benkert et al., 2011a) although the overlay 
structures do not show any distinct differences. Moreover, PROSO II, a sequence-based 




from M. tuberculosis, 
just like its orthologues from M. smegmatis and M. thermoresistibile, can be produced as a 























Msmeg_0083|MycP1   --MQRVAVMVLAVLLALFSAPPAWAIDPPVIDAGAVPP-DETGPDQPTEQRKICATPTVM 57 
KEK_05522|MycP1    -------MLITALLLAVVTAPPAGAIEPPVIDPAAVPP-DETGPDNPMEQRRVCAAPTVY 52 
Rv3883c|MycP1      ----VHRIFLITVALALLTASPASAITPPPIDPGALPP-DVTGPDQPTEQRVLCASPTTL 55 
Rv0291|MycP3       MIRAAFACLAATVVVAGWWTPPAWAIGPPVVDAAAQPPSGDPGPVAPMEQRGACSVSGVI 60 
Msmeg_0624|MycP3   MIHKSLGVVATAGLVLLIGCPSAGAVSPPQVDPQIAPPPGTAGPAQPMMQRSECITTSVL 60 
                           .  :  :     ..* *: ** :*.   ** . .**  *  **  *  . .  
 
Msmeg_0083|MycP1   PNSNFADRPWANDYLRIQEAQKFATGAGVTVAVIDTGVNGSPRVP-AEPGGDFVDAAGNG 116 
KEK_05522|MycP1    PDSNFADRPWASDYLRLTEAHKFATGAGITVAVIDTGVNGSPRVP-AEPGGDFVDAAGNG 111 
Rv3883c|MycP1      PGSGFHDPPWSNTYLGVADAHKFATGAGVTVAVIDTGVDASPRVP-AEPGGDFVDQAGNG 114 
Rv0291|MycP3       PGTDPGVPTPSQTMLNLPAAWQFSRGEGQLVAIIDTGVQPGPRLPNVDAGGDFVEST-DG 119 
Msmeg_0624|MycP3   PGTDPGAVSPNQLALNLSGAWQHSRGAGQTVAVIDTGVQPGPRLPNVEAGGDYIEST-DG 119 
                   *.:.    .  .  * :  * :.: * *  **:*****: .**:* .:.***::: : :* 
 
Msmeg_0083|MycP1   MSDCDAHGTMTAAIIGGRPSPTDGFVGMAPDVRLLSLRQTSVAFQPKGARQDPNDPNTTQ 176 
KEK_05522|MycP1    MSDCDAHGTLTASVIAGRGAPTDGFIGVAPDARILSLRHTSAAFQPVGARTDPNNPNTTQ 171 
Rv3883c|MycP1      LSDCDAHGTLTASIIAGRPAPTDGFVGVAPDARLLSLRQTSEAFEPVGSQANPNDPNATP 174 
Rv0291|MycP3       LTDCDGHGTLVAGIVAGQPGN-DGFSGVAPAARLLSIRAMSTKFSP---RTSGGDPQLAQ 175 
Msmeg_0624|MycP3   LTDCDGHGTSVAGLIAGQPGP-DGFSGVAPEARLISIRQNSPRFAP---RTPGADSEATR 175 
                   ::***.*** .*.::.*: .  *** *:** .*::*:*  *  * *   :    :.: :  
 
Msmeg_0083|MycP1   TAGSIRSLARSVVHAANLGAQVINISEAACYKVTRRIDETSLGAAINYAVNVKGAVIVVA 236 
KEK_05522|MycP1    TAGSLRSLARAIVHAANLGAQVINISEAACYKVTRPIDETGVGAAVNYAVHVKNAVVIAA 231 
Rv3883c|MycP1      AAGSIRSLARAVVHAANLGVGVINISEAACYKVSRPIDETSLGASIDYAVNVKGVVVVVA 234 
Rv0291|MycP3       ATLDVAVLAGAIVHAADLGAKVINVSTITCLPADRMVDQAALGAAIRYAAVDKDAVIVAA 235 
Msmeg_0624|MycP3   AASDAETLARAVVRAADMGARVINISLVTCLPADRTIDQSVLGAALRYAALEKDAVIVAA 235 
                   :: .   ** ::*:**::*. ***:*  :*  . * :*:: :**:: **.  *..*::.* 
 
Msmeg_0083|MycP1   AGN------TGQDCSQNPPPDPSVPSDPRGWREVQTIVSPAWYDPLVLTVGSIGQNGQPS 290 
KEK_05522|MycP1    AGN------TGQDCTQNPPPDPAVPSDPRGWQQVQTIVSPAWYSPLVLTVGGIGPTGQPS 285 
Rv3883c|MycP1      AGN------TGGDCVQNPAPDPSTPGDPRGWNNVQTVVTPAWYAPLVLSVGGIGQTGMPS 288 
Rv0291|MycP3       AGNTGASGSVSASCDSNPLTDLSRPDDPRNWAGVTSVSIPSWWQPYVLSVASLTSAGQPS 295 
Msmeg_0624|MycP3   AGNNRGGVSTGAACESNPLPSGT-PGDPRNWNGVTSVSIPSWWQPYVLSVGAVDSTGQPS 294 
                   ***      ..  * .** .. : *.***.*  * ::  *:*: * **:*..:   * ** 
 
Msmeg_0083|MycP1   NFSMSGPWVGAAAPGENLTSLGYD--GQPVNATPG-EDGPVPLNGTSFSAAYVSGLAALV 347 
KEK_05522|MycP1    NFSMSGPWVGAAAPAENITALGYG--GEPVNALQG-QDGLVPVAGTSFAAAYVSGLAALI 342 
Rv3883c|MycP1      SFSMHGPWVDVAAPAENIVALGDT--GEPVNALQG-REGPVPIAGTSFAAAYVSGLAALL 345 
Rv0291|MycP3       KFSMPGPWVGIAAPGENIASVSNSGDGALANGLPDAHQKLVALSGTSYAAGYVSGVAALV 355 
Msmeg_0624|MycP3   SFTMAGPWVGIAAPGENIVSVSNAPDGGLSNALPSERDRLVPLTGTSYAAAYVSGVAALV 354 
                   .*:* ****. ***.**:.::.    *   *.  . .:  *.: ***::*.****:***: 
 
Msmeg_0083|MycP1   KQRFPDLTPAQIINRITATARHPGGGVDNYVGAGVIDPVAALTWEIPDGPEKAPFRV--K 405 
KEK_05522|MycP1    RQRYPDLTPAQVINRITATARHPGGGVDNYVGAGVIDPVAALTWDVPEGPETAPYRA--K 400 
Rv3883c|MycP1      RQRFPDLTPAQIIHRITATARHPGGGVDDLVGAGVIDAVAALTWDIPPGPASAPYNV--R 403 
Rv0291|MycP3       RSRYPGLNATEVVRRLTATAHRGARESSNIVGAGNLDAVAALTWQLPAEPGGG-AAP-AK 413 
Msmeg_0624|Mycp3   RSKFPDLTARQVVHRLTTTAQGAARSPSNLIGAGMVDPVAALTWDVADVPLDGPAAPEGR 414 
                   :.::*.*.. :::.*:*:**:  .   .: :*** :*.******::.  *  .      : 
 
Msmeg_0083|MycP1   EVPPPVYIPPPDRGPITAVVIAGATLAFALGIGALARRALRRKQ---- 449 
KEK_05522|MycP1    EIPEPEFIPPPDRGPITWVVVSSAAVALALGIGALTRRALRRR----- 443 
Rv3883c|MycP1      RLPPPVVEPGPDRRPITAVALVAVGLTLALGLGALARRALSRR----- 446 
Rv0291|MycP3       PVADPPVPAPKDTTPRNVAFAGAAALSVLVGLTAATVAIARRRREPTE 461 
Msmeg_0624|MycP3   PIAAPPEPEPRDNTPRIIAFVGTGVLAAAVG--AAFYATYRRKDKTT- 459 
                    :. *      *  *   .      ::  :*  *       *:      
 
Figure 5.15. The global sequence alignment between MycP1sm (Msmeg), MycP1th (KEK), 









Table 5.2. Sequence identity between mycosin orthologues from M. tuberculosis, M. 
smegmatis and M. thermoresistibile 
 
SeqA Name Length SeqB Name Length Alignment 
Score
* 
Msmeg_0083|MycP1 449 M.therm KEK_05522|MycP1 443 78.78 
M. tuberculosis 
Rv3883c|MycP1 
446 Msmeg_0083|MycP1 449 71.97 
M. tuberculosis 
Rv3883c|MycP1 
446 M. therm KEK_05522|MycP1 443 71.11 
M. tuberculosis 
Rv0291|MycP3 
461 Msmeg_0624|MycP3 459 59.04 
Msmeg_0624|MycP3 459 M. therm KEK_05522|MycP1 443 44.02 
M. tuberculosis 
Rv3883c|MycP1 
446 Msmeg_0624|MycP3 459 43.95 
M. tuberculosis 
Rv0291|MycP3 
461 M. therm KEK_05522|MycP1 443 43.79 
Msmeg_0624|MycP3 459 Msmeg_0083|MycP1 449 43.21 
M. tuberculosis 
Rv0291|MycP3 
461 Msmeg_0083|MycP1 449 42.76 
M. tuberculosis 
Rv0291|MycP3 
461 M. tuberculosis Rv3883c|MycP1 446 42.38 
*
Alignment score is defined as the number of identities between the two sequences divided by 
the length of the alignment (Larkin et al., 2007) 
 
Figure 5.16. The overlay model of MycP3tb structure and MycP3sm structure. Few distinct 
differences can be observed, however, the model has a low confidence with a QMEAN Z-
score of -1.45 (Benkert et al., 2011b). 




From the results of the in silico analysis on MycP3tb, it was possible to construct an E. coli 
expression strain that is capable of producing soluble and stable MycP3tb and its orthologues 
MycP3sm, MycP1sm and MycP1th. However, some unknown mechanism inhibited the 
production of MycP3tb but not the mycosins from environmental species. Over-expression of 
M. tuberculosis MycP3 in M. smegmatis inhibited the growth of the expression host. Cell-free 
MycP3 expression was also unsuccessful because some E. coli translational machinery 
components (translation initiation factor IF-2 and elongation factor Tu1 and Tu2) were 
degraded by unidentified protease activity. The cleavage sites on these two proteins were not 
identified due to the difficulty in isolating cleaved products in the reaction milieu. The results 
from all the expression experiments suggest that MycP3 exerted a strongly toxic effect on the 
expression hosts, including the mycobacterial host, in a way that it might harm the translation 
processes of the host cells. Perhaps, in the M. tuberculosis cytoplasmic environment, MycP3 
remains inactive via an unknown inhibitory mechanism until it is transported out of the cell. 




 and find out whether 
such a mutant MycP3 may inhibit the growth of M. tuberculosis; or abolish the function of 
MycP3 via single point mutation S342A and produce inactive MycP3 mutant in vitro and in 
vivo. This would enable one to see whether stable and soluble MycP3 can be produced. These 
experiments are the subject of future investigations. 
 
ESX or T7S systems are widely found in both pathogenic and environmental mycobacterial 
species. The function of M. tuberculosis mycosins possibly no longer has the same substrate 
specificity as its orthologues in environmental mycobacterium species, considering ESX-1 in 
M. tuberculosis is associated with virulence, while in M. smegmatis it is essential for DNA 
transfer (Coros et al., 2008; Flint et al., 2004). They probably have evolved to possess 
virulence towards host cells and even to themselves if not transported correctly out of the cell. 
To differentiate enzyme specificity between mycosins is vital to further understand the 
functions of different ESXs. Furthermore, the mycosins have evolved distantly from other 
substilisins and they serve as attractive drug target candidates due to the fact that MycP1 
seems to regulate the secretion, and process the secreted antigens, from ESX-1, and MycP3 is 
involved with the iron acquisition pathway in mycobacteria. These are both essential 
processes for infection with the organism. Disabling MycP1 will attenuate the bacteria and 
abolishing the function of MycP3 may disrupt the iron acquisition thereby inhibiting the cell 
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Chapter 6. Functional Study of Mycosin-
3, a proteomics approach 
6.1 Introduction 
 
Mycobacterium tuberculosis (M. tuberculosis) has acquired various combinations of 
resistance to all the drugs to which it has been exposed to during treatment, leading to mono-, 
multi- and even extensively drug resistant strains of M. tuberculosis circulating worldwide. 
This necessitates the continuous discovery of novel drug targets to combat tuberculosis. The 
iron acquisition pathway in M. tuberculosis has several attractive drug targets (Owens et al., 
2013). M. tuberculosis cannot survive without iron as it is required for numerous enzymes 
responsible for many cellular processes such as electron transport, amino acid and pyrimidine 
biosynthesis and the tricarboxylic acid cycle. Although free iron is scarce in the host, M. 
tuberculosis has evolved effective iron acquisition machineries to survive inside the host. 
There are two sources of iron in the vertebrate hosts, the non-heme iron which is mostly 
bound in the iron transport proteins, transferrin and lactotransferrin, and the iron storage 
protein, ferritin, and the heme iron which constitutes the prosthetic group in hemoglobin 
inside erythrocytes circulating in the bloodstream. M. tuberculosis has access to both iron 
sources while residing in macrophages. Transferrin can be engulfed into macrophage 
endosomes which fuse with M. tuberculosis-containing phagosomes (Clemens and Horwitz, 
1996), and macrophages can degrade red blood cells releasing heme intracellularly (Frederick 
et al., 2009; Kontoghiorghes and Weinberg, 1995). Additionally, hemoglobin may be 
degraded by hemolysins secreted by M. tuberculosis in the bloodstream (Wren et al., 1998). 
 
The acquisition systems for the two iron sources are distinct. The non-heme iron is imported 
via a siderophore-mediated pathway. Siderophores are small iron chelators with high affinity 
for ferric iron. There are two types of siderophores which are distinguished by their core 
structures, biosynthetic pathways and transport machineries. Exochelin is a secreted, peptide-
based, water soluble molecule which is only produced by environmental mycobacteria. The 
genes responsible for exochelin assembly include fxbA, fxbB and fxbC (Fiss et al., 1994; Yu 
et al., 1998). The exochelin importers are FxuA, FxuB, FxuC and FuxD. One exochelin 
exporter, ExiT, has been identified (Zhu et al., 1998). The other siderophores are the 
salicylate-derived, chloroform extractable mycobactin and carboxymycobactin which are 
produced by most mycobacteria (Barclay and Ratledge, 1988; Messenger et al., 1986). The 
lipophilic mycobactin is cell envelope associated whereas the hydrophilic carboxymycobactin 
is secreted into the extracellular space. The two are synthesized via the same biosynthetic 
pathway encoded by two gene clusters, mbtA-J and mbtK-N (Krithika et al., 2006; Quadri et 
al., 1998). Carboxymycobactin chelates iron from transferrin and is taken up by the Msp 
family porin in the mycobacterial outer membrane (Jones and Niederweis, 2010). In the cell 
envelope, ferri-carboxymycobactin either transfers the iron to mycobactin or delivers it to the 
iron importer complex IrtA-B (Rodriguez and Smith, 2006). The ferri-carboxymycobactin 




releases the iron upon reduction by an unknown reductase (Ryndak et al., 2010). The deferri-
carboxymycobactin is recycled and exported by the membrane complex MmpL5/MmpS5 and 
MmpL4/MmpS4 to acquire more iron (Wells et al., 2013) or prevent siderophore-related self-
poisoning (Jones et al., 2014).  
 
Heme is acquired from hemoglobin by a mycobacterial hemophore Rv0203 (Tullius et al., 
2011). Rv0203 carries heme to the heme importer protein MmpL11 or MmpL3 on the plasma 
menbrane. The imported heme is either degraded by MhuD to release iron (Chim et al., 2010) 
or utilized for the biosynthesis of heme containing proteins such as KatG, catalase-peroxidase, 
and DosT/S, the redox sensing two component system (Svistunenko, 2005). 
 
The expression of the genes encoding the mycobactin biosynthesis and transport machineries 
is regulated by the global iron-dependent regulator, IdeR. When the iron level is high, iron 
binds to IdeR which in turn binds to its target promoter regions and suppresses transcription 
(Rodriguez et al., 2002). The regulation of heme uptake has not been elucidated, however, 
ESX-3, one of the type VII secretion systems, seems to influence both siderophore and 
hemophore-mediated iron acquisition in mycobacteria (Serafini et al., 2013, 2009; Siegrist et 
al., 2014, 2009). In M. tuberculosis, ESX-3 is essential for growth in iron deplete 7H9 media 
(Griffin et al., 2011; Sassetti et al., 2003). The gene expression profile of the M. tuberculosis 
ESX-3 conditional mutant resembles that of M. tuberculosis during iron starvation and this 
mutant cannot be rescued by heme supplementation (Serafini et al., 2013). Both the non-
heme and heme acquisition systems have been well characterized, indicating that ESX-3 is 
unlikely to be directly involved in iron uptake. ESX-3 may, however, modify and secrete 
unidentified factors which facilitate iron and heme acquisition, assist in the post-translational 
modification of certain membrane proteins to enable siderophore and hemophore export and 
import, or increase the permeability of the membrane to iron. ESX-3 membrane core 
structure is composed of 5 proteins, EccB3, EccC3, EccD3, EccE3 and mycosin-3 (MycP3), 
where EccB3, EccD3 and EccE3 are proposed to form the transmembrane pore of the secretion 
system on the plasma membrane, EccC3 contains an ATPase domain providing energy for the 
active export process, and MycP3 has a serine protease active site (Houben et al., 2012). 
 
MycP3 is the only protease in the ESX-3 system. Although its function is not well 
characterized (Abdallah et al., 2007; Houben et al., 2012; Wagner et al., 2013), it may play a 
role in modifying the secreted proteins and other membrane proteins. In this study, a 
Mycobacterium smegmatis MycP3 knock out (KO) mutant (ΔMycP3ms) was generated and 
used to determine the impact of the absence or presence of MycP3 on the proteome of M. 
smegmatis, under high iron conditions in vitro where MycP3 is probably at its basal level. The 
proteins with significantly different abundances were further investigated by RT-qPCR. The 
MycP3 KO mutant was complemented with MycP3 expressed episomally from both ESX-3 
promoters. The intracellular iron levels of M. smegmatis WT, MycP3 KO and complemented 
strains were assayed under high iron and low iron conditions, and after iron rescue. 




6.2 Materials and Methods 
6.2.1 Bacterial Strains, Culture media and Plasmid DNA 
 
Escherichia coli XL-1 blue (Promega, USA) was used for electro-competent cell preparation, 
manipulating and generating plasmid DNA constructs. Mycobacterium smegmatis mc
2
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was used as the wildtype (WT) parent strain from which the MycP3 mutant was derived. E. 
coli was cultured in either Lysogeny Broth (LB) liquid media (1% tryptone [Merck, 
Germany], 0.5% yeast extract [Merck, Germany], 1% sodium chloride [Sigma, Germany], or 
LB solid media (LB supplemented with 1.5 % bacterial agar [Merck, Germany]). M. 
smegmatis was cultured in either 7H9 liquid media (ammonium sulphate, 0.5 g/l; L-glutamic 
acid, 0.5 g/l; sodium citrate, 0.1 g/l; pyridoxine, 0.001 g/l; biotin, 0.0005 g/l; disodium 
phosphate, 2.5 g/l; monopotassium phosphate, 1 g/l; ferric ammonium citrate, 0.04 g/l; 
magnesium sulphate, 0.05 g/l; calcium chloride, 0.0005 g/l; zinc sulphate, 0.0001 g/l; copper 
sulphate, 0.001 g/l; pH 6.6 ± 0.2 at 25°C, BD Biosciences, Germany), or Difco 7H11 solid 
media (enzymatic digest of casein, 1 g/l; disodium phosphate, 1.5 g/l; monopotassium 
phosphate, 1.5 g/l; ammonium sulphate, 0.5 g/l; monosodium glutamate, 0.5 g/l; sodium 
citrate, 0.4 g/l; ferric ammonium citrate, 0.04 g/l; magnesium sulphate, 0.05 g/l; copper 
sulphate, 0.001 g/l; pyridoxine, 0.001 g/l; zinc sulphate, 0.001 g/l, biotin, 0.0005 g/l; 
malachite green, 0.00025 g/l; agar, 13.5 g/l, pH 6.6 ± 0.2 at 25°C, BD Biosciences, Germany), 
both supplemented with 0.05% Tween 80 (Sigma, Germany), 0.5% glucose (Kimix, South 
Africa), and 0.5% glycerol (Sigma, Germany). 
 
M. smegmatis growth was monitored in 7H9 liquid media and Fe-free Sauton’s media (3.5 
mM KH2PO4 [Merck, Germany], 25 mM L-asparagine [Merck, Germany], 10 mM citric acid 
[Merck, Germany], 4 mM MgSO4 · 6H2O [Merck, Germany], 5% glycerol (v/v), and 0.05% 
Tween-80 [Sigma, Germany]). The strains were cultured in 7H9 for gene expression analysis. 
For intracellular iron quantitation, M. smegmatis was grown in (i) 7H9, (ii) iron-deprived 7H9 
from which ferric ammonium citrate was omitted, (iii) extremely low iron 7H9 medium in 
which the iron-deprived 7H9 was treated with 1% Chelex
®
 100 resin (Bio-Rad, USA) at 
room temperature for 48 hours and filter-sterilized and all divalent cation salts except ferric 
ammonium citrate were added after filter sterilisation, or (iv) iron-rescued 7H9 which was 
initially iron-deprived 7H9 but ferric ammonium citrate was added to the level as per 7H9 
medium. Tween-80, glucose and glycerol were supplemented to all types of 7H9 media 
before use (7H9 medium mentioned in this chapter refers to the 7H9 with the Tween-80, 
glucose and glyercol supplementation). 
 
The CloneJet1.2 vector (Fermentas, USA) was used for target DNA replication and 
preservation before cloning into the target vectors. The p2Nil suicide vector (Parish and 
Stoker, 2000) (Figure S6.1) and the pGoal17 selection gene cassette (Figure S6.2) were used 
to generate ΔMycP3ms, and pMV306 (Stover et al., 1991) was used for MycP3 
complementation (Figure S6.3).  
 
 




6.2.2 Generation of M. smegmatis MycP3 gene KO strain 
 
The principle and the method of generating a gene KO mycobacterial strain using 
homologous recombination was described previously (Parish and Stoker, 2000). One 
thousand basepair (bp) fragments upstream (UP1000) and downstream (DOWN1000) of 
MycP3 (MSMEG_0624) were amplified by Polymerase Chain Reaction (PCR) with Phusion
®
 
DNA polymerase (Fermentas, USA) using two pairs of primers (Table 6.1). The UP1000 and 
DOWN1000 PCR fragments were cloned into pJet1.2 vector according to the manufacturer’s 
instructions. The UP1000 and DOWN1000 inserts were digested out of the recombinant 
DNA using the appropriate restriction enzymes. Both inserts were ligated into p2Nil via 
three-way cloning using T4 DNA ligase (Promega, USA).  
 
The selection gene cassette (PAg85-lacZ Phsp60-sacB) from pGOAL17 was inserted into the 
recombinant p2Nil-UP1000-DOWN1000 plasmid at the PacI restriction site. The 
recombinant p2Nil-UP1000-DOWN1000-lacZ-sacB construct was electroporated into 
electro-competent M. smegmatis cells and blue single-crossover colonies were selected on LB 
agar supplemented with 50 μg/ml kanamycin and 0.2% X-gal (Roche, Switzerland). The 
colonies were picked and passaged in LB media in the absence of kanamycin to induce a 
second crossover event. Double crossover colonies were selected on LB agar supplemented 
with 5% sucrose and X-gal. White colonies were further screened by colony PCR using 
screening primers (Table 6.1) to distinguish between WT and ΔMycP3ms strains. The WT 
PCR product was approximately 1600 bp while that of the ΔMycP3ms was approximately 200 
bp. 
 
6.2.3 Proteome Analysis 
 
M. smegmatis WT and ΔMycP3ms  strains were cultured in 100 ml 7H9 medium with 
supplementation to OD600nm of 0.7~0.9 (mid-log phase) and harvested by centrifugation at 
3000 xg at 4°C for 10 min in a desktop swing-bucket centrifuge (Eppendorf, USA). The cell 
pellets were washed twice with cold Tris-HCl buffer (5 mM tris, pH 7.6, 0.005% Tween 80) 
with protease inhibitors and 20 units per milliliter DNase (Roche, Germany). The pellets 
were mixed with an equal volume of 0.1 mm diameter glass beads (Biospec, USA) and 
resuspended in 500 μl sterile cold Tris-HCl buffer. The mixture was ribolyzed using a 
FastPrep
®
-24 ribolyzer (MP Biomedicals, USA) at 6.0 m/s for 30 s repeated 3 times with 30 s 
incubation on ice between each repeat. The whole cell lysate was cleared up by centrifugation 
at 12000 xg at 4°C for 30 min. The supernatant was filtered through a 0.22 micron filter 
device (Millipore, US). The protein concentrations of the samples were assayed using the 
RC-DC protein assay kit (Bio-Rad, USA). Equal amounts of the WT and ΔMycP3ms protein 
extracts (60 μg) were loaded in triplicate onto a Criterion
TM
 XT 4-12% Precast SDS-PAGE 
GEL (Bio-Rad, USA) and electrophoretically fractionated. The in-gel proteins were treated 
and cleaned up as previously described (de Souza et al., 2010; Rappsilber et al., 2007). Mass 
spectrometry was done at the Proteomics Unit of the Central Analytical Facility, Stellenbosch 
University using the Thermofisher LTQ
TM
 Orbitrap Velos mass spectrometer (Thermo 




Scientific, Bremen, Germany). The identified peptides were used to identify the proteins 
using an automated database searching software (Mascot, Matrix Science, London, UK, and 
Sequest) against the M. smegmatis protein database in TBDB (Tuberculosis Database) 
(Reddy et al., 2009). The proteins were considered positively identified when they were 
identified with at least two unique tryptic peptide per protein. Proteins were searched using 
the Adromeda function from Maxquant 1.2.2.5. The relative protein abundance was 
determined as previously described (Vogel and Marcotte, 2008) and compared between the 
















mycP3 UP1000 forward 5’-AAGCTTTCCCACGCACATCG-3’ HindIII 










mycP3 mycP3 screening 
forward 


















mycP3 reverse 5’-AAGCTTTCATGTGGTCTTGTCCTTCC-3’ HindIII 
pr2 forward 5’-CCATGGACGTGGGACGGCGACGA GAATC-3’ NcoI 








RT-qPCR assay SigA 
 
SigA forward 5’-GGGCGTGATGTCCATCTGCT-3’ N/A 
SigA reverse 5’-GTATCCCGGTGCATGGTC-3’ 
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Primer Name Primer Sequence Restriction 
Site 
RT-qPCR assay mycP3 mycP3 forward 5’-GGATCATCGCGTTCGTGGGTAC-3’ N/A 
mycP3 reverse 5’-GTCTTGTCCTTCCGACGGTAGG-3’ 
eccE3 eccE3 forward 5’-GAGCCGTTGTTGACGGTTTG-3’ 
eccE3 reverse 5’-GTTCGGTCGACAACGGGTTC-3’ 
eccC3 eccC3 forward 5’-ACACAAAGGCGAGGGCTTCC-3’ 
eccC3 reverse 5’-AATCGACTTCTCGGCGCGTG-3’ 
mmpL5 mmpL5 forward 5’-GATCAAGCTGGCCGCCAAAG-3’ 
mmpL5 reverse 5’-GTTGCCTTCCTGCATGTCCTTG-3’ 
mmpL4 mmpL4 forward 5’-AAGCGGCCATGGAGAACCAG-3’ 
mmpL4 reverse 5’-CGCGCTTGAAGTCCGGATTC-3’ 
Stellenbosch University  http://scholar.sun.ac.za




6.2.4 MycP3 Complementation 
 
The genomic region of the ESX-3 gene cluster contains two promoters, namely pr1 and pr2 
which are upstream of the MSMEG_0615 and the MSMEG_0620 genes, respectively (Figure 




Figure 6.1. Genetic organization of ESAT-6 cluster 3 in Mycobacterium smegmatis. The 
positions of the promoters, Pr1 and Pr2, are indicated (Maciag et al., 2009).  
 
The two pairs of primers for making the joined DNA fragments of pr1 and MycP3 in the first 
complementation construct and the two pairs of primers for making the joined DNA 
fragments of pr2 and MycP3 in the second complementation construct are given in Table 6.1. 
The reverse primer sequences for the two promoters contain a region which is 
complementary to a region of the sense primers for mycP3 to facilitate single-joint PCR 
connecting pr1/pr2 and MycP3. The single-joint PCR method was described previously (Yu 
et al., 2004). The final PCR products, named pr1-mycP3 and pr2-mycP3 were cloned into 
pMV306 integrative vector. The recombinant pMV306-pr1-mycP3 and pMV306-pr2-mycP3 
plasmids were electroporated into the M. smegmatis ΔMycP3ms mutant strain to generate two 
MycP3 complementation strains, designated ΔMycP3ms::pr1mycP3ms and 
ΔMycP3ms::pr2mycP3ms. 
 
6.2.5 Growth curves under iron-rich and iron-deprived conditions 
 
M. smegmatis WT, ΔMycP3ms, ΔMycP3ms::pr1MycP3ms and ΔMycP3ms::pr2MycP3ms strains 
were cultured in 7H9 broth and iron-free Sauton’s media from a starting OD600nm of 0.01. 
They were incubated at 37°C with a rotating rate of 200 rpm. The OD600nm reading was taken 
every 3 hours for 48 hours. The growth curves were generated by plotting OD600nm readings 
versus time. 
 
6.2.6 Intracellular iron quantitation 
 
The intracellular iron quantitation technique was used as previously described (Riemer et al., 
2004). Fifty millilitres of cultures at mid-log phase (OD600nm of 0.7~0.9) were harvested by 
centrifugation. The cell pellet was resuspended in 500 μl 50 mM NaOH and ribolyzed as 
previously stated. The whole cell lysate was cleared by centrifugation at 12 000 xg at 4°C for 
30 min. One hundred microliters of the whole cell lysate was used for the iron quantification 
assay while another 25 μl was used for protein quantitation using the RC-DC protein assay. 
The 100 μl whole cell lysate was transferred into one well of a 96-well microtiter plate and 




mixed with 100 μl of 10 mM HCl and then 100 μl iron-releasing reagent (a freshly made 
solution of equal volumes of 1.4 M HCl and 4.5%, KMnO4 [Merck, Germany] in water). This 
mixture was incubated at 60°C for 2 hours, cooled to room temperature, and 30 μl of iron-
detecting agent (6.5 mM ferrozine [Sigma, Germany], 6.5 mM neocuproine [Sigma, 
Germany], 2.5 M ammonium acetate [Merck, Germany], and 1 M ascorbic acid [Sigma, 
Germany]) was added to the well and incubated for 30 min at room temperature. The 
absorbance was read at 550 nm on a photospectrometer. Ferric chloride was used as iron 
standards at the concentration of 10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, and 
80 μM, in 50 mM NaOH. The iron concentration was normalized against the protein content 




Fifteen millilitres of each M. smegmatis strain was harvested at mid-log phase from each 
culturing condition (7H9, Fe-free 7H9, and Fe rescued 7H9) by centrifugation. The 
supernatant was discarded and the pellet was resuspended with 1 ml FastRNA
®
 Blue solution 
(MP Biomedicals, USA) and ribolyzed as previously described. The whole cell lysate was 
cleared by centrifugation at 12 000 xg at 4°C for 30 min, and 700 μl of the supernatant was 
transferred into a new 1.5 ml tube and thoroughly mixed with 300 μl chloroform. The 
mixture was centrifuged at 12 000 xg at 4°C for 10 min. The top aqueous layer was 
transferred to a new 1.5 ml tube and mixed with 500 μl pre-chilled 100% ethanol (Sigma, 
Germany). The mixture was transferred onto the RNA purification column from NucleoSpin
®
 
RNA isolation kit (Macherey-Nagel, Germany) and further total RNA purification was done 
according to manufacturer’s instructions. The quality of the total RNA was assayed using a 
Bioanalyzer (Agilent Technologies, USA) at the Central Analytical Facility (Stellenbosch 
University, South Africa). 
 
Five micrograms of total RNA was treated with Turbo DNase (Ambion, USA) according to 
the manufacturer’s instructions. One microgram of Turbo DNase-treated total RNA was used 




 strand cDNA synthesis kit (TaKaRa, USA) 
using the appropriate reverse primers (Table 6.1). Quantitative PCR was conducted using 
SYBR Premix Ex Taq
TM
 (TaKaRa, USA) on the Bio-Rad CFX96
TM
 Real-Time PCR 
Detection System (Bio-Rad, USA) with the following cycling conditions: initial denaturation 
at 95°C for 30 sec; 39 cycles of amplification at 95°C for 5 sec followed by 30 sec at 60°C. 
The melt curve followed with a denaturation step at 95°C for 10 sec and then a melting step 
from 65°C to 95°C with 5 sec staying at each 0.5°C interval. SigA was selected as the 
reference gene due to its constitutive expression. The expression of all genes of interest was 








6.2.8 ESX-3 promoter activity in response to iron levels 
 
The two complementation strains were generated using the two ESX-3 promoters (see section 
6.2.4). The promoter activity in response to iron levels were indirectly assayed using RT-
qPCR on the gene expression levels of MycP3 in WT, ΔMycP3ms, ΔMycP3ms::pr1MycP3ms 




6.3.1 MycP3 gene KO in M. smegmatis and genetic complementation 
 
The Mycobacterium smegmatis ΔMycP3 strain was generated via homologous recombination. 
Two MycP3 complementation strains ΔMycP3ms::pr1MycP3ms and ΔMycP3ms::pr2MycP3ms 
were obtained by electroporating recombinant pMV306-Pr1-MycP3 and pMV306-Pr2-
MycP3 plasmid DNA into the ΔMycP3ms strain respectively. The WTms, ΔMycP3ms, 





Figure 6.2 Colony PCR to validate the strains where ΔMycP3ms screening primers (Table 6.1) 
were used to distinguish between WT and ΔMycP3ms, and complementation strain generating 
primers were used to distinguish between ΔMycP3ms::pr1MycP3ms and 
ΔMycP3ms::pr2MycP3ms (Table 6.1). Lane 1: DNA Marker [1 kb DNA ladder Plus 
(Fermentas, USA)], 2: no template control, 3 and 4: WTms (1674 bp), 5 and 6: ΔMycP3ms 
(251 bp), Lane 7 and 8, ΔMycP3ms::pr1MycP3ms (1684 bp), Lane 9 and 10:  
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6.3.2 Deletion of MycP3 does not impact the growth of M. smegmatis  
 
To determine whether deletion of MycP3 would directly exert a negative effect on the growth 
of M. smegmatis, growth curves were done in 7H9 and Fe-free Sauton’s medium (Figure 6.3). 
M. smegmatis WT, ΔMycP3ms, ΔMycP3ms::pr1MycP3ms, and ΔMycP3ms::pr2MycP3ms 
showed sigmoidal growth without significant differences in iron-rich 7H9 and in iron-free 
Sauton’s medium respectively. The addition of hygromycin to the media did not influence the 
growth of the complementation strains. The standard deviation values for the growth in iron-
free Sauton’s medium are larger than those in 7H9 medium. In addition, RT-qPCR analysis 
demonstrated that the expression level of eccE3, the gene immediately downstream of mycP3, 
was the same in both WT and ΔMycP3ms strains, indicating that the deletion of mycP3 does 
not have a polar effect on the eccE3 gene. 
 































ΔMycP3ms::pr1MycP3ms + Hyg 
ΔMycP3ms::pr2MycP3ms + Hyg 
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Figure 6.3 Growth curves of M. smegmatis WT and ΔMycP3ms strains in 7H9 (a) and Fe-free Sauton’s media (b) respectively. Hygromycin was 
either added or omitted in the medium where the ΔMycP3ms::pr1MycP3ms and ΔMycP3ms::pr2MycP3ms were cultured in triplicates. The error 


























ΔMycP3ms::pr1MycP3ms + Hyg 
ΔMycP3ms::pr2MycP3ms + Hyg 
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6.3.3 Proteomic analysis on M. smegmatis WT and ΔMycP3ms strains  
 
Deletion of MycP3 did not have a significantly negative impact on the growth of M. 
smegmatis in general, however, that assay does not measure its impact on the proteome. To 
assess the impact of MycP3 KO on the M. smegmatis proteome, the WT and ΔMycP3ms 
strains were cultured in 7H9 media and subjected to proteomic analysis. The experiment was 
done in biological duplicate (strains were cultured at different time) and technical duplicate 
(each biological replicate was analysed twice separately). There were 2421 proteins identified 
from the entire set of experiments. Thirty-two proteins with significantly different 
abundances (student T-test result P value smaller than 0.05) between the two strains were 
identified (Table 6.2, Table 6.3, Table 6.4 and Table 6.5) and they represent 1.3% of the 
overall expressed proteome (32 out of 2421). These proteins were found to be involved in a 
large variety of cellular processes including iron acquisition, copper transport, glycine 
catabolism, drug resistance, the maintenance of cellular redox homeostasis and membrane 
potential, siderophore export, DNA replication, repair and protection, dTMP biosynthesis, 
cell cycle and cell division regulation, carbohydrate metabolism, energy metabolism, RNA 
and DNA catabolism, transcriptional control on multidrug efflux pumps, as well as a variety 






























Table 6.2. Proteins identified to be more abundant in the proteome of the ΔMycP3ms strain compared to the WT strain. Where available, the M. 
tuberculosis orthologs are indicated. 










Iron acquisition pathway (Siegrist et al., 2009) 2.2 0.0128 
MSMEG_1017 Glutaredoxin Unknown function, 
its orthologs are involved in cell redox homeostasis utilizing the 
reducing power of glutathione to maintain and regulate the cellular 





TrkA protein  
K
+
 ion uptake regulator 
Unknown function, it involves in controlling membrane potential, pH 
homeostasis and multidrug susceptibility in M. smegmatis. (Castañeda-





Unknown function, its orthologs are involved in redox reactions. 




Hypothetical protein Unknown function, conserved hypothetical protein 3.0 0.0098 
MSMEG_4495 
(Rv2366c) 
CBS domain protein Unknown function, orthologs are involved in multimerization and 
sorting of proteins, channel gating, and ligand binding, possibly 







Unknown function, its orthologs have copper-exporting ATPase 







Glycine catabolism, it breaks down excess glycine molecules. (Kikuchi 




Beta-lactamase It provides resistance to β-lactam antibiotics like penicillins, 
cephamycins, and carbapenems which inhibit the formation of 
3.1 0.0037 
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peptidoglycan cross-links in the bacterial cell wall. 
 
Table 6.3 Proteins only detected in ΔMycP3ms (not detected in the WT strain) 






Carbohydrate degradation, it involves in deoxyribonucleotide catabolic process 0.0085 
MSMEG_3688 Hypothetical protein Unknown function, conserved hypothetical protein 0.0020 
MSMEG_4383 
(Rv0676c) 




Table 6.4 Proteins detected in lower abundance in ΔMycP3ms than in the WT strain 







Unknown function, its ortholog is involved in binding of intermediates in 
the tetrapyrrole biosynthetic pathway 
2.2 0.0371 
MSMEG_1633 DNA polymerase III, 
alpha subunit 
DNA replication, DNA synthesis and repair 2.1 0.0463 





dTMP biosynthetic process, nucleotide metabolism 3.3 0.0202 
MSMEG_2736 
(Rv2725c) 
GTP-binding protein Signal transduction 7.3 0.0002 
MSMEG_3026 Hypothetical protein Unknown function, conserved hypothetical protein 6.1 0.0487 
MSMEG_3496 MmpL4 protein One component of siderophore export system. Iron acquisition pathway 











Catalyze step 8 of glycolysis. Carbohydrate metabolism 6.5 0.0148 
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MSMEG_5307 TetR-family protein 
transcriptional 
regulator 
Unknown function, orthologs are involved in the transcriptional control of 
multidrug efflux pumps, pathways for the biosynthesis of antibiotics, 
response to osmotic stress and toxic chemicals, control of catabolic 




Type I antifreeze 
protein 
Permit bacterial survival in subzero environments 4.6 0.0367 
MSMEG_5926 Putative secreted 
protein 
Unknown function 4.7 0.0130 
MSMEG_6401 Prenyltransferase, 
UbiA family protein 
Unknown function, orthologs catalyse the transfer of an isoprenyl 
pyrophosphate to a protein or a peptide 
6.1 0.0194 
MSMEG_6467 Starvation-induced 
DNA protecting protein 
Unknown function, orthologs are anti-stress iron proteins preserving 
bacteria from oxidative damage, also responsible for cellular iron ion 





Unknown function, oxidize aldehyde to carboxylic acid 2.0 0.0032 
 
Table 6.5 Proteins only detected in the WT strain (not detected in the ΔMycP3ms strain) 
Gene Name Gene Product Functional Category P-
value 
MSMEG_1966 Hypothetical protein Unknown function, conserved hypothetical protein 0.0477 
MSMEG_3237 ATP-binding protein Unknown function, orthologs are involved in providing energy to carry out biological 
processes including translocation of various substrates across membranes and non-
transport-related processes such as translation of RNA and DNA repair 
0.0136 
MSMEG_4559 ABC transporter, 
membrane spanning 
protein 
Unknown function, involved in substrate transport across the membrane 0.0137 
MSMEG_6029 Hypothetical protein Unknown function, conserved hypothetical protein 0.0091 
MSMEG_6945 Ribonuclease P protein 
component 
Unknown function, orthologs are responsible for RNA molecule cleavage. Ususally it is 
involved in efficient production of tRNA and other small non-coding RNA genes 
0.0199 
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6.3.4 RT-qPCR of EccC3, MmpL5, MmpL4 
 
ESX-3 was previously found to be associated with mycobactin-mediated iron acquisition 
(Siegrist et al., 2009). We were therefore interested in further exploring iron transport related 
proteins with significant difference in quantity between the WT and ΔMycP3ms strains 
cultured in 7H9 (high Fe). The proteomic results identified EccC3 (Ftsk-SpoIIIE family 
protein, ESX-3 conserved component (Gey van Pittius et al., 2001)), MmpL5 and MmpL4 
(both are related to siderophore export (Wells et al., 2013)) involved in Fe sequestration. RT-
qPCR was conducted on the genes encoding these three proteins to determine whether the 
gene expression levels correlated with the proteomics results (Figure 6.4). 
 
The expression level of eccC3 in ΔMycP3ms was higher than the WT and two 
complementation strains indicating an up-regulation in the ΔMycP3ms strain which correlates 
with the proteomic finding. MmpL4 expression was down-regulated on transcriptional level 
in ΔMycP3ms, also correlating with the proteomic finding. MmpL5 expression was down-
regulated at the transcriptional level in ΔMycP3ms but the MmpL5 protein was absent in the 
WT proteome. The complementation strains did not show the same expression level of eccC3 




Figure 6.4. Gene expression levels of eccC3, mmpL5 and mmpL4 relative to that of sigA when 
strains were cultured in 7H9 media. The experiment was done in triplicates. The gene 
expression level relative to sigA is plotted against the gene name. Error bars show standard 
deviation. Complementation strains were able to restore the expression levels of the target 
genes, thus the significance of the difference between the wildtype and ΔMycP3ms only are 
calculated which, for three genes, eccC3, mmpL5 and mmpL4, are p = 0.012, p = 0.000066, p 
















































6.3.5 Intracellular iron quantitation 
 
To investigate whether the altered expression of eccC3, mmpL5 and mmpL4 resulting from 
the deletion of MycP3 in the M. smegmatis genome might influence the intracellular iron 
level in M. smegmatis, the intracellular iron content of the four strains was quantified. 
However, no significant differences in the intracellular iron levels were detected between the 
strains cultured under the same conditions were detected (Figure 6.5). As expected, iron 
levels dropped dramatically for all 4 strains when they were sub-cultured in Fe-free 7H9, 
showing an approximately 4-fold decrease. In contrast, intracellular iron level rose to a much 
higher level than in normal 7H9, increasing by approximately 2-fold, when iron was added to 







Figure 6.5. The comparison of the intracellular iron levels of WT, ΔMycP3ms, 
ΔMycP3ms::pr1MycP3ms and ΔMycP3ms::pr2MycP3ms strains under 7H9, Fe-free 7H9 and Fe 
rescued 7H9 media. The experiment was done in triplicates. The error bars show standard 
deviations. 
 
6.3.6 Functional analysis of the two promoters in the ESX-3 gene cluster 
 
To determine how the ESX-3 promoters respond to different iron conditions, the MycP3 
expression levels from the two complementation strains were compared with those in the WT 
and KO using RT-qPCR on RNA recovered from bacteria grown in 7H9, Fe-deprived 7H9 
and Fe-rescued 7H9 media. 
 
In 7H9 media, the expression levels of mycP3 were similar in the WT and 


































level about 6-fold higher than in WTms and ΔMycP3ms::pr1MycP3ms (Figure 6.6). When 
grown in iron-deprived media, the situation reversed with a similar mycP3 expression in 
WTms and ΔMycP3ms::pr2MycP3ms but 7-fold higher mycP3 expression in 
ΔMycP3ms::pr1MycP3ms (Figure 6.6). Predictably, when the Fe-deprived culture was rescued 
with Fe, the MycP3 expression level resembled that in normal 7H9 media, where the 
expression in ΔMycP3ms::pr2MycP3ms was 6-fold higher than WT and 





Figure 6.6 Comparison of the expression levels of mycP3 in the WT, ΔMycP3ms and two 
MycP3 complementation strains under 7H9, Fe-free 7H9 and Fe rescued 7H9 media, where 
the experiments were done in triplicates. The error bars show standard deviations. Seeing that 
the mycP3 expression level of wildtype is always similar to that of one of the 
complementation strains, and those of the two complementation strains have distinct 
difference on mycP3 expression levels, the significance of difference among the strains can be 
represented by comparing the two complementation strains. In 7H9, iron deprived 7H9 and 
iron rescued 7H9 media, the p value for the significance of different mycP3 expression levels 





ESX-3 is involved in the mycobactin-mediated iron acquisition pathway (Siegrist et al., 2014, 
2009). The growth of the Mycobacterium smegmatis ΔmbtDΔesx-3 double mutant was not 
affected unless the exochelin pathway was also disabled (Siegrist et al., 2009). Possessing the 






















































mycobactin pathway. It is not known to what extent the loss of MycP3 will influence the 
functionality of the ESX-3 system with regards to mycobactin-mediated iron acquisition.  
 
To better understand the contribution of MycP3 to iron acquisition in M. smegmatis, we 
generated and characterised mycP3 knockout and complemented strains. Although ΔMycP3ms 
did not show any significant in vitro growth defect compared to the WTms (Figure 6.3), some 
molecular pathways may be altered. To address this possibility, we exploited high resolution 
mass spectrometry to analyse the proteomes of WTms and ΔMycP3ms under normal nutrient 
sufficient conditions. These were compared to determine the effect of the absence of MycP3 
on overall metabolism in M. smegmatis. This revealed that, although deletion of MycP3 did 
not have a major impact on the overall proteome of M. smegmatis (1.3%), it led to the 
differential abundance of iron homeostasis-related proteins including EccC3, MmpL5 and 
MmpL4 between WTms and the ΔMycP3ms.  
 
To investigate whether the differential abundance of iron-homeostasis-related proteins had 
impact on proteins played a role in iron acquisition/homeostasis, we compared intracellular 
iron levels in the WT, mutant and complemented strains. This demonstrated that the 
intracellular iron levels were consistent across all strains (Figure 6.5) suggesting that the 
ΔMycP3ms mutant did not show a defect in iron acquisition. This is likely because exochelin 
is able to compensate for the loss of carboxymycobactin as carboxymycobactin constitutes 
less than 5% of the total extracellular iron-binding capacity in M. smegmatis (Ratledge and 
Ewing, 1996). Such a loss of carboxymycobactin might exert a negative effect on the iron 
acquisition efficiency. The intracellular iron levels for all strains decreased when sub-cultured 
to iron-deprived media from iron rich media but increased to a level even higher than that in 
the original iron rich media when rescued with iron. This observation may be explained by 
the hypothesis that cell envelope-associated mycobactins serves to temporarily store iron 
(Ratledge, 2004). Therefore we reason that the production of mycobactin was suppressed in 
the original iron rich conditions, but derepressed during iron deprivation to produce a large 
amount of mycobactin which was transported into the cell envelope (Figure 6.7). When the 
iron was added to rescue the culture, the normal iron uptake was restored. The increased iron 
is possibly from the iron-bound mycobactin retained in the cell envelope (Figure 6.7). 
 





Figure 6.7 An illustration of the change in intracellular iron levels of M. smegmatis cultured 
in 7H9 medium along iron deprivation and iron rescue processes. When iron is sufficient, free 
Fe
3+
 can be imported freely through porin (a). When Fe
3+
 is depleted, carboxymycobactin and 





 can be imported freely again meanwhile there are still significant 
amount of Fe
3+
-containing mycobactin in the cell envelope playing an Fe
3+
 storage role thus 
elevating the intracellular iron content (c).  
 
Proteomic analysis demonstrated that the ESX-3 component, EccC3, was more abundant in 
ΔMycP3ms than in WT. This was confirmed by RT-qPCR, which also demonstrated that 
eccC3 expression was reduced upon complementation. It appears that an unknown 
mechanism, possibly feedback from the downstream effectors of ESX-3, compensates for the 
loss of the functional ESX-3 by up-regulating the production of the entire system (Figure 6.8). 
The other components of ESX-3 were not detected by mass spectrometry, probably due to the 
protein extraction protocol which did not enrich for membrane proteins and the low 
expression of ESX-3 under iron sufficient conditions. Evidence in the literature shows that 
ESX-3 not only affects the siderophore-mediated iron acquisition but also heme uptake 
(Serafini et al., 2013). It is thus interesting to speculate that ESX-3 influences the secretion 
and maturation of multiple growth factors, as well as post-translational modification on 
membrane-bound proteins. The higher abundance of ESX-3 might result in more growth 
factors being secreted and facilitating nutrient acquisition, including Fe
3+
, resulting in excess 
intracellular quantity (although this was not observed in the assay).  
 
The proteomic results also showed differential abundance of many other proteins playing 
various roles in the metabolism of the bacteria. The changes in the abundance of these 




proteins are probably the downstream effects of the excess intracellular Fe
3+
 ions imported 
via the exochelin pathway, and it is probably not affected by ESX-3. It is hypothesized that 
all those downstream effects are linked (Figure 6.8). After being transported into the 
cytoplasm, the ferric iron bound to exochelin is reduced to ferrous iron upon release by an 
unknown reductase (Zhu et al., 1998) which in turn needs to be reduced for recycling. The 
extra pressure on redox homeostasis maintenance might be relieved by producing more redox 
regulators such as glutaredoxin as observed (Table 6.2) (Lillig et al., 2008). Another 
downstream effect is the disruption of the existing membrane potential of the bacteria due to 
the excess intracellular positive charges exerted by the Fe ions. The higher abundance of the 
TrkA K
+
 uptake regulator (Table 6.2) may remedy the situation to maintain a normal 
membrane potential (Castañeda-García et al., 2011). This could also be reinforced by the 
more abundant copper exporters (copper translocating P-type ATPase, Table 6.2) which may 
render the bacteria more resistant to copper toxicity (Hodgkinson and Petris, 2012). The 
ESX-3 is a multi-component membrane transporter complex consisting of the EccB3, EccC3, 
EccD3 and EccE3 transmembrane partners, with EccE3 possibly stretching into the outer 
membrane (Houben et al., 2012). This machinery may play a role in maintaining the cell wall 
integrity, disruption of which by deleting MycP3 may have resulted in the increased 
production of β-lactamase as seen by the increased levels of MSMEG_6575 (Table 6.2). This 
may confer resistance to many antibiotics, including penicillin, cephamycin and carbapenems 
which inhibit peptidoglycan cross-link formation. These proteomic findings can be further 
investigated on transcriptional level by RT-qPCR. Alternatively, the downstream products of 
the enzymes involved in those cellular processes can be used as markers to assess and 
compare their activities in the WTms and ΔMycP3ms strains. 
 
The proteomics data also provided evidence that the MycP3 mutant had slowed down cellular 
metabolism on a micro-scale (not observed from the growth curves) with many house-
keeping enzymes present in lower abundance (Figure 6.8). These include the DNA 
replication and repair enzyme (DNA polymerase III), nucleotide biosynthetic enzyme 
(thymidylate synthase), cell cycle and cell division regulator (MSMEG_3741), carbohydrate 
metabolic enzyme (phosphoglycerate mutase), as well as some components in bacterial 
survival mechanisms against physiological stress (MSMEG_5307, MSMEG_5479 and 
MSMEG_6467). A few proteins were not identified in the mutant including an ATP-binding 
protein (MSMEG_3237) possibly providing energy to various substrate transport systems 
across the membrane as well as RNA translation and DNA repair systems, and a ribonuclease 
P protein component which is involved in tRNA production (Guerrier-Takada et al., 1983).  
Although technical limitations might have limited sensitivity, the failure to identify these 
proteins suggests that the mutant was not at its optimal growth where full scale production of 
cellular components and the survival mechanism are not required. 
 
An interesting observation is that MmpL5 was only detected in ΔMycP3ms mutant whereas 
MmpL4 was less abundant compared to WTms (Figure 6.8). MmpL5 and MmpL4, together 
with MmpS5 and MmpS4, are components of a hetero-tetramer complex on the plasma 
membrane which is involved in/responsible for siderophore export (Wells et al., 2013). 
Although the genes encoding MmpL4 and MmpL5 are located in different operons 




(Rodriguez et al., 2002), the expression of both is regulated by iron and they should show 
similar levels of transcription and translation. Since deletion of MycP3 is likely to 
compromise ESX-3 function, mycobactin mediated iron uptake may be impaired making 
mycobactin export less important in the ΔMycP3ms mutant compared to WTms. Expression of 
this export system may therefore be down-regulated. This is supported by RT-qPCR results 
(Figure 6.3) which showed that both genes were down-regulated in the ΔMycP3 mutant and 
the effect was reversed by MycP3 complementation. Down-regulation of transcription 
corresponded to less MmpL4 protein in the whole cell lysate of ΔMycP3ms, although similar 
was not observed for MmpL5. This study did not enrich for membrane proteins and MmpL5 
was abundant in the soluble fraction, suggesting that the maturation and export of this protein 
onto plasma membrane may be impaired, and that MycP3 may play a direct or indirect role in 




























Figure 6.8 The proposed model of the downstream effects of MycP3 knock-out in M. 
smegmatis under high iron conditions. Loss of MycP3 had a negative impact on the 
siderophore-mediated iron acquisition pathway and this effect signalled the bacteria to 
produce more ESX-3 which in turn allowed more ferric ion to be imported via exochelin-
mediated iron acquisition pathway. The increased import of Fe
3+
 resulted in more oxidized 
form of Fe
3+
 reductases which were possibly reduced by glutareductase to maintain the redox 
homeostasis in the bacteria. Meanwhile the increased amount of Fe
2+
 elevated the 





 exporters were more abundant to secrete excess positive charges. A 
number of cellular metabolisms were slowed down, including DNA replication and repair, 
nucleotide biosynthesis, carbohydrate metabolism, tRNA production, and some survival 
mechanisms. Interestingly, MmpL5 was not observed from ΔMycP3ms possibly implying that 














The M. smegmatis ESX-3 is expressed from two promoters as mentioned previously (Maciag 
et al., 2009). The efficiency of complementation using both promoters in the ESX-3 gene 
cluster was investigated. Previous studies did not find major differences in expression of the 
genes in the cluster downstream of these two promoters under various culturing conditions 
except acid stress (Maciag et al., 2009). The transcription of MycP3 gene from the promoter 
immediately upstream of the cluster (pr1) responds to different iron levels in the same fashion 
as WTms (Figure 6.6) implying that the transcription of mycP3 gene is controlled by the first 
promoter (pr1) in the gene cluster even though the gene is downstream of the 2
nd
 promoter 
(pr2) (Figure 6.1) (Maciag et al., 2009). However, the transcription level of MycP3 under the 
control of the first promoter is almost 5 fold higher than in the WTms. In the integrative 
complementation vector, the mycP3 gene was positioned directly downstream of the promoter, 
rather than being 9 genes downstream as in the WTms genome. Such a gene re-arrangement 
brings the gene closer to the transcription start site increasing the rate of transcription, hence 
a higher number of transcripts (Lim et al., 2011). The second promoter is not regulated in the 
same manner as the first, indicating its independence from the IdeR regulation. It was 
proposed that the first promoter in ESX-3 gene cluster is responsible for the transcription of 
the entire operon while the second promoter only influences the transcription of the 6 genes 
downstream of it (Maciag et al., 2009). Although iron was deprived, the expression level of 
MycP3 by the second promoter still reached the same level as in WTms, possibly to match 
with those of other ESX-3 components. When iron was sufficient, the second promoter was 
up-regulated by an unknown mechanism to express the downstream PE protein 
(MSMEG_0620), esx-like antigen 7 (MSMEG_0621) and secreted protein EspG3 
(MSMEG_0622) which may be required in other metabolic pathways. The two promoters in 
the gene cluster are not redundant as they respond to the different iron levels in opposite ways 
which was not observed previously. The regulation of the second promoter is of interest for 
further investigation. 
 
The influence of MycP3 on the proteome under iron-deprived conditions may reveal more 
clues as to the protein’s function. The proteomes of both MycP3 complementation strains can 
be analysed together with the WTms and the ΔMycP3 ms mutant as the two promoters are non-
redundant. This work is currently under investigation. For further validation of the 
modification role of MycP3 on MmpL5, both proteins need to be produced in vitro and their 
binding affinities or possible cleavage activity may then be analysed. The cellular localization 
of MmpL5 in the WT and ΔMycP3ms mutant can be determined and compared using MmpL5 













This study confirmed the direct relationship between siderophore-mediated iron acquisition 
and ESX-3 secretion system. Loss of one component of this secretion system, Mycosin-3, 
leads to various downstream effects on divalent cation transport, redox homeostasis, 
membrane potential, drug resistance, and many other house-keeping processes. Evidence has 
started to reveal and support the pleiotropic effect of substrate secretion and modification by 
ESX-3. Abolishing the ESX-3 secretion system may impair many cellular functions to stop 
the bacterial growth of M. tuberculosis, attenuating the pathogen in the host, hence offering 
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Type VII secretion systems are essential for the survival and virulence of Mycobacterium 
tuberculosis. Much is still unknown about the five copies of the T7SS in this pathogen, 
including the identity of all substrates, the secretion mechanism, and the role in pathogenicity. 
It is evident that a large number of substrates of ESX-1 and ESX-5, such as the Esp and PPE 
proteins, are responsible for maintaining the cell wall integrity of the bacteria and conferring 
specific antigenic features. It seems the well-known T-cell antigens, ESAT-6 and CFP-10, are 
more likely to target and lyse the bacterial membranes than the host membranes (de Jonge et 
al., 2007; Garces et al., 2010). We postulate that that the substrates of ESX-1 and ESX-5 
appear not to be directly related to the virulence of the pathogen. ESX-3 influences the 
acquisition of both iron and heme, mediated by siderophores and hemophores respectively. 
Possibly the substrates or the membrane complex of ESX-3 facilitate either the export of 
siderophores and hemophores or the iron and heme acquisition processes extracellularly. 
 
The subtilisin-like serine protease, mycosin-3, one of the membrane component of ESX-3, 
was unable to be produced either by expression hosts or in vitro, suggesting that it may exert 
a toxic effect on the host if not exported.  
 
The connection between ESX-3 and iron/heme acquisition has been observed previously by a 
few international research groups. However, how ESX-3 influences the iron/heme uptake has 
not been studied in detail. Our proteomics and RT-qPCR data on the wild type and mycosin-3 
deletion mutant of M. smegmatis suggests that ESX-3, especially mycosin-3, may enable the 
functionality of siderophore export system by facilitating the localization of MmpL5, without 
which siderophore can no longer get recycled and exported to acquire iron and intracellular 
accumulation of siderophores is toxic to mycobacteria possibly through intracellular iron 
chelating. Although this result needs to be validated, primarily mycosin-3 can be regarded as 
an important anti-TB drug target, the abolishment of which may lead to iron deprivation of 
the bacteria which cannot be rescued by heme. Without iron, the pathogen may not survive 
and cause disease in the host. 
7.2 Future Directions 
 
Many protein production methods were used to investigate the production of recombinant 
MycP3, however, despite many attempts with different methods, it was not possible with all 
the tools available to us. Two other international groups also did not manage to clone and 
produce M. tuberculosis orthologues of MycP1 and MycP3 either (Solomonson et al., 2013; 




Wagner et al., 2013). Their results agree with our findings that mycosins from M. 
tuberculosis may be toxic to the expression host and not possible to be expressed at this stage. 
 
To test this hypothesis, the following approaches can be employed in future studies: 
 
1. The signal peptide of MycP3 could be deleted in the M. tuberculosis genome to determine 
whether the un-exported MycP3 exerts a toxic effect on the M. tuberculosis mutant, and/or 
 
2. The catalytic triad of MycP3 can be deactivated by generating a point mutation at the serine 
residue to establish whether E. coli is able to produce inactive MycP3. 
 
The functional studies of MycP3 have provided new insights into the regulation of iron 
homeostasis in the mycobacteria. To validate the possible impact of MycP3 on MmpL5, the 
following methods can be adopted: 
 
1. The soluble domains of MmpL5 can be cloned and produced and anti-MmpL5 antibodies 
generated against them. The antibodies may be used to determine the cellular localization of 
MmpL5 in the wild type and ΔMycP3 mutant of M. smegmatis to assess whether MycP3 
affects the export of MmpL5. 
 
2. An enzyme assay can be done using the soluble domains of MmpL5 and MycP3 in vitro to 
determine whether MycP3 has catalytic activity against MmpL5. The cleavage results can be 
visualized using SDS-PAGE. 
 
In addition, to reveal novel substrates of ESX-3, the secretomes of WTms, ΔMycP3 ms and 
ΔMycP3ms::pr1MycP3ms can be compared. The proteins which are absent from, or 











Figure S5.1 Plasmid DNA map of pJET1.2 cloning vector. 
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Figure S5.2 Plasmid DNA map of pGEX-6P-1 expression vector. 
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Figure S5.4 Plasmid DNA map of pCOLD expression vector. 
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Table S4.1 can be found in the CD attached. 
 
Table S4.2. Proteins in carbohydrate metabolism and its regulation 
Accession 
Number 
Gene  Protein Function Reference info 
Rv0062 celA1 Cellulase Endoglucanase for cellulose.  (Varrot et al. 2005) 
Rv0126 treS Trehalose synthase Glucan synthesis: isomerize trehalose to maltose (Roy et al., 2013) 
Rv0363c fba Fructose-1,6-biphosphate 
aldolase 
Reversible cleavage of fructose 1,6-bisphosphate to 
dihydroxyacetone phosphate and glyceroldehyde 3-
phosphate in glycolysis/gluconeogenesis. 
(de la Paz 
Santangelo et al. 
2011) 
Rv0946c pgi Phosphoglucose isomerase 2
nd
 enzyme of glycolysis, converting glucose-6-phosphate 
and fructose-6-phosphate 
(Mathur et al. 











Carbon metabolism regulator. NAD
+
-dependent deacetylase 
to reverse PAT-acetylation. 
(Lee et al. 2012) 
Rv1098c fum Fumarase Fumarate to L-malate hydration in tricarboxylic acid cycle  (Mechaly et al. 
2012) 
Rv1326c glgB α-(1,4)-glucan branching 
enzyme 
Transfers oligosaccharide from α-(1,4)-glucosidic link to 
new α-(1,6)-branch (glucogen biosynthesis) 
(Garg et al. 2007) 






Table S4.3. Proteins in amino acid metabolism 
Accession Gene Protein Name Function Reference 
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 enzyme in lysine biosynthesis from L-
aspartate  
(Weyand, Kefala & Weiss 
2006) (Weyand, Kefala & 
Weiss 2007) 
Rv0884c SerC Phosphoserine aminotransferase 2
nd
 enzyme in phosphorylated serine 
biosynthesis 
(Coulibaly, et al., 2012) 
Rv0948c Not 
assigned 
Intracellular chorismate mutase Chorismate to prephenate conversion in 
Shikimate aromatic amino acid pathway  




Secreted chorismate mutase (Qamra et al. 2005) (Qamra et 







 enzyme in the conversion of proline to 
glutamate in proline utilizatiom system 
(Lagautriere et al., 2014) 
Rv1201c dapD Tetrahydrodipicolinate N-succin-
yltransferase 
diaminopimelate (DAP) pathway to L-lysine: 
5
th
 step  




lysA Diaminopimelate decarboxylase L-lysine biosynthesis: Last step, duplicated 
gene  
(Gokulan et al. 2003) (Kefala, 
Perry & Weiss 2005) (Weyand 





Sulfur carrier protein complex 
OM 
Cysteine biosynthesis: CysM replaces O-
acetylserine acetyl by Cys-O thiocarboxylate. 
Resulting cysteine released proteolytically.  
(Jurgenson et al. 2008) 
Rv1603 hisA Histidine/Tryptophan 
biosynthesis isomerase 
Histidine/tryptophan biosynthesis: Metabolite 
isomerization 
(Due et al. 2011) 




 step (Cherney et al. 2007) (Moradian 
et al. 2006) 
Rv1656 argF Ornithine carbamoyltransferase Arginine biosynthesis: 6
th
 step (Moradian et al. 2006) 
(Sankaranarayanan et al. 2008) 
Rv1826 gcvH Glycine cleavage system protein 
H 
Glycine cleavage system: intermediate and 
electron shuttling. 
(Abendroth et al. 2010) 




 step (Cho, Sharma & Sacchettini 
2003) 




 step (Javid-Majd et al. 2008) 
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(Webby et al. 2005) (Webby et 
al. 2010) (Jiao et al. 2012) 




 step (Lee et al. 2006) 
Rv2220 glnA1 Glutamine synthetase Binds ammonia to glutamate to produce 
glutamine 
(Krajewski, Jones & Mowbray 
2005) 
Rv2391 nirA Siroheme-dependent sulphite 
reductase 
Reduces sulphite to sulphide in sulphur-
containing amino acids and cofactors. 
(Schnell et al. 2005) 
Rv2537c aroD 3-dehydroquinate dehydratase Shikimate/quinate pathways: 3-dehydroquinate 
dehydration to 3-dehydroshikimate 
(Evans et al. 2002) 
Rv2539c aroK Shikimate kinase Chorismate biosynthesis: 5
th
 step   (Hartmann et al. 2006) 
Rv2753 dapA Dihydrodipicolinate synthase L-lysine biosynthesis: 1
st
 step (Kefala & Weiss 2006) 
Rv2773c dapB Dihydrodipicolinate reductase L-lysine biosynthesis: 2
nd
 step (Kefala et al. 2005) 
Rv2780 ald L-alanine dehydrogenase L-alanine to pyruvate reversible oxidative 
deamination  
(Tripathi & Ramachandran 
2008) 
Rv2995c leuB 3-isopropylmalate dehydrogenase Leucine biosynthesis: 3
rd
 step (Singh et al. 2005) 
Rv3290c lat Lysine ε-aminotransferase L-lysine ε-amino transfer  to α-ketoglutarate to 
yield L-glutamate and α-aminoadipate-δ-semi-
aldehyde 
(Tripathi & Ramachandran 
2006) 
Rv3710 leuA α-isopropylmalate synthase Leucine biosynthesis: 1
st







Table S4.4. Proteins in lipid and polyketide metabolism 
Accession Gene Name of Protein Function Reference 
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Fatty acyl-AMP ligase and 
acyl carrier protein 
Lipopeptide biosynthesis: transfer of fatty-acyl chains to 
Rv0100. 
(Liu et al. 2013) 
Rv0242c fabG4 β-ketoacyl coA reductase Disaggregated fatty acid synthesis acetoacyl-CoA 
reduction to 3-hydroxyacyl-CoA 
(Dutta et al. 2011) (Dutta 




Keto- and methoxymycolate production by methylation. (Boissier et al. 2006) 






Acyl-ACP desaturase Mycolic acid precursor synthesis: variable double bonds 
for diverse mycolic acids 
(Dyer et al. 2005) 
Rv0855 far Fatty acid-CoA racemase Fatty acid metabolism: (2R)-branched-chain fatty acid-
CoA to (2S)-stereoisomer conversion  
(Rhee et al. 2005) 
Rv0859-
R0860 
fadA-fadB Acyl-CoA thiolase  fatty 
acid oxidation protein 
β-Oxidation lipid degradation: trifunctional enzyme (Venkatesan & Wierenga 
2013) 
Rv1143 mcr α-methylacyl-coA 
racemase 
Interconversion of (2R)- and (2S)-methylacyl-CoA. (Savolainen et al. 2005) 
(Bhaumik et al. 2007) 
Rv1208 gpgS Glucosyl-3-
phosphoglycerate synthase 




(Gest et al. 2008) (Urresti 
et al. 2012) 
Rv1256c cyp130 Cytochrome P450 
CYP130 
Unknown function. Binds primary arylamines  (Ouellet, Podust & Ortiz 
de Montellano 2008) 
Rv1284-
Rv3588c 
canA-canB Carbonic anhydrases Fatty acid biosynthesis: hydration of CO2 to bicarbonate 
(reversible)  
(Covarrubias et al. 2005) 
(Covarrubias et al. 2006)β 
Rv1372 pks18 Type III polyketide 
synthase 18 
Aliphatic long-chain acyl-CoA starter unit conversion to 
tri- and tetraketide pyrone precursors for cell wall lipid 
synthesis by fatty acid synthases. 
(Sankaranarayanan, et al., 
2004) 
Rv1411c lprG Conserved lipoprotein 
LprG 
Binds glycolipid to enhance Toll-Like Receptor 2 
recognition of triacylated glycolipids. Potential  support 
of glycolipid transport in bacterial cell wall biogenesis 
(Drage et al. 2010) 
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Rv1483 fabG1 β-ketoacyl reductase Long-chain fatty acid biosynthesis: NADPH-dep. reduc-
tion of long-chain β-ketoacyl derivatives. 
(Cohen-Gonsaud et al. 
2002) 
Rv1484 inhA NADH-dependent 2-trans-
enoyl-ACP reductase 
Mycolic acid elongation. Drug target of isoniazid (INH). (He et al. 2006) 
Rv2217 lipB Octanoyl-[acyl carrier 
protein]-protein 
acyltransferase 
Lipolyation: octamoic acid transfer to lipoyl domains for 
derivative lipolation by LipA. 





Malonyl coA-acyl carrier 
protein transacylase 
Fatty acid biosynthesis: malonate transfer from malonyl-
CoA to holo-ACP  
(Li et al. 2007) (Ghadbane 
et al. 2007) 
Rv2244 acpM Acyl carrier protein M, 
AcpM 
Type II fatty acid synthesis: Intermediate shuttling. (Wong et al. 2002) 
Rv2245 kasA β-ketoacyl-ACP synthase 
(KAS) 
Fatty acid biosynthesis: condense acyl-AcpM and 
malonyl-AcpM in each elongation cycle of the FAS-II 
pathway 
(Luckner et al., 
2009)(Schiebel et al., 
2013) 
Rv2266 cyp124 Cytochrome P450 124 Hydroxylates methyl-branched lipids at chemically 
disfavoured ω-position 
(Johnston et al. 2009) 
Rv2276 cyp121 Cytochrome P450 121 Unknown function: Possibly involved in lipid or 
polyketide metabolism 
(McLean et al. 2008) 
Rv2498c citE Citrate lyase β-subunit Fatty acid biosynthesis: Protein bound citryl-CoA 
cleavage to oxaloacetate and protein-CoA derivative.  
(Goulding et al. 2007) 
Rv2701c suhB Inositol monophosphatase 
(IMPase) 
Myo-inositol-I-phosphate dephosphorylation to myo-
inositol for cell-wall phosphatidyl inositol (PI) synthesis. 




Isopentenyl diphosphate synthesis: 2
nd
 step. Precursor of 
isoprenoids such as steroid hormones, carotenoids, 
cholesterol and ubiquinone 
(Henriksson et al. 2007) 
Rv2941 fadD28 Fatty acyl-AMP ligase 
D28 
Fatty acyl activation and transfer to polyketide synthases 
for complex lipid production 
(Goyal et al. 2012) 
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Rv3089 fadD13 Fatty acid CoA ligase 13 Binds CoA to fatty acids  (Goyal et al. 2012) 




 step. Biotinylates acetyl-CoA 
carboxylase  
(Gupta et al. 2010) 
Rv3280 accD5 Acyl-CoA carboxylase Mycolic acid synthesis: acyl-CoA carboxylation to 
produce extender subunits for fatty acids and polyketide 
natural product biosynthesis.  




Tuberculosinyl transferase Biosynthesis of 1-tuberculosinyladenosine (1-TbAd) (Layre et al., 2014) 
Rv3518c cyp142 Cytochrome P450 142 Sterol oxidation: Converts cholesterol to 5-cholestenoic 
acid or cholest-4-en-3-one to cholest-4-en-3-one-27-oic 
acid. 
(Driscoll et al. 2010) 
Rv3545c cyp125A1 Cytochrome P450 125A1 Cholesterol side-chain transfer to cellular lipids. (McLean et al. 2009) 
Rv3566c nhoA Arylamine N-
acetyltransferase 
Cholesterol catabolism: Links n-propionyl-CoA to 
cholesterol metabolism 




Cholesterol catabolism: Hydrolyses DSHA. (Lack et al. 2008) (Lack et 
al. 2010) 
Rv3582c ispD Cytidyl transferase Isoprenoid biosynthesis (MEP pathway): 3
rd









Table S4.5. Proteins in nucleotide metabolism and modification 
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Gene Name Protein Name Function Reference 
Rv0233 nrdB Mn/Fe R2-like ligand-binding oxidase 
protein 
Deoxyribonucleotide biosynthesis (Andersson & Hogbom 
2009) (Andersson, Berthold 
& Hogbom 2012) 
Rv0321 dcd Deoxycytidine triphosphate deaminase Deoxycytodine triphosphate (dCTP) 
deamination to deoxyuridine triphosphate 
(dUMP). 
(Helt et al. 2008) 
Rv0733 adk Adenylate kinase  ATP terminal phosphate transfer to AMP 
producing 2 ADP. 
(Bellinzoni et al. 2006) 
Rv0805 Not 
assigned 
Cyclic nucleotide phosphodiesterase Cleaves cNMPs to NMPs (Shenoy et al. 2006) 




Purine biosynthesis: Last two steps (Le Nours et al. 2011) 
Rv1900c lipJ (mis-
annotated) 




Exoribonuclease Possess exoribonuclease activity, cleaving 
3’ single strand overhangs of duplex RNA. 
It was annotated as hypothetical protein 
(Abendroth et al., 2013) 
Rv2465c rpiB Ribose-5-phosphate isomerase Nucleotide biosynthesis: Ribose-5-
phosphate/ribulose-5-phosphate 
(Roos et al. 2004) (Roos et 
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Diadenosine polyphosphate (ApnA) 
conversion to ATP and ADP. 
(Mori et al. 2011) 
Rv2754c thyX Flavin-dependent thymidylate synthase Thymidylate biosynthesis: Interconversion 
of dUMP/dTMP.  
(Sampathkumar et al. 2005) 
(Sampathkumar et al. 2006) 
Rv2763c dfrA Dihydrofolate reductase Purines, thymidylic acid and amino acid 
biosynthesis: Converts dihydrofolate to 
tetrahydrofolate. Target for isoniazid. 
(Argyrou, et al., 2006) 
Rv2793c truB ψ55 tRNA pseudouridine synthase Modifies uridine in tRNA, rRNA or 
snRNA to pseudouridine 
(Chaudhuri et al. 2004) 
Rv2883c pyrH Uridine monophosphate kinase Converts UMP plus ATP to UDP plus 
ADP. 
(Labesse et al. 2011) 
Rv2966c rsmD RsmD-like methyltransferase Nucleotide methylation (Kumar et al. 2011) 
Rv3628 ppa Inorganic pyrophosphatase pyrophosphate to orthophosphate 
conversion 
(Tammenkoski, et al., 







Table S4.6. Proteins in glycan biosynthesis and metabolism 
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Protein Name Function Reference 
Rv1018c glmU Probable UDP-N-acetylglucosa-
mine pyrophosphorylase 
Peptidoglycan and lipid A synthesis: Last 2 steps 
in UDP-N-acetyl-D-glucosamine synthesis 
(Zhang et al. 2009) 
Rv1449c tkt Transketolase Cell wall synthesis: Links non-oxidative pentose 
phosphate pathway to pentose sugar (arabinan) 
biosynthesis  
(Fullam et al. 2011) 
Rv1477 ripA Peptidoglycan endopeptidase Cleaves peptidoglycan peptide crosslinks during 
cell division. 
(Ruggiero et al. 2010) 
Rv1566c ripD Peptidoglycan hydrolase Unlike other peptidoglycan hydrolases, ripD has 
evolved to a non-catalytic PG-binding PH.  




Cell wall synthesis: Incorporates amino acids 
such as m-DAP and L-lysine into peptidoglycan.  
(Basavannacharya et al. 







Peptidoglycan fragment recycling: hydrolyzes 
muramyl dipeptide (MDP) releasing N-acetyl 
muramide and L-Ala-iso-D-Gln dipeptide 
products. 
(Prigozhin et al., 2013) 
Rv3808c glfT2 Galactofuranosyltransferase Cell wall synthesis: Generates galactan for 
mycolyl-arabinogalactan complex. 
(Wheatley et al. 2012) 
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Rv3910 mviN Peptidoglycan biosynthetic 
pseudokinase 
Peptidoglycan biosynthesis: Regulates  FhaA by 
phosphorylation-dependent complex formation. 









Protein Name  Function Reference 
Rv0548c menB 1,4-dihydroxy-2-naphthoyl-CoA 
synthase  
Menaquinone (vitamin K2) biosynthesis: 4
th
 step  (Truglio et al. 2003) 
Rv1092c panK Pantothenate kinase Coenzyme A (CoA) biosynthesis: 1
st
 step. ATP-
dependent phosphorylation of pantothenate. 
(Das et al. 2005) 
(Chetnani et al. 2010) 
(Bjorkelid, et al., 
2013) 






 step (Shi et al. 2011) 
Rv1596 nadC Quinolinic acid 
phosphoribosyltransferase 
NAD biosynthesis. (Sharma, Grubmeyer 
& Sacchettini 1998) 
Rv2447c folC Folylpolyglutamate synthase Poly-glutamation of folate for improved cell retention (Young et al. 2008) 
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and affinity of folate-dependent enzymes. 
Rv3248c sahH S-adenosylhomocysteine hydrolase Reversibly hydrolyses S-adenosylhomocysteine (SAH) 
to adenosine and L-homocysteine, to limit  feedback 
inhibition of SAM-dependent methyltransferases 
(Reddy et al. 2008) 
Rv3607c folB 7,8-dihydroneopterin aldolase Folate biosynthesis: 2
nd
 step (Goulding et al. 2005) 
Rv3608c folP1 6-Hydroxymethyl-7,8-dihydro-
pteroate synthase 
Produces the folate precursor 6-hydroxymethyl-7,8-di-
hydropteroate (H2PtPP). 





Table S4.8. Protein in bacterial self-defense and detoxification 
Accession 
Number 
Gene  Protein  Function Reference 
Rv0253 nirD Nitrite reductase Nitrate assimilation/anaerobic respiration: Subunit of nitrite 
reductase to reduce nitrite to ammonia  
(Izumi, Schnell & 
Schneider 2012) 
Rv0262c aac Aminoglycoside 2’-N-
acetyltransferase 
Exact function unknown. CoA-dependently acetylates 2-
hydroxy or amino group of aminoglycolsides and possibly 
mycothiol to regulate cellular redox potential 
(Hedge, Javid-Majd & 
Blanchard 2001) (Vetting 
et al. 2002) 
Rv0407 fgd1 F420-dependent glucose-
6-phosphate 
dehydrogenase 
Exact function unknown. Reduces F420 for low-redox potential 
reactions during anaerobic survival and persistence. Rv3547 
uses reduced F420 to activate prodrug PA-824. 
(Bashiri et al. 2008) 
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Rv0467 icl Isocitrate lyase Diverts acetyl-coA from fatty acid β-oxidation to glyoxylate 
shunt pathway for net carbon gain. 
(Sharma, et al., 2000) 
Rv0819 mshD Mycothiol synthase Mycothiol biosynthesis: Last step. Transfers acetyl to the 
cysteinyl amine of cysteine-glucosamine-inositol. 
(Vetting et al. 2003) 
(Vetting et al. 2006) 
Rv1876 bfrA Bacterioferritin Iron storage and detoxification: Critical for adaptation and 
survival of tubercule bacilli in the host. 
(Gupta et al. 2009) 
Rv1908c katG Catalase-peroxidase Convert pro-drug isoniazid to its active form so it will interfere 
with the enzyme inhA which is involved in Fatty Acid 
Synthase II. 
(Zhao et al., 2013) 
Rv1938 ephB Epoxide hydrolase B Hydrolyses epoxides to trans-dihydrodiols during drug metabo-
lism and signalling molecule processing.  
(Biswal et al. 2006) 
(Biswal et al. 2008) 
Rv2043c pncA Pyrazinamidase Activates first-line drug pyrazinamide converting it to 
pyrazinoic acid to inhibit fatty acid synthase I  
(Petrella et al. 2011) 
Rv2068c blaC β-Lactamase BlaC Hydrolyzes β-lactam related antibiotics (Tremblay, Fan & 
Blanchard 2010) 
Rv2275 albC Cyclodityrosine 
synthetase 
Converts 2 Tyr-tRNA to cyclo(L-Tyr-T-Tyr) of potential anti-
bacterial, antifungal and antitumor activity. 
(Vetting, Hedge & 
Blanchard 2010) 
Rv2416c Eis Enhanced intracellular 
survival protein 
It is a structurally and functionally unique acetyltranferase 
which unusually acetylates aminoglycosides at multiple 
positions, conferring drug resistance against kanamycin for M. 
tuberculosis. 
(Chen et al., 
2011)(Houghton et al., 
2013) 
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Rv2428 ahpC Alkyl hydroperoxidase, 
AhpC 
Part of NADH-dependent peroxidase and peroxynitrite 
reductase. 
(Guimaraes et al. 2005) 
Rv2429 ahpD Alkyl hydroperoxidase 
AhpD 
Same function as AhpC despite unrelated amino acid sequence (Nunn et al. 2002) 
(Koshkin et al. 2003) 
Rv2461c clpP1 Caseinolytic protease Degrades misfolded, short-lived, dysfunctional, denatured and 
aggregated proteins. 
(Ingvarsson, et al., 2007) 
Rv2579 dhaA Haloalkane dehalogenase Cleaves carbon-halogen bonds of halogenated alphatic 
hydrocarbons yielding a halide anion and an aliphatic alcohol. 
(Mazumdar et al. 2008) 
Rv2740 ephG Epoxide hydrolase B 
EphG 
Detoxifies and processes signalling molecules by converting 
reactive epoxides to diols. 
(Johansson et al. 2005) 
Rv3682 PonA2 Penicillin binding 
protein 
Its C-terminal PASTA domain has untypical binding ability 
compared to other PASTA domains 
(Calvanese et al., 2013) 
 
 
Table S4.9. Proteins involved in transcriptional regulation 
Accession 
number 







VapC: endoribonuclease cleaving mRNA to 
stop cell growth. VapB inhibits VapC. 







As VapBC-3 (Miallau et al. 2009) 
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Rv0678 marR Transcriptional regulator 
MarR 
Transcriptional regulation of MmpS5-
MmpL5 transporter 
(Radhakrishnan et al., 2014) 
Rv0735-
Rv0736 
sigL-rslA Sigma factor L and anti-
sigma factor RslA 
Transcriptional regulation of cell envelope 
and secreted protein modification genes. 






Transcriptional regulation of multidrug efflux 
system Rv1217c-Rv1218c 
(Kumar et al., 2014) 
Rv1267c embR  Putative arabinosyltransferase transcriptional 
regulator. 
(Alderwick et al. 2006) 
Rv1657 argR Arginine repressor Arginine biosynthetic transcription regulator. (Lu et al. 2007) (Cherney et al. 2010) 
(Cherney et al. 2008) (Cherney et al. 
2009) (Cherney et al. 2008) 
Rv1846c blaI β-Lactamase operon 
transcriptional repressor 
Transcriptional repression of β-lactamase 
genes 
(Sala et al. 2009) 
Rv1985c argP Arginine permease Transcription regulator for arginine export 
and transport/metabolism of other amino acid 








Regulator of P1-type ATPase for export of 
toxic metal ions. 
(Cavet et al. 2003) 
Rv2069 sigC Sigma factor C Sigma C-dependent DNA transcription 
regulator virulence associated genes such as 
hspX, senX3 and mtrA 
(Thakur, Joshi & Gopal 2007) 
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Rv3291c lrpA Leucine-responsive 
global regulator 
Global transcriptional regulator during 
starvation and stationary phase transition 
(Shrivastava & Ramachandran 2007) 
(Reddy et al. 2008) (Shrivastava, Dey & 
Ramachandran 2009) 
Rv3849 espR Virulence regulator ESX-1 secreted activator of espACD operon 
of virulence associated ESX-1 type VII 
secretion system;  
(Blasco et al. 2011) 
Rv3854c ethR TetR/CamR family 
repressor 
ethA repressor, preventing ethionamide 
(ETH) activation by EthA, conferring drug 
resistance.  
(Dover et al. 2004) (Carette et al. 2011) 
 
 
Table S4.10. Proteins in protein synthesis 
Accession 
Number 
Gene  Protein   Function Reference 
Rv0009 ppiA Peptidyl-prolyl cis-
trans isomerase A 
Peptide cis-trans isomerase for protein folding, 
signalling, cell surface recognition, chaperoning and 
heat-shock response 
(Henriksson et al. 2004) 
Rv1014c pth Peptidyl-tRNA 
hydrolase 
Cleaves peptides from tRNA to avoid peptidyl-
tRNA toxicity  
(Selvaraj et al. 2007) (Pulavarti et al. 
2008) 
Rv2969c DsbA Disulfide bond 
forming protein 
It facilitates proper folding and disulfide bond 
formation of periplasmic and secreted proteins. 
(Chim et al., 2013) 
Rv3417c groEL1 Chaperonin  Facilitates protein folding. (Sielaff, Lee & Tsai 2010) (Sielaff, Lee 
& Tsai 2011) 
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Rv3462c infA Translation initiation 
factor I 
IF1/2/3 constitute the translation initiation complex (Hatzopoulos & Mueller-Dieckmann 




Table S4.11. Proteins in DNA replication and repair 
Accession 
Number 
Gene  Protein Function Reference 
Rv0002 dnaN DNA polymerase IIIβ sliding 
clamp 
Component of DNA polymerase III for 
genome replication 






DNA gyrase DNA topology regulation. Drug target for 
quinolone. 
(Piton et al. 2010) (Tretter & Berger 
2012) 
Rv0058 dnaB DNA helicase ATP-dependent helicase unwinding parental 
duplex DNA during replication 
(Biswas & Tsodikov 2008) 
Rv0938 ligD Non-homologous end-joining 
(NHEJ) DNA repair 
polymerase  
Catalyses NHEJ-mediated DNA repair (Gong et al. 2004) (Pitcher et al. 
2005) (Akey et al. 2006) (Pitcher et 







-alkylguanine in double-stranded 
DNA  preventing G:C to A:T transition 
mutations. 
(Miggiano et al. 2013) 
Rv2593c ruvA Holliday junction DNA 
helicase 
Processes/resolves Holliday junctions with 
ruvB and ruvC for homologous recombination 
orientated DNA repair. 
(Prabu et al. 2006) 
Rv2976c ung Uracil-DNA glycosylase First step in uracil excision-repair pathway. (Singh et al. 2006) (Kaushal et al. 
2010) 
Rv3053c nrdH NrdH. Probable glutaredoxin 
electron transport component   
Provides electrons for ribonucleotide reduction 
(RR) for DNA replication and repair 
(Phulera & Mande, 2013) 
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Table S4.12. Proteins in cellular information processing and substrate transport 
Accession 
Number 
Gene  Protein  Function Reference 
Rv0014c pknB  Serine/threonine 
kinase B 
Unknown substrates. Regulates mycobacterial life cycle. (Ortiz-Lombardia et 
al. 2003) (Barthe et 
al. 2010) 
Rv0491 regX3 Transcriptional 
regulatory protein 
RegX3 
Part of two component system RegX3/SenX3 (King-Scott et al. 
2007) 
Rv0757 phoP Transcriptional 
regulatory protein 
PhoP 
Part of two component system PhoP/PhoQ. A probable positive 
regulator for phosphate regulon for intracellular growth 
(Wang, Engohang-
Ndong & Smith 
2007) 
Rv0899 ompA Outer membrane 
protein A 
Pore-forming protein for uptake of water-soluble compounds. (Li et al. 2012) 
Rv0934 pstS1 Phosphate-specific 
transport substrate 
binding protein-1 
Primary extracellular receptor for the ABC phosphate transporter 
regulating phosphate uptake. 
(Vyas, Vyas & 
Quiocho 2003) 
Rv1266c pknH Serine/threonine 
kinase H 
Phosphorylation by PknH enhances Rv1267 binding to the promoter 
of the embCAB arabinosyltranferase genes that promote cell wall 
synthesis. PknH also phosphorylate kasA, kasB and MtFabH 
promoting mycolic acid synthesis 
(Cavazos, Prigozhin 





It is the sensor part of a two component system. It provides the 
linkage between the phosphorylation cascade of the two component 
(Morth et al. 2004) 
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yet antiterminator systems with the antitermination event in the transcriptional 
machinery 
Rv1743 pknE Serine/threonine 
kinase E 
The function of PknE is unknown. But in vitro the activated kinase 
domain phosphorylate Rv1747, an ABC transporter of unknown 
specificity, and GarA, a conserved hypothetical protein 
(Gay, Ng & Alber 
2006) 
Rv2027c dosT Histidine kinase DosT The N-terminal sensory domain of DosT directly binds to oxygen gas, 
NO, and CO. NO or CO binding to or O2 dissociate from the N-
terminal GAF domain initiates autophosphorylation by the C-terminal 
histidine kinase domain, with subsequent phosphoryl transfer to the 
Asp residue of the transcriptional regulator DosR. DosT functions as a 
hypoxia sensor, mediating an early M. tuberculosis response on the 
host immune factor (NO). 
(Sardiwal et al. 
2005) (Podust, 
Ioanoviciu & Ortiz 
de Montellano 2008) 
Rv2386c mbtI Salicylate synthase The 1
st
 enzyme in the siderophore mycobactin synthetic pathway, 
catalysing the 1
st
 step from chorismate to salicylate 
(Harrison et al. 
2006) 
Rv2919c glnB Nitrogen regulatory 
PII protein 
It acts as nitrogen sensor. The precise function is unknown. It might 
play a key role in the nitrogen regulatory pathway 
(Shetty et al. 2010) 
Rv3132c dosS Histidine kinase DosS DosS is sensor kinase, responsible for recognition of hypoxia in M. 
tuberculosis. It is structurally similar to DosT but DosS is a redox 
sensor while DosT is direc oxygen sensor 
(Cho et al. 2009) 
(Cho et al. 2011) 
(Cho et al. 2013) 
Rv3220 pdtaS Histidine kinase PdtaS PdtaS is cytosolic sensor protein. The two component system 
PdtaR/PdtaS structurally and functionally is equivalent to the 
EutW/EutV TCS involved in regulatory ethanolamine catabolism in 
many gram positive bacteria 
(Preu et al. 2012) 
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Rv3676c crp Cyclic AMP receptor 
protein 
It acts as a sensor o cAMP level in cells. cAMP mediates a large 
variety of cellular signalling processes 
(Akif et al. 2006) 
(Gallagher et al. 









Protein Name Function Reference 
Rv0153c ptpB Tyrosine phosphate It is secreted into the host cells where it disrupts unidentified 
signalling pathways 
(Grundner, Ng & 
Alber 2005) (Grundner 
et al. 2007) 
Rv0198c zmp1 Zinc-dependent 
metalloprotease-1 
It plays a key role in the process of phagosome maturation 
inhibition and emerged as an important player in pathogenesis 
(Ferraris et al. 2011) 
Rv2111c mpa Mycobacterium 
proteasome 
Upon binding to ubiquitin-like protein, Mpa delivers proteins 
into the mycobacterial proteasome for destruction 






PE25 and PPE41 The function is unknown. They are cell wall associated, 
immunoantigenic, secreted virulence factors 
(Strong et al. 2006) 
Rv2945c lppX Probable conserved 
lipoprotein 
It is required for the translocation of phthiocerol 
dimycocerosates (DIM) from cell wall layer to outside OM. 
The exact function is still unknown. Attenuation is observed 
when knocked out in mouse model 
(Sulzenbacher et al. 
2006) 
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It binds to DNA gyrase and inhibits its activity. Such 
inhibition causes the resisitance to ciprofloxacin and 
sparfloxacin (fluoroquinolone) 




Putative serine protease It maintains the bacteria near neutral intrabacterial pH. It 
confers resistance to acidification and protection from 
oxidative stress 





Culture filtrate protein 10-
Early secretory antigenic 
target 6 
They are secreted antigenic virulence factors. They are 
believed to form larger complex with Esp protein upon 
secretion via ESX-1 
(Renshaw et al. 2005) 
Rv3914 trx Thioredoxin C It regulates cellular redox homeostasis, enabling resistance to 
host cell phagocytosis 
(Hall et al. 2011) 
 
 
Table S4.14. Hypothetical protein and proteins with unrecognized possible functions 
Accession 
Number 
Gene Name Protein Name Possible function Reference 
Rv0020c fhaA Conserved protein with FHA 
domain 
It might be linked to cell wall biosynthesis regarding the 
functions of its neighbouring genes in the genome 
(Roumestand et al. 
2011) 
Rv0130 htdZ Probable 3-hydroxyl-
thioester dehydratase 
It has R-specific hydratase motif, hydrating a trans-2-enoyl-
coA moiety 
(Johansson et al. 
2006) 
Rv0216 Not assigned 
yet 
Double hotdog hydratase It is able to catalyse the R-specific hydration of 2-enoyl 
coenzyme A 
(Castell et al. 
2005) 
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It catalyzes the allylic rearrangement of Δ5-3-ketosteroids 
to Δ4-3-ketosteroids. It might be a steroid binding protein 
(Cherney, Garen & 
James 2008) 
Rv0802c Not assigned 
yet 
Possible succinyltransferase It belongs to GNC5-related N-acetyltransferase family. 
Substrate is unknown 
(Vetting, Errey & 
Blanchard 2008) 
Rv0813c Not assigned 
yet 
Resemble eukaryotic fatty 
acid binding protein 
It plays a role in the recognition, transport, and/or storage of 
small molecules 
(Shepard et al. 
2007) 





It has no binding activity towards FMN. It might have 
evolved a new unknown function 
(Canaan et al. 
2005) 
Rv1873 Not assigned 
yet 
Unknown Unknown (Garen et al. 2006) 
Rv1980c mpt64 Immunogenic protein Mpt64 It contains a protein-protein interaction motif. Function is 
unknown. It might be a virulence factor 
(Wang et al. 2007) 
Rv2140c Not assigned 
yet 
Unknown It shares strong structural homology with the phos- 
phatidylethanolamine-binding family of proteins. It might 
be involved in lipid metabolism 
(Eulenburg, et al., 
2013) 
Rv2175c Not assigned 
yet 
Unknown It is a DNA binding protein. It can be phosphorylated by 
Ser/Thr kinase. It might act as a transcriptional regulator 
(Cohen-Gonsaud et 
al. 2009) 
Rv2543 lppA Probable conserved 
lipoprotein 
It might play a role in host-pathogen interaction (Grana et al. 2010) 
Rv2704 Not assigned Putative σ
A
 regulator It might be involved in metabolic interactions (Thakur, Praveena 
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yet & Gopal 2010) 
Rv2714 Not assigned 
yet 
Unknown A representative of a new nucleoside phosphorylase-like 
family of duplicated actinobacterial proteins  
(Grana et al. 2009) 
Rv2827c Not assigned 
yet 




A broad specificity 
phosphatase 
It is important for mycobacterial phosphate metabolism. 
Exact function is unknown 
(Watkins & Baker 
2006) 
Rv3547 ddn Deazaflavin-dependent 
nitroreductase 
It catalyzes the reduction of nitroimidazoles such as PA-
824, resulting in intracellular release of lethal reactive 
nitrogen species. Exact function is unknown 




Table S4.15. Structural research groups involved in structural work on M. tuberculosis H37Rv strain proteins 
Name of P. I. Institution Proteins investigated 
Tom Alber Department of Molecular and Cell 
Biology, University of California, 
Berkeley, USA 
Ser/Thr Kinases PknH and PknE, Tyrosine phosphatase PtpB, Protein lysine 
acetyltransferase, pseudokinase (peptidoglycan biosynthesis) , N-
acetylmuramyl L-analine amidase 
Pedro, M. Alzari Unite´ de Biochimie Structurale, Institut 
Pasteur, Paris, France 
Adenylate kinase, lipoprotein LppA, peroxidase AhpC,  fumarase, ser/thr 
kinase PknB, lactamase transcriptional regulator BlaI, fatty acid binding 
protein Rv0813, glucosyl-3-phosphoglycerate synthase 
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Kristina Bäckbro Department of Cell and Molecular 
Biology, Uppsala University, Sweden 
Hypothetical proteins Rv0130 and Rv0213 
Edward, N. Baker Maurice Wilkins Centre for Molecular 
Biodiscovery and School of Biological 
Sciences, University of Auckland, New 
Zealand 
F420-dependent glucose-6-phosphate dehydrogenase FGD1, mycobactin 
biosynthetic enzyme MbtI, α-isopropylmalate synthase, purine biosynthetic 
enzyme PurE, TrpD (tryptophan biosynthesis), Phosphatase Rv3214, 3-
deoxy-D-arabino-heptulosonate 7-phosphate synthase, folypolyglutamate 
synthase, GlmU (UDP-GlcNAc synthesis), Phosphoserine aminotransferase 
(SerC, serine biosynthesis), NAD
+
-dependent 
-1-pyrroline-5-carboxylic dehydrogenase (PruA) 
Marco Bellinzoni Unité de Microbiologie Structurale, Institut 
Pasteur, Paris, France 
Adenylate kinase, lipoprotein LppA, Rv2714, Class II fumarase Rv1098c 
James, M. Berger Division of Biochemistry, Biophysics, and 
Structural Biology, Department of 
Molecular and Cell Biology, University of 
California, Berkeley, USA 
DNA ligase D, DNA gyrase 
Sanjib Bhakta Institute of Structural and Molecular 
Biology, Department of Biological 
Sciences, University of London, UK 
MurE (Peptidoglycan biosynthesis) 
John S. Blanchard Department of Biochemistry, Albert 
Einstein College of Medicine, New York, 
USA 
aminoglycoside 2'-N-acetyltransferase (AAC(2')-Ic), Fluoroquinolone 
resistance protein, β-lactamase, succinyltransferase, cyclodityrosine 
synthetase, Mycothiol synthase, Dihydrofolate reductase (isoniazid target) 
Yves Bourne Architecture et Fonction des 
Macromole´cules Biologiques, CNRS, 
Marseille, France 
Hypothetical protein Rv1155, lipoprotein LppX  
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Centre National de la Recherche 
Scientifique UMR 5048, Centre de 
Biochimie Structurale, Montpellier, France 
Ser/Thr Kinase PknB, and its substrates Rv2175c and FhaA, MabA (long-
chanin fatty acid biosynthesis) 
Stewart T. Cole Global Health Institute, Ecole 
Polytechnique Fédérale 
de Lausanne, Lausanne, Switzerland 
Virulence regulator EspR, transketolase, alkyl hydroperoxidase AhpC, 
CYP121, BlaI, fatty acid binding protein Rv0813c 
Amit Kumar Das Department of Biotechnology, Indian 
Institute of Technology, Kharagpur, West 
Bengal, India 
Pantothenate kinase, β-ketoacyl coA reductase FabG4 
Thomas Dick Novartis Institute for Tropical Disease, 
Singapore 
Ddn (deazaflavin-dependent nitroreductase), putative dihydropteroate 
synthase ortholog Rv1207 
Snezana Djordjevic Department of Biochemistry and 
Molecular Biology, University College 
London, UK 
alkylhydroperoxidase AhpD, redox sensor DosS 
Aidan, J. Doherty genome damage and stability centre, 
University of Sussex, Brighton, UK 
NHEJ polymerase, NHEJ DNA repair ligase 
David Eisenberg Howard Hughes Medical Institute, UCLA-
Department of Energy Institute of 
Genomics and Proteomics, University of 
California, Los Angeles, USA 
Mycobacterial folate biosynthetic enzyme, Citrate lyase β-subunit CitE, 
toxin-antitoxin system VapBC5 and VapBC3, PE/PPE protein complex 
Lindsay D. Eltis Department of Microbiology and 
Immunology, Life Sciences Institute, 
University of British Columbia, 
Steroid-degrading hydrolase HsaD, carbon-carbon hydrolase (cholesterol 
metabolism) 
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Klaus, Fűtterer School of Biosciences, The University of 
Birmingham, UK 
Ser/Thr kinase, Inositol monophosphatase, TetR/CamR family repressor 
EthR, mtFabD, Trehalose synthase (TreS) and Maltokinase (Pep2) 
Lalit, C. Garg Gene Regulation Laboratory, National 
Institute of Immunology, New Delhi, India 
Phosphoglucose isomerase,  
Balasubramanian 
Gopal 
Molecular Biophysics Unit, Indian Institute 
of Science, Bangalore, India 
Sigma factor C, Rv2704, antisigma factor RslA 
Marcelo E. Guerin Mycobacteria Research Laboratories, 
Department of Microbiology, Immunology 
and Pathology, Colorado State University, 
Fort Collins, USA 
Fructose-1,6-bisphosphate aldolase, GpgS (methylglucose 
lipopolysaccharide biosynthesis), glucosyl-3-phosphoglycerate synthase 
Kalervo J. Hiltunen Biocenter oulu and Department of 
Biochemistry, University of Oulu, Finland 
α-methyl-acyl-coA raemase,  
Martin Hőgbom Department of Cell and Molecular 
Biology, Uppsala University, Sweden 
Mn/Fe R2-like ligand-binding oxidase protein (Mn/Fe R2lox protein), β-
Carbonic Anhydrase 
Wim, G. J. Hol Howard Hughes Medical Institute, 
University of Washington, Seattle, USA 
Thymidylate synthase ThyX, 6-Hydroxymethyl-7,8-dihydropteroate 
synthase (Folate biosynthesis) 
Mary Jackson Mycobacteria Research Laboratories, 
Department of Microbiology, Immunology 
and Pathology, Colorado State University, 
Fort Collins, USA 
Fructose-1,6-bisphosphate aldolase, GpgS (methylglucose 
lipopolysaccharide biosynthesis), lipoprotein LppX, glucosyl-3-
phosphoglycerate synthase 
Michael N. G. Group in Protein Structure and Function, Epoxide hydrolases A and B, Arginine repressor protein, N-acetyl-γ-
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James Department of Biochemistry, University of 
Alberta, Edmonton, Canada 
glutamyl-phosphate reductase, Δ5-3-ketosteroid isomerase, hypothetical 
protein Rv1873, haloalkane dehalogenase, ArgC and ArgF (Arginine 
biosynthesis), ornithine carbamoyltranferase 
Alwyn, T. Jones Department of Cell and Molecular 
Biology, Uppsala University, Biomedical 
Center, Sweden 
Hypothetical proteins Rv0130 and Rv0213, deazaflavin-dependent 
nitroreductase Ddn, β-carbonic anhydrase, transketolase, 1-deoxy-D-
xyululose-5-phosphate reductoisomerase, epoxide hydrolase glutamine 
synthetase, ribose-5-phosphate isomerase, cytidyl transferase IspD, 
pantothenate kinase 
Beom Slk Kang School of Life Science and Biotechnology, 
Kyungpook National University, Daegu, 
South Korea 
Histidine kinase DosS  
Jane E. Ladner Biochemical Science Division, Chemical 
Science and Technology Laboratory, 
National Institute of Standards and 
Technology, Gaithersburg, Maryland, USA 
Intracellular chorismate mutase, Secreted chorismate mutase 
Shaun J. Lott Centre for Molecular Biodiscovery and 
School of Biological Sciences, University 
of Auckland, New Zealand 
Salicylate synthase (mycobactin biosynthesis), TrpD (lung colonization) 
Shekhar, C. Mande Centre for DNA Fingerprinting and 
Diagnostics, Nacharam, Hyderabad, India 
cAMP receptor protein, chorismate mutase, NrdH, Probable glutaredoxin 
electron transport component   
Claudine Mayer Unite´ de Dynamique Structurale des 
Macromole´cules, De´partement de 
Biologie Structurale et Chimie, Institut 
Glycine cleavage system protein H, DNA gyrase 
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Pasteur, Paris, France 
Virginie Molle Institut de Biologie et Chimie des 
Prote´ines, Universite´ Lyon, France 
Response element for Ser/Thr kinase signalling EmbR, Ser/Thr kinase 
substrate Rv2175c, PknB interaction partner Rv0020c 
Sherry L. Mowbray Department of Molecular Biology, 
Biomedical Center, Swedish University of 
Agricultural Sciences, Uppsala, Sweden 
carbonic anhydrase, peptidyl-prolyl cis-trans isomerase A, 1-deoxy-D-
xylulose-5-phosphate reductoisomerase, epoxide hydrolase, glutamine 
synthetase, D-ribose-5-phosphate isomerase 
Jochen Mueller-
Dieckmann 





Unite´ de Chimie et Biocatalyse, De´ 
partement de Biologie Structurale et 
Chimie, Paris, France 
adenylate kinase, uridine monophosphate kinase 
Andrew W. Munro Manchester Interdisciplinary biocentre, 
faculty of Life Sciences, University of 
Manchester, UK 
Cycochrome P450 CYP142, CYP121, CYP125 
Paul R. Ortiz de 
Montellano 
Department of Pharmaceutical Chemistry, 
University of California, San Francisco, 
USA 
Enoyl acyl carrier protein reductase, Cytochrome P450 CYP124, CYP130, 
alkylhydroperoxidase AhpD, sensory histidine kinase DosT 
Emily J. Parker Centre of Structural Biology, Institute of 
Fundamental Sciences, Massey University, 
Palmerston North, New Zealand 
α-isopropylmalate synthase, 3-deoxy-D-arabinoheptulosonate 7-phosphate 
synthase (aromatic amino acid biosynthesis) 
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Florence Pojer Global Health Institute, Ecole 
Polytechnique Federale de Lausanne, 
Switzerland 
EspR, transketolase 
Annaïk Quemard Institut de Pharmacologie et de 
Biologie Structurale, Centre 
National de la Recherche 
Scientifique, Toulouse, France 




Verna and Marrs McLean Department of 
Biochemistry and Molecular Biology and 
Howard Hughes Medical Institute, Baylor 
College of Medicine, Houston, Texas, 
USA 
ABC phosphate transport receptor 
Ravishankar 
Ramachandran 
Molecular and Structural Biology Division, 
Central Drug Research Institute (Council 
of Scientific and Industrial Research), 
Lucknow, Uttar Pradesh, India 
DNA polymerase β-clamp, feast/famine regulatory protein Rv3291c, ε-
aminotransferase, Alanine dehydrogenase 
Zihe Rao National Laboratory of macromolecules, 
Institute of Biophysics, Chinese Academy 
of Science, Beijing, China 
Arginine permease, MCAT (fatty acid biosynthesis) 
Prasad T. Reddy Biochemical Science Division, Chemical 
Science and Technology Laboratory, 
cAMP receptor protein, intracellular chorismate mutase, secreted chorismate 
mutase 
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National Institute of Standards and 
Technology, Gaithersburg, Maryland, USA 
Menico Rizzi DISCAFF Department of Chemical, Food, 
Pharmaceutical and Pharmacological 
Sciences, University of Piemonte Orientale 




Steven L. Roderick Department of Biochemistry, Albert 
Einstein College of Medicine, Bronx, New 
York, USA 
Fluoroquinolone resistance protein Rv3361, Aminoglycoside 2'-N-
acetyltransferase, Mycothiol synthase 
James C. 
Sacchettini 
Department of Biochemistry and 
Biophysics, Texas A & M University, 
College Station, Texas, USA 
ATP phosphoribosyltransferase, lipoprotein LprG, diaminopimelate 
decarboxylase (lysine biosynthesis), phosphoribosyl-ATP 
pyrophosphohydrolase, FadD10 (lipid metabolism), S-adenosyl-L-
homocysteine hydrolase, leucine-responsive global regulator LrpA, 




Centre for Cellular and Molecular Biology, 
Council of Scientific and Industrial 
Research, Hyderabad, India 
Fatty acyl-AMP ligase, ornithine carbamyoyltransferase 
Gunter Schneider Department of Medical Biochemistry and 
Biophysics, Karolinska Institutet, 
Stockholm, Sweden 
Nitrite reductase, Sulfite reductase 
Christopher J. 
Squire 
School of Biological Sciences and Maurice 
Wilkins Centre for Molecular 
Biodiscovery, University of Auckland, 
F420-dependent glucose-6-phosphate dehydrogenase FGD1, α-
isopropylmalate synthase, GlmU (peptidoglycan and lipid A biosynthesis) 
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Francis T. F. Tsai Departments of Biochemistry and 
Molecular Biology, and Molecular and 
Cellular Biology, Baylor College of 
Medicine, Houston, Texas, USA 
GroEL1 (chaperone protein) 
Oleg, V. Tsodikov Department of Medicinal Chemistry, 
College of Pharmacy, University of 
Michigan, Ann Arbor, USA 
Serine protease Rv3671c, DnaB helicase 
Paul A. Tucker EMBL Hamburg Outstation, Germany Two-component system component RegX3, putative transcriptional 
antiterminator, cytosolic sensor kinase PdtaS 
Anil K. Tyagi Department of Biochemistry, University of 
Delhi South Campus, New Delhi, India 
Biotin protein ligase, Bacterioferritin A 
Mamannamana 
Vijayan 
Molecular Biophysics Unit, Indian Institute 
of Science, Bangalore, India 
Pantothenate kinase, uracil-DNA glycosylase, Holliday junction DNA 
helicase RuvA, peptidyl-tRNA hydrolase 
Rik, K. Wierenga Biocenter Oulu and Department of 
Biochemistry, University of Oulu, 
Linnanmaa, Finland 
α-methyl-acyl-coA racemase, β-oxidation trifuctional enzyme 
Matthias Wilmanns EMBL-Hamburg Unit, European 
Molecular Biology Laboratory, Germany 
Histidine/tryptophan biosynthesis isomerase, Acyl-CoA carboxyltransferase, 
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